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Organic molecules accomplish different crucial functions in nature, pharmaceuticals, and 
technology. Organic synthesis, as such, represent a key tool to access and realise a broad 
array of transformations, ranging from simple- to highly complex and selective molecular 
modifications. In times where sustainable and green chemistry is gaining importance day by 
day, the development of highly efficient catalytic methodologies constitutes one of the main 
aims of the organic chemistry research and pharmaceutical industry. 
Protein misfolding and Endoplasmic-reticulum-associated protein degradation play an 
important role in the pathogenesis of different diseases. Among a wide variety of related 
disorders, hereditary liver and pancreas diseases like the Wilson's disease and acute 
pancreatitis consist two diseases for which no causal treatment is available. During this 
thesis, the synthesis of potential biologically active molecules for targeting different 
pharmacological relevant targets is adressed by the mean of classical organic chemistry and 
photoredox catalysis to develop new possible therapeutic approaches for the 
beforementioned diseases. 
The first chapter during this thesis describes a brief introduction to photochemistry and 
the former employments of pyrimidopteridine N-oxide derivatives in photochemical 
transformations. Different substituted pyrimidopteridine N-oxide derivatives and their 
deoxygenated analogs are highlighted. Also, corresponding electro- and photochemical data 
were investigated. 
The second chapter describes a photo-mediated photoredox decarboxylative 
methodology for the CC coupling of different non-activated carboxylic acids to electron-
deficient alkenes using pyrimidopteridine N-oxides as photocatalysts. This metal-free 
protocol comprises the use of catalytic amounts of base and low photocatalyst loading to 
achieve a regioselective decarboxylative coupling. The optimization of reaction conditions as 
well as the scope of both carboxylic acids and electron-deficient alkenes is described. 
Furthermore, mechanistic investigations and derivatization reactions of synthesized scaffolds 
are presented. 
In the third chapter, a photomediated hydroamination reaction of different stilbene 
derivatives with primary unprotected amines is highlighted. Different primary amines were 
employed and tested for their suitability in this photocatalytic protocol using 
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pyrimidopteridine N-oxides as photocatalysts. In addition, kinetic experiments were 
conducted to reveal the operational mechanism of this reaction. 
Next, during the fourth chapter, the total synthesis of two literature known turn-on 
copper chemosensors, indispensable for the evaluation of possible medicinally relevant 
compounds in live-cell cultures, and two glitazone derivatives, which could demonstrate 
beneficial effects during the Wilson's disease, are revised and newly evaluated. In addition, 
the quantification of cellular copper levels is demonstrated in HepG2 cell cultures. 
In the last part, the total synthesis of ZD-0892, a literature known peptidyl trifluoromethyl 
ketone possesing a high elastase inhibition effect, is described. A safer and easier way to 
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1 Photochemistry and Photocatalysis 
1.1 Introduction 
During the past decades, the development and application of photochemistry and 
photoredox catalysis have gained tremendous attention in the chemical community, 
especially in the field of synthetic organic chemistry.[1-3] Many scientists, ranging from 
pharmaceutical to materials sciences, are rapidly adopting the use of photochemistry and 
photocatalysis as a powerful tool to achieve unique chemical reactivity and produce 
scaffolds inaccessible by classical approaches.[4, 5] The ability to conduct complex, thus highly 
selective, chemical transformations under very mild reaction conditions is especially 
intriguing for potential industrial applications. 
First, it is essential to distinguish between frequently used terms in chemical reactions 
involving the use of light. Photochemistry, as such, describes the use of energy derived from 
absorbed photons to promote a chemical transformation.[6] This can be achieved by either 
direct excitation of the reactants or, in case of non-absorbing reactants, by the addition of a 
photocatalyst (PC) or photosensitizer (PS).[7, 8] Photocatalysts and photosensitizers are able 
to absorb the energy of light and interact with a reactant (E) via different mechanisms and 
provoke a chemical transformation (Scheme 1.1). 
Scheme 1.1 General scheme of a (A) photosensitized-, (B) photo-mediated hydrogen atom transfer- and (C) 




In this context, a photosensitization process involves, most frequently, an energy transfer 
(EnT) from the excited photosensitizer to the reactant (Scheme 1.1, entry A).[7] In contrast, a 
photocatalyzed reaction includes an electron- (ET) or hydrogen atom transfer (HAT) between 
a reactant and a photocatalyst in its excited-state (Scheme 1.1, entries B and C).[7] In general, 
these mechanisms allow the formation of different activated intermediates susceptible to 
chemical modifications. 
In the first attempts to harness light energy for chemical reactions, the usage of solar light 
as the most abundant energy source to catalyze a chemical reaction has been initially 
reported by Hermann Trommsdorff and pioneered by Giacomo Ciamician in the early 
1900s.[9, 10] The utilization of solar light as an inexhaustible renewable energy source paved 
the way to a new era in chemistry, establishing an environmentally sustainable key pillar in 
chemistry.[11, 12] Nonetheless, the wide wavelength range of solar light (300-1400 nm), along 
with generated heat and fluctuations in solar radiation impedes the selectivity, the scope of 
excitable organic molecules and the reproducibility of photochemical reactions. 
As a result, the joint venture of developments in chemistry and the field of light 
technology has led to the employment of custom designed and more suitable photocatalysts 
along with modern light sources such as LEDs (light-emitting diodes). Hence, leading to a 
notable enhancement in the selectivity and effectiveness of photocatalytic reactions.[13] 
An prominent example of an industrially used photochemical process is the synthesis of 
vitamin D3 starting from provitamin D3 (Scheme 1.2).
[14, 15] The depicted synthesis includes a 
light-induced isomerization step from provitamin D3 to previtamin D3 via a photo-mediated 
conrotary 6-ring-opening. 
 
Scheme 1.2 Industrial synthesis of Vitamin D3.
[14]
 
Also, photoredox catalysis has been applied in industry. For instance, the synthesis of 
LY2784544, a selective JAK2-V617F inhibitor, was accessible through an iridium-




Scheme 1.3 Iridium-photocatalyzed -arylation step during the synthesis of a precursor of LY2784544.
[16]
  
1.2 Photophysical and electrochemical processes of photocatalysts 
For the sake of clarity and simplicity and since photosensitization and photoredox events 
might not be clearily distinguishable in relevant protocols, photoredox catalysts and 
photosensitizers are refered to as photocatalysts (PC).  
First, during a photocatalytic reaction, a photocatalyst PC is excited from its singlet ground 
state (S0) into an energetically higher singlet excited state by the absorption of a photon (h) 
of a specific energy (Scheme 1.4). Thus, a variety of singlet excited states with different 
vibrational energies (Sn) are achieved. According to Kasha's rule, all higher energetic excited 
states Sn relax back to the lowest energy level of the first excited state (S1).
[17] The first 
electronic transition from S0 to S1 leads to two semi occupied molecular orbitals (SOMO). 
Accordingly, the lack of one electron in the former highest occupied molecular orbital 
(HOMO) in its excited state, refered to as the electron hole, increases its electron affinity 
and therefore its oxidizing ability. Likewise, owing to the energetically higher laying electron 
during the excited state of the photocatalyst PC*, donation to an acceptor molecule is more 
favorable in contrast to the ground state S0. Thus, an increase in the reducing capability of 
the excited state catalyst PC* is evident. In case PC* is considered as an isolated molecule, 
two relaxation scenarios from S1 back to S0 are possible; either a radiative pathway via 
emission of light (fluorescence) or a non-radiative pathway refered to as internal conversion 
(IC) in form of heat (thermal decay). Additionally, a spin-forbidden intersystem crossing (ISC) 
from S1 to an energetically lower laying triplet excited state (T1) is possible. From T1, a 
relaxation to S0 is possible via a radiationless IC or a second ISC, also referred to as 
phosphorescence. It is worth to mention that ISC-events are spin-forbidden and therefore 
slower by a factor of 106 compared to the radiative relaxation from S1 to S0 (fluorescence).
[18] 
This is evident through a large difference in magnitude between the lifetime of fluorescence 




Scheme 1.4 Photophysical and electrochemical processes of photocatalysts. 
During a photocatalytic reaction, a substrate (E) can interact with a photocatalyst in the 
excited state PC* via three different reaction modes. Depending on the nature of the 
photocatalyst, a redox process involving single electron transfer (SET), an atom-transfer (AT) 
or an energy transfer (EnT) is prevalent.[19]  
Electron transfer photocatalysis, also called photoredox catalysis, makes use of the 
enhanced redox activity of the excited-state photocatalyst PC* and the ability to participate 
in single electron transfer events.[18] Notably, photoinduced electron transfer (PET) occurs 
likely from the strong oxidizing and reducing S1 excited state.  
During a photoredox catalyzed event, the single electron transfer can occur through either 
an oxidative or reductive quenching of the excited state photocatalyst PC* (Scheme 1.5). In 
the course of an oxidative quenching cycle, the excited state photocatalyst PC* is oxidized by 
a substrate E in a SET fashion. The transfer of one electron from PC* to E furnishes the 
radical anion (E) and the oxidized form of the ground state photocatalyst (PC. 
Subsequently, the highly reactive radical intermediate E can undergo the desired chemical 
transformation. The catalytic turn-over of the formed oxidized ground state photocatalyst 
PC is accomplished by an electron transfer from an intermediate of substrate E or a 
sacrificial electron donor (red). This event closes the catalytical cycle providing the product 
and regenerating the photocatalyst in its ground state PC. In case of a reductive quenching 
cycle, the excited state photocatalyst PC* is reduced by a substrate E to form the radical 
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cation (E) and the reduced form of the photocatalyst (PC). The turnover of the reduced 
photocatalyst PC is accomplished in a similar fashion to the oxidative quenching cycle by an 
electron transfer from an intermediate of substrate E or a sacrificial electron acceptor (ox), 
affording hereby an efficient turn-over of the photocatalyst.[18] 
  
Scheme 1.5 Oxidative and reductive quenching cycles of a photoredox catalyst. 
On the other hand, energy transfer EnT photocatalysts act by transferring energy from 
their excited state form PC* to the respective acceptor substrate E (Scheme 1.6).[20] In this 
case, a bimolecular quenching process in form of energy transfer EnT is rational from the 
triplet excited state T1 owing to the longevity of T1 of the photocatalyst (T  100 ns). After 
the formation of an encounter complex between PC* and  acceptor E in solution, a double 
electron transfer within the formed exciplex, also referred to as Dexter energy transfer, 
takes place.[20, 21] This event excites acceptor E to a higher energy state (E*).[22] Diffusion out 
of the solvent complex releases excited E* and ground-state photocatalyst PC. 
 




1.3 Feasibility of photo-induced electron transfer processes 
In order to achieve the desired reactivity in a photocatalytic reaction, the photophysical 
and electrochemical properties of both photocatalyst and reactants must be chosen 
carefully.[18] First, a suitable light source is determined by comparing the emission spectrum 
of the considered light source and the absorption spectrum of the photocatalyst. An overlap 
of both spectra is essential to ensure an excitation of the photocatalyst PC. As for the 
photoredox ability of potential photocatalysts, the electrochemical data of both 
photocatalyst excited- and ground state as well as of reactant E are considered. 
The feasibility of photo-catalyzed transformations depends on the electrochemical 
potentials of the involved reactants. The reduction potential of the excited state 
photocatalyst PC* can be calculated using two methods. The first method relies on the 
comparison of excited-state electron transfer rates to molecules with known ground-state 
redox potentials.[23] The second method, being the most utilized, is an estimation of the 
redox potentials of PC* using the equations (Scheme 1.7, Eq. 2 in case of oxidation of PC*, 
Eq. 3 in case of reduction of PC*) derived from the general equation of the Gibbs energy of 
photoinduced electron transfer (Scheme 1.7, Eq. 1) after the omission of the electrostatic 
work term .[18, 24] 
 
Scheme 1.7 Electrochemical processes and redox potential equations of a photoredox catalyst. 
The excited state energy (E0,0) of the photocatalyst PC, which is needed for the calculation 
of the corresponding redox potentials, can be approximated spectroscopically (Scheme 1.8). 
An estimation of E0,0 is possible by identifying the photon energy of the wavelength at the 
crossing point between the absorption and emission spectra of a given species (Scheme 1.8, 
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entry A), which is a good approximation of the energy difference between the lowest 
vibrational level of ground state S0 and the excited state Sn or Tn. In addition, in case of 
absence of the UV-vis spectra electronic transitions, E0,0 can be determined by considering 
the long wavelength from the tail of the corresponding absorption spectrum (Scheme 1.8, 
entry B).[25] Excited state energy E0,0 values in eV can be obtained readily by employing the 
equation for photon energy (Scheme 1.8, Eq. 1). Furthermore, ground state redox potentials 
of the employed photocatalyst PC, essential for the calculation of the redox potentials of the 
excited state species, are accessible by cyclic voltammetry measurements.[26]  
 
Scheme 1.8 Spectroscopical determination and calculation of the excited state energy (E0,0). 
Having the electrochemical potentials of ground- and excited state PC in hand in addition 
to the corresponding redox values of a reactant E, the thermodynamic feasibility of a light-
driven reaction can be assessed. 
In case the oxidation of a reactant E is desired during a photocatalytic reaction, the 
reduction potential (    
 ) of the excited-state photocatalyst PC* must be more positive 
compared to the oxidation potential (Eox) of reactant E (    
      ) (Scheme 1.9, right side). 
Likewise, if the reduction of reactant E is to be feasible, the excited state oxidation potential 
(   
 ) of photocatalyst PC* must be greater negative than the reduction potential (Ered) of 
reactant E     




Scheme 1.9 Thermodynamic feasibility of electron transfer during a photocatalytic reaction. 
1.4 Pyrimidopteridine N-oxides as photoredox catalysts 
During the last century, a significant number of organic dyes and transition metal 
complexes, with various electrochemical properties, were developed and used as powerful 
redox- and energy transfer photocatalysts (Scheme 1.10).[27-30] Notable examples of 
transition metal photocatalysts include polypyridyl iridium, ruthenium and copper 
complexes.[31, 32] As for organo- photocatalysts, acridinium-, xanthene- and benzophenone-
based photocatalysts represent some of the most famous and well-investigated examples in 
the field of visible-light photocatalysis.[18, 27, 33] 
 
Scheme 1.10 Examples of transition-metal-based and organo-photocatalysts and their redox potentials.
[18, 31]
 
These tailored photocatalysts cover a wide range of redox potentials that facilitate 
photomediated electron transfer (PET) processes in addition to energy- and atom transfer 
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during a photomediated transformation.[18] For example, Eosin y (Scheme 1.10) with an 
excited state oxidation potential of Eo 
   1.15 V vs. SCE in MeOH is a potent reducing 
photocatalyst with an average oxidation potential.[18] On the other hand, 9-mesityl-10-
methylacridinium (Mes-Acr-Me+) (Scheme 1.10) possesses a high oxidizing ability in its 
excited state (Ere 
   2.08 V vs. SCE in MeCN) and is therefore a good oxidant during PET 
events. In addition, photocatalysts like tris(bipyridine)ruthenium (II) Ru(bp   
   are able to 
engage in energy transfer- as well as PET events.  
Beside previously mentioned synthesized photocatalysts, natural analogs exhibit also 
outstanding chemical reactivities as photocatalysts. Among prominent examples, riboflavin 
also know as vitamin B2, acts as a photocatalyst during the contra-thermodynamic (E→Z) 
isomerization of retinal, a polyene chromophore indispensable for the mammalian visual 
cycle (Scheme 1.11).[34, 35] 
 
Scheme 1.11 Mammalian visual cycle via (E→Z) isomerization of retinal with riboflavin. 
In the early 1970s, Maki et al. primarily reported the synthesis of n-butyl 
pyrimidopteridine N-oxide (1.1).[36] Pyrimidopteridine N-oxides (PPTNO) are heterocyclic 
molecules that are structurally related to pterins and flavins, two heterocycles known as 
cofactors in cytochrome-P450-enzymes and to participate in redox reactions 
(Scheme 1.12).[26, 37, 38]  
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Scheme 1.12 PPTNO structural similarity to flavin and pterin core structures and corresponding redox 
activity. 
Later, Maki and co-workers described the synthetic application of n-butyl 
pyrimidopteridine N-oxide (1.1) as a stoichiometric photochemical reagent in a variety of 
oxidative transformations. The photochemical hydroxylation of a large excess of benzene 
derivatives was accessible via an oxygen atom transfer from 1.1 (Scheme 1.13).[28, 29]  
 
Scheme 1.13 Photochemical hydroxylation of benzene derivatives using N-oxide derivative 1.1.
[28]
  
In addition, photolysis of tryptophan-derivatives in the presence of stoichiometric 
amounts of 1.1 and catalytic amounts of acid resulted in an oxidative CC bond cleavage of 
tryptophan derivatives, generating 3-indolcarboxaldehydes and the corresponding glycine-
derivatives (Scheme 1.14).[39]  
 
 Scheme 1.14 Photocatalytic CC bond cleavage of tryptophan derivatives using N-oxide derivative 1.1.
[40]
 
In later reports, Maki et al. reported an oxidative decarboxylation protocol of phenyl 
acetic acid derivatives in the presence of stoichiometric amounts of n-butyl substituted 1.1.   
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This methodology allowed the generation of benzaldehyde derivatives under UV-/visible-
light via a singlet-excited state (Scheme 1.15).[40, 41]  
 
Scheme 1.15 Photocatalytic oxidative decarboxylation of phenylacetic acid derivatives using (1.1).
[41]
 
Yet, since the early reports of Maki et al., no additional analysis of pyrimidopteridine N-
oxide derivatives regarding their photoredox activity and applicability as photoredox 
catalysts was conducted.  
Lately, differently substituted pyrimidopteridine N-oxide derivatives (1.1-1.4) and their 
deoxygenated analogs (1.5-1.8) were synthesized and characterized by the Pospech 
group.[38] The corresponding photo- and electrochemical data are showcased in Table 1.1. 
The absorption maximum of the synthesized derivatives lies within the range of   a 
a s  
 359-371 nm, rendering them suitable to UV-A/visible-light excitation. No significant 
difference in the excited state redox potentials of the synthesized N-oxide derivatives (1.1-
1.4) was observed. Also, the effect of different substitution on the excited state redox 
potentials of the deoxygenated derivatives (1.1a-1.4a) is minimal, accounting up to a 
difference of 0.04 V for the excited state reduction potentials and 0.58 V for the excited 
state oxidation potentials. Calculated excited state reduction potentials of pyrimidopteridine 
N-oxide derivatives vary between (Ere 
   2.30(2.33) V vs. SCE in MeCN), which implies a 
strong oxidative ability capable of substracting an electron from a wide range of organic 
molecules.[26] Furthermore, the low lying ground state reduction potential of newly 
synthesized photocatalysts (E   
re  = 0.91(0.95) V vs. SCE in MeCN) enables a smooth and 
facile turnover of the reduced photocatalyst. In the following two chapters, the suitability of 






Table 1.1 Photophysical and electrochemical data of PPTNO derivatives (1.1-1.4) and the corresponding 
deoxygenated analogues (1.1a-1.4a).  
 
Compound 
    












     
   
 [V]
[b]













1.1 371 3.25 −0.92 2.47 +2.33 −0.78 
1.1a 363 3.31 −1.59 1.82 +1.72 −1.49 
1.2 370 3.25 −0.95 2.42 +2.30 −0.83 
1.2a 363 3.31 −1.59 1.80 +1.72 −1.51 
1.3 368 3.24 −0.91 2.42 +2.33 −0.82 
1.3a 361 3.31 −1.58 1.82 +1.73 −1.49 
1.4 366 3.25 −0.93 2.33 +2.32 −0.92 
1.4a 359 3.30 −1.54 1.87 +1.76 −1.43 
[a]values corresponding to the energy at the intersection of the excitation and emission spectra. [b]Potentials were measured using 
cyclicvoltammetry (CV) and differential pulse voltammetry (DPV) relative to Fc+/Fc; deoxygenated compounds (1.1a-1.4a) were measured 
by Tobias Täufer; referenced to SCE by adding 0.42 V to the value relative to Fc+/Fc.[26] [c] Calculated by     
       
        
   . [d] Calculated by 
   
       
        
  . 
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2 Pyrimidopteridine N-oxide photo-mediated decarboxylative 
Giese-type addition 
2.1 Introduction 
Carboxylic acids and their derivatives have long served as a multifaceted feedstock to 
construct valuable carbon frameworks.[42] Advantages like low cost, wide availability and 
noticeable bench stability turned them into ideal substrates.[43, 44] The carboxyl group, as 
such, can be used as a regioselective traceless leaving group via extrusion of carbon dioxide 
(CO2) which readily evaporates from the reaction mixture. The radical nature of this 
transformation allows the construction of a multitude of carboncarbon or 
carbonheteroatom bonds.[45] Nevertheless, the decarboxylation of carboxylic acids requires 
often rather harsh and forcing conditions (e.g. high temperatures, high-energy UV light, 
stoichiometric amounts of oxidants and/or strong acids/bases) which impedes late stage 
functionalization of labile carboxylic acid frameworks and limits its use.[46] 
Initial decarboxylation reactions were reported by Hunsdiecker and Kochi furnishing 
haloalkanes from alkane carboxylic acids (Scheme 2.1).[47, 48] Carboxylate silver salts or strong 
oxidizing agents like lead(IV) acetate in addition to a halide source were essential to promote 
the oxidative radical decarboxylation. Later on, Barton et al. disclosed a novel reductive 
decarboxylation methodology through the activation of the carboxylic acid moiety from 
thiohydroxamate esters.[48] Heating the esters in the presence of azobisisobutyronitrile 
(AIBN) as a radical initiator and tributyltin hydride (n-Bu3SnH) as a hydrogen-atom donor 
afforded the protodecarboxylated product. Successive efforts from Hasebe and Tsuchiya led 
to a photomediated variant of the reductive decarboxylation by employing oxime esters as 
activated carboxylic acids.[49] A similar strategy adopted by Okada et al. unveiled a robust 
visible-light mediated reductive decarboxylation of N-acyloxy phthalimides (NHPI-esters), 
which tolerates aqueous solvents in contrast to prior methods.[50, 51] NHPI-esters, regarded 
as redox-active-esters (RAE) capable of engaging in single electron transfer reactions and 




Scheme 2.1. Evolution of oxidative and reductive decarboxylation methods over time.
[47-51] 
Since the middle of the last century, tremendous development has been made in the field 
of decarboxylative coupling. Especially, transition-metal catalyzed methodologies using 
palladium and copper reagents, were intensively reported.[45, 52, 53] Yet, given the progress of 
visible-light induced photochemical transformations in the last years and the efforts to 
depict more environmentally-friendly methodologies, photocatalytic decarboxylation 
variants emerged as a key pathway to forge new CC and Cheteroatom bonds.[54] For 
example, differently hybridized CC frameworks are accessible, using a broad range of 
radical acceptors such as alkyne-, aryl-, alkenyl- and alkyl substructures.[55-58] 
Within this framework, one possibility to generate C(sp3)C(sp3) bonds is the trapping of a 
nucleophilic neutral carbon centered radicals with electron-deficient olefins, also referred to 
as Giese-type reaction.[59, 60] The seminal report described by B. Giese discloses the 
formation of alkyl carbon-centered radicals by a radical chain reaction of alkyl mercury salts 
and sodiumborohydride (NaBH4), followed by a subsequent 1,4-addition to an electron-
deficient unsaturated alkene (Scheme 2.2). A hydrogen atom transfer to the formed radical 
intermediate gave access to the alkylated products.[61] 
 





A photocatalyzed decarboxylative variant of the Giese-addition to olefins starting from 
carboxylic acids would eliminate the initial usage of stoichiometric heavy metal salts and 
provide a reaction conducted under mild conditions. Accordingly, this alternative would 
offer a more environmentally benign option for the alkylation of olefins using alkyl carboxylic 
acids. In order to generate carbon-centered radicals by a photocatalyzed decarboxylation 
means, two conceivable approaches are possible.  
Carboxylic acids, as such, possess high oxidation potentials (Eox ≈ 2.0 V vs. SCE in MeCN) 
and are therefore challenging to oxidize.[26] Hence, an activation of the carboxyl moiety is 
essential to render the decarboxylation thermodynamically feasible. One way to activate the 
carboxylic acid is via a base-promoted deprotonation to the corresponding carboxylate, 
which decreases its oxidation potential (e.g. Boc-Pro-O-; Eox  0.95 V vs. SCE in MeCN) and 
facilitates electron transfer.[26, 62] Another method of activation is by the formation of redox-
active esters (RAE), resulting in a more positive reduction potential 
(Boc-Pro-O-NPhth; Ered  1.20 V vs. SCE in MeCN); ergo, a higher tendency to gain an 
electron and engage in an oxidative quenching of the photocatalyst. The choice of activation 
mode depends strongly on the reaction conditions and the electrochemical properties of 
utilized photocatalysts. 
Therefore, two different reaction mechanisms are possible (Scheme 2.3). The first 
mechanism requires a preactivation of the carboxylic acid moiety as a RAE (Scheme 2.3, 
entry A). First, the irradiation of a photoredox catalyst PC using an appropriate light source 
(h) generates the excited state photocatalyst PC*. An added sacrificial electron donor 
additive (RedH) quenches the excited photocatalyst PC* in a SET fashion. Hereby, the 
reduced form of the photocatalyst PC and the oxidized form of (RedH) are formed. Next, 
the photocatalyst PC is regenerated from the reduced form PC by an SET to the 
N-hydroxyphthalimide-ester 2.1. Subsequently, cleavage of the NO bond of radical anion 
2.2 followed by a rapid decarboxylation leads to the formation of carbon dioxide, 
phthalimidyl anion and the corresponding carbon-centered radical 2.3. The nucleophilic 
neutral radical 2.3 attacks the electron-deficient olefin 2.4 generating radical intermediate 
2.5 which, upon hydrogen atom abstraction from radical cation RedH, furnishes desired 
alkylated product 2.6. On the other hand, the second mechanism (Scheme 2.3, entry B) 
proceeds directly from the carboxylate form 2.1a of the corresponding carboxylic acid 
without the need for a preactivation as a RAE. The addition of a base to shift the equilibrium 
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to the side of the conjugate base of the corresponding carboxylic acid, in this case the 
carboxylate, is beneficial. Upon the generation of excited state photocatalyst PC* from PC, a 
direct SET from carboxylate 2.1a to the excited photocatalyst PC* takes place. Quick 
decarboxylation of the generated carboxylate radical cation furnishes carbon-centered 
radical intermediate 2.3 and the reduced form of the photocatalyst PC. Following 
nucleophilic attack of radical intermediate 2.3 towards olefin 2.4 provides intermediary 
radical species 2.5. Next, quenching of the radical intermediate 2.5 by an SET from the 
reduced photocatalyst PC and subsequent protonation delivers product 2.6. 
Scheme 2.3. General mechanism of (A) redox-active ester- and (B) base-promoted photocatalyzed 
decarboxylative Giese-addition to electron-deficient olefins. 
Seminal reports of a metal-free photocatalyzed decarboxylative radical addition to an 
electron-deficient alkene was first reported by Yoshimi et. al (Scheme 2.4).[63] Catalytic 
amounts of phenanthrene and 1,4-dicyanonaphthalene as an electron-acceptor were 
sufficient to induce the formation of alkyl radicals via PET and subsequent decarboxylation 
when irradiated with a 400 W high-energy mercury lamp. 
 






After a while, a transition-metal photocatalyzed decarboxylative Giese-type reaction was 
described by MacMillan and co-workers in 2014 (Scheme 2.5).[64] 




An iridium photoredox catalyst, in this case Ir[dF(CF3)ppy]2(dtbbpy)
+ (2.7) 
(    
       
  1.21 V vs. SCE in MeCN) proved to be suitable for the decarboxylation and 
subsequent addition of a wide variety of acyclic and cyclic alkyl- and heteroatom 
carboxylic acids to different Michael-acceptors. 
A racemic synthesis of pregabalin, an anticonvulsant drug, was demonstrated through a 
three-step synthesis starting from NBoc protected glycine and an electron-deficient 
Michael-acceptor (Scheme 2.5). 
Two years later, König and Schwarz reported a metal-free, photocatalytic reductive 
decarboxylative protocol for the alkylation of preactivated carboxylic acids (Scheme 2.6).[65] 
This transformation was accessible using Eosin Y (2.8) (  (Eosin Y*/Eosin    ) 0.83 V vs. 
SCE in MeCN:H2O 1:1) as a photoredox catalyst. An activation of the carboxyl moiety as a 
redox-active ester as well as the presence of super-stoichiometric amounts of a sacrificial 
reductant were indispensable for the reaction to take place. 
 
Scheme 2.6 Metal-free, photocatalytic decarboxylative alkylation of pre-activated carboxylic acids.
[65]
 
Also, Gonzalez-Gomez and co-worker showcased in 2017 a metal-free oxidative 
photocatalytic methodology using [Mes-Acr]+ as a photocatalyst (Scheme 2.7).[66] The 
alkylation of electron-deficient alkenes was possible while using non-activated carboxylic 
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acids and catalytic base amounts. Yet, two different reaction systems were employed for the 
screening of electron-deficient alkenes and carboxylic acids. Solvent variation as well as 
different reactant loadings and prolonged reaction times (up to 96 hours), along with 
repeated addition of both photocatalyst and base limit the applicability of this protocol. 
 




The formation of new CC bonds plays a pivotal role in organic chemistry. Especially, 
decarboxylative transformations present a versatile methodology for the construction of 
complex organic motifs. 
Inspired by the precedent work of our group, we surmised that pyrimidopteridine N-oxide 
derivatives 1.1-1.4 and their deoxygenated analogues 1.1a-1.4a would operate efficiently in 
a photocatalytic decarboxylative Giese-type addition to electron-deficient alkenes. This 
protocol would offer an atom-economical and inexpensive methodology for the alkylation of 
different electron-deficient olefins using widely abundant carboxylic acids (Scheme 2.8). 
Advantages like the high atom economy of this transformation, translated by the lack of 
stoichiometric waste products, as well as the metal-free nature would offer a more 
environmentally friendly method as compared to previous reports. In addition, the synthetic 
applicability is probed by using pharmaceutical- and complex natural product-derived 
carboxylic acids as substrates. Furthermore, attempts to lower the loading of needed base 
are envisioned. 
 




2.3 Results and discussion 
2.3.1 Optimization of the reaction conditions 
To evaluate pyrimidopteridine N-oxides 1.1-1.4 and their deoxygenated analogues 
1.1a-1.4a as photoredox catalysts in the decarboxylative Giese-type reaction, control 
experiments were carried out using a model reaction (Scheme 2.9). This reaction consisted 
of boc-L-proline (2.1a) as the carboxylic acid component, dimethyl maleate (2.4a) as the 
electron-deficient alkene and equimolar amounts of tripotassium phosphate. Catalytic 
amounts (5.0 mol%) of n-propyl derivative 1.2 was used as a photocatalyst. The reaction was 
conducted in a 9:1 mixture of MeCN:H2O and irradiated with UV-light (396 nm) for 16 hours. 
Scheme 2.9 Model reaction of the PPTNO photoredox catalyzed decarboxylative Giese reaction. 
The desired product 2.6aa was obtained in a very good yield of 88% with no modification 
of standard conditions (Table 2.1, entry 1). To varify the photocatalytic nature of this 
reaction, various alterations from standard conditions were applied (Table 2.1). In the 
absence of photocatalyst 1.2 or UV-light, no product formation was observed (Table 2.1, 
entries 2 and 3). Furthermore, the removal of the base from the reaction mixture yielded 
only 10% of product 2.6aa (Table 2.1, entry 4). This is attributed to the slightly shifted acid-
base equilibrium towards the corresponding carboxylate form due to the basicity of the 
catalyst 1.2. 
Table 2.1 Control experiments of the photocatalyzed decarboxylative Giese-reaction. 
 
Entry Alteration from standard conditions Yield[a,b] 
1 none 96% (88%) 
2 without photocatalyst (1.2) n.d. 
3 In the dark/ without light n.d. 
4 without base 10% 
[a]





Next, optimization of the reaction conditions was conducted by modification of solvent, 
photocatalyst and catalyst loading. Also, different bases and the amount of base as well as 
the molarity of the reaction were examined. First, differently substituted pyrimidopteridine 
N-oxides 1.1-1.4 and their deoxygenated analogues 1.1a-1.4a were screened employing 
standard reaction conditions (Table 2.2). Propyl- and butyl-substituted PPTNO derivatives 
(1.1 and 1.2) furnished the product 2.6aa in very good yields up to 88% isolated yield 
(Table 2.2, entry 1 and 3). Methyl- and phenyl-PPTNO's (1.3 and 1.4) delivered the desired 
product 2.6aa in moderate yields of 49% and 38%, respectively (Table 2.2, entries 5 and 7). 
Despite similar electrochemical properties of 1.3 and 1.4 in comparison to other PPTNO- 
derivatives (1.1 and 1.2), low solubility of 1.3 and 1.4 in addition to the susceptibility of 
phenyl derivative 1.4 to decompose could be responsible for the diminished yields of desired 
product 2.6aa. The utilization of deoxygenated PPT-derivatives 1.1a-1.4a furnished 
consistently a yield improvement of up to 7% in comparison to the N-oxide analogues 
1.1-1.4 (Table 2.2; entries 2,4,6 and 8). The deoxygenated n-propyl PPTN 1.1a provided 
product 2.6aa in quantitative GC- as well as isolated yield (Table 2.2, entry 2). This indicates 
most likely that the N-oxide derivatives 1.1-1.4 operate as pre-catalysts, revealing their 
catalytical activity shortly after deoxygenation. 
Table 2.2 Photocatalyst screening of PPTNO (1.1-1.4) and PPT derivatives (1.1a-1.4a). 
. 
Entry Photocatalyst Yield[a,b] 
1 PrPPTNO (1.2) 96% (88%) 
2 PrPPTN (1.2a) >99% (>99%) 
3 BuPPTNO (1.1) 96% (87%) 
4 BuPPTN (1.1a) 98% (91%) 
5 MePPTNO (1.3) 49%  
6 MePPTN (1.3a) 56%  
7 PhPPTNO (1.4) 38%  
8 PhPPTN (1.4a) 43%  
[a]
 Yields were determined by GC using biphenyl as internal standard.
 [b]
 Yields in parentheses represent isolated yields. 
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Next, the results of different catalyst loadings of the n-propyl photocatalyst 1.2 and the 
corresponding deoxygenated analogue 1.2a were explored (Table 2.3).  
Table 2.3 Catalyst-loading screening of n-propyl PPTNO (1.2) and n-propyl PPTN (1.2a). 
 
Entry Photocatalyst Catalyst loading Yield[a] 
1 PrPPTNO (1.2) 5.0 mol% 96% 
2 PrPPTN  (1.2a) 5.0 mol% >99% 
3 PrPPTNO (1.2) 2.5 mol% 58% 
4 PrPPTN  (1.2a) 2.5 mol% 72% 
5 PrPPTNO (1.2) 1.0 mol% 41% 
6 PrPPTN (1.2a) 1.0 mol% 41% 
7 PrPPTNO (1.2) 0.5 mol% 18% 
8 PrPPTN (1.2a) 0.5 mol% 28% 
[a]
 Yields were determined by GC using biphenyl as internal standard. 
Unfortunately, lowering the catalyst loading of 1.2 and 1.2a below 5.0 mol% led to a 
decline in product formation (Table 2.3, entries 3-8) in comparison to a 5.0 mol% loading of 
1.2 and 1.2a (Table 2.3, entries 1 and 2). Furthermore, deoxygenated n-propyl analog 1.2a 
delivered in most cases a better yield than the corresponding N-oxide derivatives, in 
exception of the reaction with 1.0 mol% catalyst loading of 1.2 and 1.2a (Table 2.3, entries 5 
and 6). 
Subsequently, different polar protic- and aprotic solvents were screened using 
photocatalyst 1.2 (Table 2.4). Moderate to good yields of product 2.6aa (40-73%) were 
obtained using polar aprotic solvents like MeCN, DCM, acetone, THF or DCE (Table 2.4, 
entries 3-6). A low Coulombic barrier for charge separation of the radical ion pair 
intermediates in MeCN compared to other polar aprotic solvents allows an effective 
diffusive separation.[67] In this context, productive competition to back electron transfer, 





A superior yield of 96% GC-yield of 2.6aa was obtained when a 9:1 ratio of MeCN:H2O was 
used (Table 2.4, entry 1). The enhanced solubility of the generated carboxylate salts in a 
MeCN:H2O mixture over pure MeCN could explain the improved yield. Nonetheless, further 
increase of amount of H2O with respect to acetonitrile impaired the product formation 
(Table 2.4, entry 2) indicating a delicate balance between the solubility of organic 
components 2.1a, 2.4a and photocatalyst 1.2 as well as the inorganic base. 
On the other hand, running the reaction in polar protic solvents (e.g. iPrOH, H2O, HFIP or 
DMSO) attenuated the generation of 2.6aa (Table 2.4, entries 7-11). Strongly diminished 
yields of product 2.6aa could be attributed to competing side reactions of the formed 
neutral radicals with the protic solvent. Hydrogen atom abstraction and/or enhanced 
solvating and stabilizing properties of radical intermediates by the solvation shell could 
negatively influence the reactivity of intermediate radicals.[68] 
Table 2.4 Solvent screening of the PPTNO-catalyzed decarboxylative Giese-addition. 
 
Entry Solvent Yield[a] 
1 MeCN:H2O (9:1) 96% (88%) 
2 MeCN:H2O (7:3) 73%  
3 MeCN 73%  
4 DCM 61%  
5 Acetone 58%  
6 DCE 40%  
7 iPrOH 17%  
8 THF 12%  
9 H2O 8%  
10 HFIP 8%  
11 DMSO 1%  
[a]
 Yields were determined by GC using biphenyl as internal standard. Yields in parentheses represent isolated yields. 
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Following, the effect of the molarity was investigated (Table 2.5). The highest yield of 96% 
GC- and 88% isolated yield of 2.6aa was obtained when running the reaction in a molar 
concentration of 0.1 M with respect to the used carboxylic acid (Table 2.5, entry 2). 
Increasing the reaction concentration would automatically lead to a gain in the absorbance 
(extinction) of the reaction solution at a given wavelength.[69] Thus, the employed light will 
be more strongly absorbed as compared to lower concentrations. An increase in the molarity 
up to 0.2 M resulted in a decrease in the yield of 2.6aa to 50% (Table 2.5, entries 3 and 4). 
On the other hand, reducing the molar concentration down to 0.05 M resulted in a lower 
impact on the yield of 2.6aa (Table 2.5, entry 1). A lower concentration of the radical 
scavenger, in this case the electron-deficient alkene 2.4a, could be the reason for the slightly 
declined yield. 
Table 2.5 Molarity effect on the decarboxylative Giese-type addition. 
 
Entry Molarity Yield[a] 
1 0.05 M 83%  
2 0.10 M 96%  
3 0.15 M 69%  
4 0.20 M 50%  
[a]
 Yields were determined by GC using biphenyl as internal standard. 
In the next step, a variety of organic- and inorganic bases were tested (Table 2.6). 
Equimolar amounts of inorganic bases including phosphates and carbonates (Table 2.6, 
entries 1-9) delivered 2.6aa in good to very good isolated yields, accounting up to 88% after 
16 hours. The yield fluctuation of 2.6aa between tested inorganic bases could have its origin 
in the different solubility and basicity of the tested bases in acetonitrile. The use of tertiary- 
(Table 2.6, entries 10 and 11) and aromatic amines (Table 2.6, entry 12) as organic bases 
decreased the yield of 2.6aa. The high oxidation ability of the deoxygenated n-propyl 
pyrimidopteridine photocatalyst 1.2a in the excited-state (Ere 
   1.72 V vs. SCE in MeCN) 
favors one-electron oxidation of tertiary amines like triethylamine (TEA) (E   
    (TEA)  1.0 V 
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vs. SCE). Hence, intermediary formed ammonium radical cations could impede the course of 
the reaction. Satisfyingly, reducing the amount of base from equimolar to a catalytical 
amount of 20 mol% of tripotassium phosphate did not impair the yield of 2.6aa 
(87% isolated yield) (Table 2.6, entry 13).  
Table 2.6 Base screening of the photomediated decarboxylative Giese-addition. 
 
Entry Base Equivalents of base Yield[a] 
1 K3PO4 1.0 88%  
2 K2HPO4 1.0 64%  
3 K2CO3 1.0 72%  
4 Cs2CO3 1.0 88%  
5 Na2CO3 1.0 83%  
6 NaHCO3 1.0 86%  
7 NaOH 1.0 71%  
8 CsF 1.0 85%  
9 NaOAc 1.0 63%  
10 NEt3 1.0 28%  
11 DIPEA 1.0 34%  
12 pyridine 1.0 35%  
13 K3PO4 0.2 87%  
[a]







2.3.2 Scope of the carboxylic acids in the decarboxylative Giese-type addition 
Based on the optimized conditions for the decarboxylative Giese-addition, the reaction 
scope was explored with a range of different carboxylic acids and electron-deficient alkenes. 
The screening of carboxylic acids was conducted using dimethyl maleate (2.4a) (Table 2.7) 
and diethyl ethylidenemalonate (2.4b) (Table 2.8) as 1,2- and 1,1'-disubstituted electron-
deficient alkenes, respectively. Tertiary hydrocarbon carboxylic acids delivered 
corresponding alkylated products in good to excellent yields (Table 2.7, entry 1 and 
Table 2.8, entries 1-4). Substrates with unprotected hydroxy- and ,- unsaturated carbonyl 
moieties, such as in the case of the triterpenoid carboxylic acid enoxolone 2.1c (Table 2.7, 
entry 2) and the adamantane carboxylic acid derivative bearing a free hydroxy group 2.1k 
(Table 2.8, entry 5), were well tolerated under the reaction conditions. Tertiary carboxylic 
acids bearing - and -heteroatom like in the case of 2.1d (Table 2.7, entry 3) and 
2.1l (Table 2.8, entry 6) resulted in lower yields of 45% and 29% of alkylated products, 
respectively. Hydrolysis of the acetale subunit in 2.6lb could be responsible for the declined 
yield when using carboxylic acid precursor 2.1l in an aqueous solvent mixture. Also, 
destabilization of the generated carbon-centered radical by the inductive effect of the 
electronegative oxygen in the -position may impair the yield of 2.6lb.[70] Substrates 2.1e 
and 2.1f (Table 2.7, entries 4 and 5) bearing a phenol ether substructure exhibit an 
antioxidative effect due to the enhanced resonance stabilization of the phenoxy radical 
(RSE  121 kJ/mol) and could act as an electron scavenger during the reaction.[71, 72] As a 










Table 2.8 Photocatalyzed decarboxylative Giese-addition of tertiary carboxylic acids to diethyl 
ethylidenemalonate (2.4b). 
 
The decarboxylative coupling of pharmaceutical bezafibrate 2.1g resulted in a 
concomitant dehydration yielding the enamide 2.6ga (Table 2.7, entry 6). This side-reaction 
putatively proceeds through an SET induced oxidation of the amid moiety in the desired 
product (Scheme 2.10). The deprotonation of formed amid radical cation could lead to the 
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generation of a neutral amidyl radical species. A fast abstraction of an adjacent hydrogen 
atom and a subsequent rearrangement would generate the enamide 2.6ga with an extended 
-system. 
 
Scheme 2.10 Possible mechanism for the photomediated formation of unsatured product (2.6ga). 
The structure of alkylated product 2.6ba, generated from the reaction of adamantane 
carboxylic acid (2.1b) with dimethyl maleate (2.4a) was confirmed by X-ray analysis 
(Figure 2.1). 
 
Figure 2.1 X-ray crystal structure of alkylated compound (2.6ba) in the solid state. Displacement ellipsoids 
correspond to 30% probability. 
Secondary carboxylic acids furnished products 2.6ma-2.6vb in isolated yields up to 75% 
(Table 2.9, entries 1-10). Dipeptide derivative 2.6ma consisting of L-proline and amide 
protected L-valine was tolerated and obtained in a good yield of 75% (Table 2.9, entry 1). 
Furthermore, N-protected secondary amino acids delivered desired products 2.6na and 
2.6qb in moderate to good yields of 68% and 45%, respectively (Table 2.9, entries 2 and 5). 
Significant interaction of the molecular orbital containing the unpaired electron of the 
Chapter 2 
29 
neutral C-centered radical with the lone-pair of the adjacent heteroatom could explain 
the better yield of generated product 2.6pb (Table 2.9, entry 4). 




Table 2.9 (continued) Scope of secondary carboxylic acids in photocatalyzed decarboxylative Giese-addition. 
 
On the other hand, the decarboxylative Giese-addition of cyclic and acyclic secondary 
hydrocarbon carboxylic acids yielded the desired alkylated products 2.6rb, 2.6sb, and 2.6ub 
in rather lower yields (Table 2.9, entries 6,7, and 9). Also, a lower yield of product 2.6vb was 
obtained, most likely due to enhanced benzylic radical stabilization (Table 2.9, entry 10). In 
the case of 2.1t, a difficult decarboxylation was observed, yielding the desired product 2.6tb 
in 34% isolated yield after 24 hours (Table 2.9, entry 8). 
In contrast, the decarboxylation of primary carboxylic acids was more challenging in 
comparison to secondary and tertiary counterparts (Table 2.10). The strong C(sp3)CO2H 
bond of primary carboxylic acids (e.g. acetic acid, BDE = 93.1 kcal/mol)[73] accentuates the 
extrusion of carbon dioxide. In addition, the stability of C-centered radicals is known to 
decrease with decreasing number of substituents on the carbon-center 
(radical stability = 3 °> 2 °> 1 °).[72] Hence, products 2.6wb and 2.6xb derived from N-Boc-
glycine and 2-(cyclohexyloxy)acetic acid were obtained in low yields of 18% and 21%, 
respectively (Table 2.10, entries 1 and 2). Also, the conversion of the pharmaceutically 
relevant, benzylic secondary carboxylic acid flurbiprofen (2.1y) did not yield any 
decarboxylative CC coupling product (Table 2.10, entry 3). 
Chapter 2 
31 
Table 2.10 Scope and limitations of primary carboxylic acids in photocatalyzed decarboxylative Giese-
addition. 
Both insufficient decarboxylation, which was evident in the course of the reaction, as well as 
the formation of reductive decarboxylation product 2.6yc, impeded the formation of the 
desired product 2.6ya (Scheme 2.11). Thus, protodecarboxylation product 2.6yc was isolated 
in a yield of 17% after 16 hours. Also, rapid decomposition of N-phenyl substituted primary 
amino acid 2.1z was evident. In this case, the formation of desired product 2.6za was almost 
completely supressed (Table 2.10, entry 4). 
 




2.3.3 Scope of electron-deficient olefins in the decarboxylative Giese-type addition 
Subsequently, the scope of electron-deficient alkenes was investigated. Monosubstituted- 
in addition to 1,1'- and 1,2- disubstituted olefins bearing strongly electron-withdrawing 
groups, commonly esters, nitriles, as well as carbonyl- and sulfonyl group-containing alkenes 
were tested (Table 2.11). The reaction of diethyl ethylidenmalonate (2.4b) and carboxylic 
acid 2.1b delivered alkylated product 2.6bb in a excellent yield of 92%. Also, diethyl maleate 
(2.4c) as well as dimethyl maleate (2.4a) participated efficiently in this transformation, 
generating products 2.9c (Table 2.11, entry 1) and 2.6ba (Table 2.7, entry 1) in very good 
yields of 83% and 82%, respectively. Conversely, trans-alkene di-tert-butyl fumarate (2.4d) 
delivered product 2.9d in a moderate yield of 53% (Table 2.11, entry 2). Hence, the 
superiority of cis-isomeres of olefins over trans-analogs became evident. Possible enhanced 
quenching of the excited-state photocatalyst 1.2a* in the presence of (E)-alkene isomers as 
compared to (Z)-analogues might be evident. Cyclic alkylated ketones 2.9e and 2.9f were 
also obtained from their corresponding ,-unsaturated precursors 2.4e and 2.4f in very 
good yields of 89% and 81%, respectively (Table 2.11, entries 3 and 4). Yet, the expansion of 
the cyclic precursors to a seven-membered ring 2.4g impaired the yield of 2.9g (Table 2.11, 
entry 5). The lack of ideal bond angle as well as considerable ring strain putatively reduces 
the stability of the corresponding radical intermediate, leading to a competing ring 
opening.[70] Also, the introduction of an -methyl group in 2.4h furnished product 2.9h in a 
moderate yield of 57% (Table 2.11, entry 6). Next, we investigated the efficiency of 
differently substituted chromone derivatives (2.4i-2.4l). Desired products 2.9i-2.9l were 
obtained in yields varying between 29-55% (Table 2.11, entries 7-10). A visible trend in yield 
was observed depending on the electronegativity of the halogen substituent at the 4-
position of chromones. 2.4j furnished product 2.9j in a diminished yield of 29% with fluorine 
being the substituent with the highest electronegativity[74], whereas bromo derivative 2.4l 
gave access to 2.9l in a moderate yield of 55%. Phenyl vinyl sulfone 2.4m proved to be 
compatible with the reaction conditions. Corresponding product 2.9m was obtained in a 
synthetically useful yield of 69% (Table 2.11, entry 11). Diverse acrylates as well as acyclic 
,-unsaturated aldehyde (2.4n-2.4r) delivered the corresponding alkylated products 2.9n-
2.9r in rather lower yields (26-40%) (Table 2.11, entries 12-16). Radical polymerization of 
acrylate monomeres is feasible under the employed reaction conditions. Thus, the 
concentration of available acrylate in solution would be considerably decreased. 
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2.3.4 Derivatization of synthesized products and scale-up 
To demonstrate the synthetic utility of products formed from the photo-mediated 
decarboxylative coupling, different derivatization reactions were conducted. Synthesized 
1,2-diester 2.6ba was readily reduced with lithium aluminium hydride in THF to the 
corresponding diole 2.10 in 93% yield after 23 hours (Scheme 2.12).  
 
Scheme 2.12 Reduction of 1,2-diester (2.6ba) to the corresponding primary diole (2.10) with LiAlH4. 
Moreover, a concerted alkylation and lactonization of 2.6ba with methyl magnesium 
bromide in THF furnished the 5,5'-disubstituted lactone 2.11 in a very good yield of 87% 
after 24 hours (Scheme 2.13). 
 
Scheme 2.13 Concerted dialkylation and lactonization of 1,2-diester (2.6ba) with methyl magnesium 
bromide. 
Also, tri-substituted barbiturate 2.12, a class of compounds with high pharmaceutical 
value, was directly obtained from 1,1'- diester 2.6bb and N,N'-dimethyl urea under reflux 
conditions in EtOH via a dual alkoxid-base-promoted amidation (Scheme 2.14).[75]  
 
Scheme 2.14 Base-promoted direct synthesis of barbiturate derivative (2.12) from 1,1'-diester (2.6bb).
[75]
 
In addition, a six-fold scale up of the photo-mediated coupling using 1-
adamantanecarboxylic acid (2.1b) and dimethyl maleate (2.4a) was performed. The 
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corresponding alkylated product 2.6ba was obtained in 45% isolated yield after irradiation 
for 24 hours (Scheme 2.15). 
 
Scheme 2.15 Scale-up of the photo-mediated decarboxylative coupling of (2.1b) and dimethyl maleate (2.4a). 
The decline in the yield of 2.6h from 92% in a small-scale reaction (Table 2.7, entry 1) to 
45% is probably attributed to the change of the reaction vessel. The big scale reaction was 
conducted in a round bottom Schlenk flask (FengTecEx® F53 250 mL schlenk flask) rather 
than a microwave reaction vessel (Biotage® 5 mL microwave reaction vessels). Both reaction 
vessels possess different diameters at the widest point. According to the Beer-Lambert law, 
the penetration of electromagnetic waves is known to decrease with increasing path length 
through a given medium.[76] Thus, enhanced excitation of the photocatalyst molecules closer 
to the surface of the reaction vessel in contrast to molecules located in the center of the 
reaction solution is conceivable. A possible route to solve this hurdle is by applying flow 
techniques, which possess a more efficient surface-to-volume ratio. 
2.3.5 Mechanistic considerations 
To gain a better insight into the reaction, multiple mechanistic experiments targeting the 
key steps of the pyrimidopteridine-N-oxide photocatalyzed decarboxylative Giese-type 
addition were conducted. First, quenching of the reaction of carboxylic acid 2.1b and 
electron-deficient alkene 2.4b with 2,2,6,6-Tetramethylpiperidin-1-yl)oxyl (TEMPO) was 
investigated (Scheme 2.16). The formation of the corresponding product 2.6bb was 
completely inhibited. Furthermore, the radical adduct 2.13 consisting of decarboxylated 2.1b 
and TEMPO was detected by LC-MS, confirming a decarboxylative radical mechanism 





Scheme 2.16 TEMPO radical quenching experiment of the reaction of (2.1b) with (2.4b). 
Subsequently, deuterium incorporation experiments were evaluated (Scheme 2.17). The 
reaction of carboxylic acid 2.1b with 2.4b was conducted in two different deuterated solvent 
mixtures. The usage of a MeCN:D2O (9:1) mixture revealed a high deuterium content (93% D) 
in the corresponding product 2.6bb, whereas the utilization of a D3CN:H2O (9:1) mixture 
furnished the desired product 2.6bb with a minimal deuterium incorporation (4% D) (see 
experimental section to chapter 2 for further details and spectra). Hence, this indicates that 
the protonation step of the anionic form of product 2.6bb happens solely from H2O with no 
hydrogen atom transfer from MeCN. 
 
Scheme 2.17 Deuterium incorporation experiments. 
Since the overlap of the absorption spectrum of PrPPTN (1.2b) and the emission spectrum 
of the used lamp is minimal, the formation of a possible red-shifted electron-donor-acceptor 
(EDA) complex between the carboxylic acids and the deoxygenated propyl derivative 
photocatalyst PrPPTN (1.2b) was probed (Scheme 2.18). Therefore, stoichiometric excess 
amounts (20, 50, 100, and 500 equivalents) of acetic acid and strong acidic trifluoro acetic 




Scheme 2.18 Possible formation of EDA-complex between carboxylic acids and deoxygenated PrPPTN (1.2a). 
 The UV-absorption of the corresponding solutions was measured and compared 
(Figure 2.2). 

























 PrPPTN (1.2a) + 20 equiv. CH3CO2H
 PrPPTN (1.2a) + 50 equiv. CH3CO2H
 PrPPTN (1.2a) + 100 equiv. CH3CO2H
 PrPPTN (1.2a) + 500 equiv. CH3CO2H

























 PrPPTN (1.2a) + 20 equiv. CF3CO2H
 PrPPTN (1.2a) + 50 equiv. CF3CO2H
 PrPPTN (1.2a) + 100 equiv. CF3CO2H
 PrPPTN (1.2a) + 500 equiv. CF3CO2H
 
Figure 2.2 UV-absorption spectra of PrPPTN (1.2a) after addition of excess amounts of acetic acid (top) and 
trifluoroacetic acid (bottom). 
No bathochromic shift of spectral band position, which can result from the formation of 
an EDA complex, was observed. Furthermore, the formation of a colored solution from a 
colorless PrPPTN (1.2a) solution, typical for EDA-complexes, was absent. 
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Based on the conducted control experiments and the preceding work of our group, a 
plausible reaction mechanism is proposed in (Scheme 2.19). Propyl pyrimidopteridine N-
oxide (1.2) most likely acts as a pre-catalyst. Rapid deoxygenation during the initial reaction 
time delivers the active form of the photocatalyst 1.2a. The deoxygenation of 1.2 occurs 
most likely via the generation of hydroxyl radical upon photolysis.[77] The photoexcitation of 
1.2a gives access to the highly oxidative excited-state photocatalyst 1.2a* 
(    
  (1.2a)1.72 V vs. SCE in MeCN).[38] Single-electron oxidation of the carboxylate form 
int-1 (e.g. Boc-Pro-O , (    
    0.95 V vs. SCE in MeCN)[64], generated after deprotonation 
of 2.1, provides radical intermediate int-2 after CO2 extrusion. Subsequent addition of 
neutral radical intermediate int-2 across an electron-deficient olefin 2.4 furnishes -acyl 
radical intermediate int-3 (potential of alkyl radicals are in the range of     
    = 0.6 - (0.8) V 
vs. SCE in MeCN).[78] The turnover of the reduced form of the photocatalyst 1.2a 
(    
    1.59 V vs. SCE in MeCN) is feasible through an single-electron transfer from 1.2a 
to int-3, thus regenerating the ground-state photocatalyst 1.2a. Eventually, protonation of 
the anionic form of the product int-3 regenerates the base and delivers the desired product 
2.6. 
 





In conclusion, a metal-free oxidative variant of a photocatalytic decarboxylative Giese-type 
addition to electron-deficient olefins was developed using pyrimdopteridine N-oxides and 
their deoxygenated analogues as organo-photocatalysts (Scheme 2.20). A variety of primary, 
secondary, and tertiary carboxylic acids including amino acids and natural products as well as 
various electron-deficient olefins were suitable for this transformation. Also, the utilization 
of catalytic amounts of base proved to deliver comparable yields. In addition, good 
functional group tolerance, including halides, unprotected alcohols and ,-unsaturated 
ketone moieties were showcased. Mechanistic experiments confirmed the presence of a 
C-centered radical as a key intermediate. Furthermore, derivatization reactions of the 
synthesized products and a scale-up reaction were demonstrated. 
 




3 Pyrimidopteridine N-oxide photo-mediated hydroamination of 
unactivated stilbenes 
3.1 Introduction 
Alkyl amines are a substantial class of chemical compounds that are widely encountered in 
synthetic pharmaceuticals and natural products.[79-81] Some of the advantages present in 
broad classes of nitrogen-containing drugs (Scheme 3.1) such as the improvement of 
biological potency, bioavailability and physicochemical properties render them highly 
attractive for the chemical as well as pharmaceutical research.[82-84] As such, methods for the 
catalytic synthesis of differently hybridized CN bonds are of particular interest and subject 
of intensive investigation.[85] Among numerous available methodologies, the hydroamination 
of CC multiple bonds holds great potential in terms of atom economy in addition to the 
high abundance and availability of amines and alkene precursors.[86]  
 
Scheme 3.1 Nitrogen-containing pharmaceuticals. 
The hydroamination reaction of C(sp2)C(sp2) and C(sp)C(sp) hybridized bonds describes 
the addition of primary or secondary NH amines to internal/terminal olefins or alkynes, 
with cleavage of the NH bond and formation of a new CN and CH bond (Scheme 3.2). 
Despite the seemingly simplicity of this transformation, thermodynamic-, kinetic-, and 





Scheme 3.2 General scheme of the intermolecular hydroamination of internal/terminal olefins and alkynes. 
The addition of an amine to an unsaturated CC multiple bond is kinetically challenging.[87] 
The high electron density of the amine moiety and the electron-rich olefin result in a strong 
electrostatic repulsion between the amine lone-pair and the olefins -bond. Consequently, a 
high activation barrier needs to be surmounted to achieve this transformation. Also, due to 
the negative entropy of this reaction, a shift in the equilibrium toward the starting materials 
is conceivable if high temperatures are used to overcome the high activation barrier.[88] 
Thus, this kinetic hurdle suggests the use of a catalyst to activate the CC multiple bond or 
the amine moiety in order to assure a positive reaction outcome. Other significant hurdles of 
hydroamination reactions of alkenes are chemo-, regio-, and stereoselectivity (Figure 3.1). 
Notably, the control of a regioselective addition across olefins possesing alike or bulky 
substituents on both sides of the unsaturated bond is critical and non-trivial. For example, 
the addition of amines to terminal olefins can furnish two regioisomers, Markovnikov and 
anti-Markovnikov products. Furthermore, the control of stereoselectivity is crucial to 
achieve an asymmetric product formation. This is strongly driven by steric properties of both 
reaction partners and the employed catalyst, favoring a nucleophilic attack of the amines 




Figure 3.1 Selectivity aspects of the hydroamination reaction of unsaturated bonds. 
Pursuing the search for a convenient catalyst for the addition reaction of NH 
nucleophiles to CC multiple bonds, early transition metal catalysts such as zirconium and 
lanthanum have been found to promote this transformation through the activation of the 
NH bond via coordination to the metal center.[89, 90] Nevertheless, drawbacks of early 
transition metals catalysts such as the high oxophilicity and consequent diminished 
tolerance of oxygen containing functional groups in addition to air and moisture sensitivity 
complicates the handling of those catalysts and limits their use.[91] Later on, late transition 
metals like rhodium, iridium, palladium and ruthenium were found to be more suitable for 
the hydroamination reaction, showing enhanced tolerance of functional groups.[86] The 
mechanism of late transition-metal catalyzed hydroamination reaction proceeds via the 
activation of the CC multiple bond, resulting in an enhanced regio- and stereoselectivity.[92-
94] For instance, Beller et al. reported the first anti-Markovnikov hydroamination of styrene 
derivatives employing an in situ generated cationic COD-Rh complex with a phosphine ligand 
(Scheme 3.3).[92] 
 
Scheme 3.3 anti-Markovnikov selective hydroamination of styrenes with cationic COD-Rh complex.
[92]
 
The activation of CC unsaturated bonds was also possible via palladium catalysis. In a 
seminal report of Hartwig and co-workers, the hydroamination of vinylarenes with anilines 
was accessible through the catalysis of phosphine-ligated palladium triflates (Scheme 3.4).[95, 
96] Mechanistic investigations of this intermolecular hydroamination protocol revealed that it 
proceeded via the generation of a -phenethyl palladium complex, formed upon insertion 
of an olefin into a palladium-hydride species. 
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Scheme 3.4 Palladium-catalyzed intermolecular hydroamination of vinylarenes using arylamines.
[95, 96] 
At a later date, a cationic Ir(I)-C3-TUNEPHOS complex was used by Shibata et al. to catalyze 
a solvent-free asymmetric intermolecular hydroamination of styrene derivatives with 
different heteroaromatic amines (Scheme 3.).[93] This methodology furnished Markovnikov 
products with defined regio- and good to high enantioselectivities, reaching up to 93% ee. 
 
Scheme 3.5 Iridium-catalyzed intermolecular enantio- and regioselective hydroamination of alkenes.
[93]
 
In 2013, Buchwald and co-workers disclosed an enantio- and regioselective copper-
hydride catalyzed hydroamination of monosubstituted styrenes (Scheme 3.6).[97] This 
transformation was achieved using an electrophilic amine source as well as a chiral 
phosphine ligand to generate chiral tertiary amines with high enantiomeric excess. 
 
Scheme 3.6 Asymmetric regioselective copper-hydride catalyzed hydroamination reaction of styrenes.
[97]
 
In addition to the mentioned methodologies, photomediated approaches for the 
regioselective hydrofunctionalization of CC multiple bonds, especially olefins, were 
described. In the early 1990s, Yasuda and co-workers reported a photomediated 
hydroamination protocol of differently substituted stilbenes utilizing ammonia and 
stoichiometric amounts of 1,4-dicyanobenzene (p-DCB) (Scheme 3.7).[98] Upon direct 
excitation of stilbenes utilizing a high-energetic mercury lamp, a SET towards p-DCB enabled 
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the formation of a radical cation intermediate. Subsequent nucleophilic addition of ammonia 
across the radical cation intermediate, followed by a reduction and protonation, gave access 
to the aminated product. 
 
Scheme 3.7 Photoamination of stilbene derivatives using ammonia.
[98]
 
Later, a seminal report by Nicewicz et al. described an intramolecular anti-Markovnikov 
selective hydroamidation of electron-rich alkenes utilizing N-protected electron-deficient 
amides (Scheme 3.8).[99] This transformation was realized using Fukuzumi's photocatalyst 
(Mes-Acr+) and thiophenol (PhSH) as a hydrogen-atom donor. Later mechanistic studies 
validated the proposed catalytic cycle which commences with an oxidative electron transfer 
from the electron-rich alkene to the excited-state photocatalyst. Next, the addition of the 
amine component to the generated alkenyl radical cation intermediate, followed by a 
subsequent hydrogen-atom transfer from thiophenol furnished the desired hydroamidation 
product. The formed thiyl radical reoxidized the reduced form of the photocatalyst, ensuring 
an efficient turn-over and regeneration of the photocatalyst.[100] 
 
 Scheme 3.8 Photochemical intramolecular anti-Markovnikov hydroamidation of unsaturated amines.
[99, 100]
  
The preceeding protocol for the photochemical intramolecular hydroamidation of 
unsaturated alkenes was extended to an intermolecular variant (Scheme 3.9). This expanded 
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protocol allowed the hydroamidation of - and -substituted styrenes as well as aliphatic 
alkenes.[101] The addition of triflylamides and heterocyclic amine nucleophiles provided 
access to medicinally relevant motifs, including phenethylamines. In the course of the 
reaction, a reduction of the amount of catalytic hydrogen-atom donor was achieved by 
replacing thiophenol with phenyl disulfide [(PhS)2], maintaining hereby the good reaction 
outcome. Yet, this methodology was limited to electron-poor amines given the high 
oxidation susceptibility of electron-rich amines, which could lead to undesirable side 
reactions and competetive quenching of the excited photocatalyst. 
 
Scheme 3.9 Photochemical intermolecular anti-Markovnikov hydroamidation of olefins.
[101]
 
Knowles and co-workers described a mechanistically orthogonal iridium photocatalyzed 
hydroamination protocol of unactivated electron-rich olefins using primary and secondary 
alkyl amines (Scheme 3.10).[102, 103] In contrast to the beforementioned methodology by 
Nicewicz and co-workers comprising the oxidation of unsaturated alkenes, an oxidation of 
the amine moiety by an SET from alkyl amines to the excited-state photocatalyst enabled the 
generation of an electrophilic key aminium radical cation intermediate. Thus, an nucleophilic 
attack from electron-rich olefins towards the aminium radical cation, followed by a 
hydrogen-atom transfer (HAT), selectively furnished secondary and tertiary amine 
anti-Markovnikov products. The ability of 2,4,6-triisopropylbenzenthiol (TRIP) to reduce 
-amino radical intermediates resulting from tertiary amine oxidation is probably 
responsible for the protective effect.[102] In this context, the impact of possible further 
oxidation of the formed tertiary alkyl amines is likely prevented by the added (TRIP) 
co-catalyst.  In recent years, numerous research groups have taken advantage of the 








The hydroamination reaction of unsaturated bonds present a key tool to access alkylated 
amines, known for their pharmaceutical importance and essential as fine chemicals. In 
addition to well-established transition-metal catalyzed hydroamination protocols, 
photomediated variants present a complementary tool to access high-value alkylated 
amines. Nevertheless, numerous photocatalytic methodologies suffer from the need of 
additional hydrogen-atom transfer reagents to ensure an efficient turnover of the 
photocatalyst. Also, restrictions regarding the electrochemical properties of used reactants 
limit the scope of previously mentionend methodologies to electron-poor amines. 
 This project was outlined to investigate the photocatalytic hydroamination of various 
stilbene derivatives using primary alkyl amines. Encouraged by the results in our group, we 
investigated the efficiency of pyrimidopteridine N-oxides as photocatalysts in this 




Scheme 3.11 Pyrimidopteridine N-oxides photo-mediated hydroamination of stilbenes using primary alkyl 
amines. 
3.3 Results and discussion 
Recently, our group investigated the photoredox catalyzed hydroamination of differently 
substituted stilbenes using primary alkyl amines. This transformation was possible using 
catalytic amounts of n-propyl pyrimidopteridine-N-oxide (1.2) as a photocatalyst 
(Scheme 3.12). The optimization of the reaction conditions revealed that a 5.0 mol% catalyst 
loading of n-propyl-pyrimidopteridine-N-oxide (1.2) in acetonitrile (0.1 M) as well as a five-
fold excess of primary benzylamine (3.1a) with respect to (E)-stilbene (3.2a) generated the 
best yield of the hydroamination product (3.3a) after 16 hours of irradiation. 
 
Scheme 3.12 Optimized conditions for the metal-free PrPPTNO (1.2) photocatalyzed hydroamination of 
electron-deficient stilbenes (3.2) with primary alkyl amines (3.1). 
In order to evaluate the applicability of this protocol, differently substituted stilbenes 3.2 
and primary alkyl amines 3.1 were investigated (Tables 3.1 and 3.2). 
3.3.1 Scope of alkyl amines in the photo-mediated hydroamination reaction 
The scope of primary alkyl amines 3.1 was examined in the hydroamination reaction using 
(E)-stilbene (3.2a) as an olefin (Table 3.1). Benzylamine (3.2a) delivered the corresponding 
product 3.3a in a synthetically useful yield of 66% (Table 3.1, entry 1). Notably, generated 
product 3.3a could deliver potential biologically active phenethylamine derivative upon 
deprotection of the benzylic group. Aliphatic amines like n-butylamine (3.1b) and 
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cyclohexylamine (3.1c)  participated in the hydroamination reaction, generating 
corresponding products 3.3b and 3.3c in a comparable moderate yield of 50% (Table 3.1, 
entries 2 and 3). Also, sillyl protected amino alcohol 3.1d was well tolerated under reaction 
conditions, furnishing product 3.3d (Table 3.1, entry 4). Remarkably, unsaturated allyl amine 
3.1e delivered the corresponding product 3.3e in only 34% yield (Table 3.1, entry 5). Possible 
5-exo-trig cyclic adduct of the radical intermediate of 3.1e was not detected during the 
reaction. Fortunately, no CC bond formation was observed between benzylic carbon of 
benzylamine (3.1a) and stilbene 3.2a, disfavoring the intermediacy of a carbon-centered 
radical resulting from a benzylic CH abstraction upon amine oxidation. 





Table 3.1 (continued) Scope of primary amines (3.1) with (E)-stilbene (3.2a) in the photocatalytic 
hydroamination reaction. 
 
3.3.2 Scope of stilbene-derivatives in the photo-mediated hydroamination reaction 
Next, the scope of differently substituted stilbene derivatives 3.2 in the hydroamination 
reaction with benzylamine (3.1a) was explored (Table 3.2). Methyl-substituted stilbene 3.2b 
generated product 3.3f (Table 3.2, entry 1) in a comparable yield to non-polarized 
(E)-stilbene (3.2a) (Table 3.1, entry 1). Stilbene derivatives bearing electron-withdrawing 
substituents delivered corresponding products 3.3g, 3.3h and 3.3i in rather lower yields 
(Table 3.2, entries 2-4). Also, electron-rich arene produced product 3.3k in a comparatively 
low yield of 20% after 24 hours (Table 3.2, entry 5). 




Tabelle 3.2 (continued) Scope of (E)-stilbenes (3.2) with benzylamine (3.1a) during the photocatalytic 
hydroamination. 
 
The diminished yields in the case of highly polarized stilbenes could be attributed to the 
concomitant isomerization reaction of stilbene derivatives (Table 3.2, entries 2-5). For 
example, the oxidation of the electron-rich arene 3.2f (    
   (3.2f) 0.79 V vs. Ag/AgNO3)
[98] 
by the excited-state photocatalyst 1.2a* (E*[PrPPTN*/PrPPTN•−] = 1.72 V vs. SCE in MeCN) 
is conceivable under reaction conditions.[106] Thus, a subsequent One-Bond-Flip (OBF) about 
the ethylene double bond during the radical cation transition state would furnish a mixture 
of (E)- and (Z)-stilbenes (Scheme 3.13). Furthermore, an increased amount of homocoupling 
product of benzylamine (3.1a) was observed in the case of 3.2c, 3.2d and 3.2e. Accordingly, 
this suggest a reaction mechanism comprising also amine oxidation. Hence, simultaneous 
oxidation of amines as well as stilbenes during the reaction could be considered. 
 
 
Scheme 3.13 Photomediated oxidation and subsequent isomerization of stilbenes during the hydroamination 
reaction. 
Moreover, challenging stilbene derivatives bearing biologically active moieties were 
investigated (Scheme 3.14). Stilbene derivative 3.2g, possessing a tetrahydrocannabinol 
subunit, was generated over four steps from (S)-cis-verbenol according to a literature 
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procedure.[107] 3.2g delivered with benzylamine (3.1a) the hydroamination product 3.3l in 
69% isolated yield after 24 hours (Scheme 3.14, entry A). Remarkably, the acetyl-protecting 
group in 3.2g was cleaved during the hydroamination reaction. In addition, stilbene 3.2h 
derived from steroid estrone participated well in the reaction with benzylamine (3.1a) 
(Scheme 3.14, entry B). Corresponding product 3.3m was obtained in a moderate yield of 
59% after 24 hours. 
 
Scheme 3.14 Hydroamination of (A) THC-stilbene derivative (3.2g) ; (B) Estrone-stilbene derivative (3.2h). 
3.3.3 Mechanistic considerations 
In the course of the photocatalytic hydroamination reaction of (E)-stilbene (3.2a) and 
(Z)-stilbene (3.2i) with benzylamine (3.1a), we noticed that product 3.3a was formed in a 
good GC-yield of 72% after 26 hours when using (E)-stilbene (3.2a) (Figure 3.2), whereas the 
GC-yield of 3.3a was diminished to 35% after 26 hours when employing (Z)-stilbene (3.2i) in 
the reaction (Figure 3.3). Furthermore, increasing the polarity of the used stilbene, as in the 
case of ester derivative 3.2c, showed a deteriorating effect on the product yield of 3.3g 
(48%, 26 hours) (Figure 3.4). To evaluate the effect of stilbene geometry and polarity on the 
rate of product formation, kinetic profiles of the corresponding reactants and products were 
obtained (Figures 3.2, 3.3, and 3.4). 
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First, the hydroamination reaction of (E)-stilbene (3.2a) with benzylamine (3.1a) was 
examined (Figure 3.2). The corresponding product 3.3a was formed with an initial rate of 
 .6 ∙ 0−6 M∙s−  reaching a yield of 72% after 26 hours. In addition, minimal 
(E→Z) isomerization of 3.2a to 3.2i was detected in the presence of benzylamine (3.1a), 
furnishing (Z)-stilbene (3.2i) in only 6% after 26 hours (initial rate of formation of 3.2i is 
 .06∙ 0−7 M∙s− ). The total of yields of 3.3a, 3.2a and 3.2i acccount for 99% at any specific 
time, indicating a low yield of side products (<1%). 

























Figure 3.2 Course of formation of (3.3a) from (E)-stilbene (3.2a). 
On the other hand, in case of the reaction of (Z)-stilbene (3.2i) with benzylamine (3.1a), 
the hydroamination product 3.3a was formed with an initial rate of 4.45∙ 0−7 M∙s−  and 
reached a yield of 35% after 26 hours (Figure 3.3). The total of yields of 3.3a, 3.2a and 3.2i 
acccount for 94% at any specific time, indicating a higher yield of side products (≈ 4%) when 
using (Z)-stilbene (3.2i). Similar to the reaction with (E)-stilbene (3.2a) (Figure 3.2), (Z→E) 
isomerization of 3.2i to 3.2a provided (E)-stilbene (3.2a) in 5% GC-yield after 26 hours.  
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The product formation of 3.3a is 3.6 times faster from (E)-stilbene (3.2a) in comparison to 
(Z)-stilbene (3.2i). Yet, the grade of isomerization reactions is comparable in both cases 
accounting to 5-6% after 26 hours. 

























Figure 3.3 Course of formation of (3.3a) from (Z)-stilbene (3.2i). 
Next, the effect of polarized (E)-stilbene ethylester (3.3g) in the hydroamination reaction 
with benzylamine (3.1a) was investigated (Figure 3.4). The initial rate of formation of the 
corresponding product 3.3g ( .9 ∙ 0−7 M∙s− ) is two times higher as compared to the 
unpolarized (E)-stilbene (3.2a) ( .6 ∙ 0−6 M∙s− ). The amount of formed (Z)-isomer of 
stilbene ethylester 3.2k reached 9% after 26 hours. Thus, the isomerization of the polarized 
stilbene 3.3g ( .9 ∙ 0−7 M∙s− ) is 1.5 times faster as compared to the unpolarized stilbene 
3.2a ( .06∙ 0−7 M∙s− ). The induction of nonbonding interactions in polarized (E)-stilbene 
ethylester (3.2c) results in a reduced conjugation and bond-order of the ethylene group.[108, 
109] Thus, a decrease in rotational barrier around the CC double bond in 3.2c is evident. This 
translates through an enhanced susceptibility of 3.2c for (E→Z) isomerization. 
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Figure 3.4 Course of formation of (3.3g) from (E)-stilbene ethylester (3.2c). 
In the absence of benzylamine (3.1), different isomerization patterns of both stilbene 
isomers 3.2a and 3.2i became obvious under standard reaction conditions (Figure 3.5). 
When starting with (Z)-stilbene (3.2i), thermodynamic (Z→E) isomerization from 3.2i to 3.2a 
occurred during the first 8 hours of the reaction furnishing a maximum of 89% of (E)-isomer 
3.2a (Figure 3.5, top). Subsequently, a slower conversion back to (Z)-stilbene (3.2i) was 
evident (49% of 3.2i after 50 hours). This oscillating behaviour of photoisomerization is 
atypical.[110] On the other hand, conducting the reaction with the trans-isomer (E)-stilbene 
(3.2a) resulted in a considerably slower and constant contra-thermodynamic (E→Z) 
isomerization (Figure 3.5, bottom), accounting up to 25% of (Z)-isomere 3.2i after 50 hours. 
No photostationary states were achieved in both reactions during the investigated reaction 
time of 50 hours. The shape of both (Z)- and (E)-stilbene concentration-time curves are 
almost symmetrical to each other, suggesting that none of the used reactants were 
consumed considerably during the photoisomerization reactions. 
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To confirm the photocatalytic nature of the investigated hydroamination protocol, an On-
Off experiment was conducted (Figure 3.6). The reaction of benzylamine (3.1a) with stilbene 
3.2a under standard reaction conditions was irradiated for two hours, then the light source 
was switched off for two consecutive hours. This process was repeated alternately for 
12 hours. Samples were taken every two hours and analyzed by calibrated GC. No 
hydroamination product 3.3a was formed during the off phases. Thus, a radical propagation 
mechanism leading to product formation can be excluded. 
 
Figure 3.6 Course of PrPPTNO (1.2) photo-mediated formation of (3.3a) during the On-Off experiment. 
Additionally, Stern-Volmer quenching experiments conducted with Richy Hauptmann 
revealed that both reaction partners, (E)-stilbene (3.2a) (Ksv = 40.0 M
-1) and benzylamine 
(3.1a) (Ksv = 27.8 M
-1), are able to quench the fluorescence of the excited-state form of the 
deoxygenated photocatalyst 1.2a*. Accordingly, three reaction mechanisms are feasible 
from the singlet excited state S1 of 1.2a*. 
All mechanistic proposals for the photo-mediated hydroamination of stilbenes with 
primary amines commence with a light-promoted deoxygenation of the N-oxide 
photocatalyst 1.2. The oxygen atom is transferred to stilbene 3.2 to form stilbeneoxide 3.2x 




Scheme 3.15 Photo-mediated deoxygenation of the propyl pyrimidopteridine N-oxide (1.2). 
Upon irradiation, the deoxygenated heterocycle 1.2a is promoted to its excited state 
1.2a*. In the first two scenarios, the amine (e.g. benzylamine (3.1a), 
    
   [3.1a• /3.1a] = 1.29 V vs. SCE in MeCN) is oxidized by the excited state photocatalyst 
1.2a* (E*[1.2a*/1.2a•−] = 1.72 V vs. SCE in MeCN) to yield the corresponding aminium 
radical cation int-1.1 (Scheme 3.16).  
The generated aminium radical cation int-1.1 can either participate directly in the 
hydroamination reaction of stilbenes 3.2 in an electrophilic manner (Scheme 3.16, entry A). 
The resulting radical intermediate int-2.1  is then reduced to the corresponding anion by SET 
from the reduced photocatalyst 1.2a    
    [1.2a•/1.2a] = 1.58 V vs. SCE in MeCN) which 
regenerates the ground state catalyst. The desired product 3.3 can be formed from the 
benzylic carbanion intermediate via an intramolecular 1,3-proton shift or more likely 
through deprotonation of excess amine 3.1.  
In another plausible mechanism involving nitrogen centered radicals, the formed aminium 
radical cation can be deprotonated by the reduced form of the photocatalyst 1.2athrough 
a proton coupled electron transfer (PCET)which allows the formation of a neutral aminyl 
radical int-1.2 and the protonated form of the radical photocatalyst 1.2aH (Scheme 3.16, 
entry B). Subsequent addition of the the neutral aminyl radical int-1.2 across the 
unsaturated stilbene 3.2, followed by a fast hydrogen-atom transfer from 1.2aHto radical 
intermediate int-2.2 in a second PCET step gives access to the desired hydroamination 
product 3.3, simultaneously restoring the active form of the photocatalyst 1.2a.  
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Scheme 3.16 Proposed mechanism for the photocatalytic hydroamination via oxidation of amines; (A) 
involving aminium radical cation (int-1.1) ; (B) involving neutral aminyl radical (int-1.2). 
Alternatively, the strong reduction potential of the excited-state photocatalyst 1.2a allows 
also the oxidation of stilbenes (    
   ≥ 1.50 V vs. SCE in MeCN), generating radical cation 
intermediate int-3.2 (Scheme 3.17). Next, nucleophilic attack of the amine of 3.1 towards 
int-3.2 and subsequent deprotonation furnishes the neutral benzylic radical int-2.2. The 
reduction of radical intermediate int-2.2 by an SET from the reduced form of the ground-
state photocatalyst 1.2aensures the turnover of the photocatalyst. Finally, protonation of 
the anionic form of int-2.2 gives access to the desired product 3.3. 
 
Scheme 3.17 Proposed mechanism of the photocatalytic hydroamination via oxidation of stilbenes. 
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In cooperation with Richy Hauptmann and Dr. Jabor Rabeah, electron paramagnetic 
resonance (EPR) spectroscopy of two irradiated solutions of 1) benzylamine (3.1a) and the 
deoxygenated photocatalyst 1.2a and 2) (E)-stilbene (3.2) and photocatalyst 1.2a were 
conducted. Indeed, a reduced radical form of the photocatalyst (1.2a or 1.2aH)  was 
detected in the first solution, indicating an electron transfer from benzylamine (3.1a) to the 
excited-state photocatalyst 1.2a* (Figure 3.7). Yet, further analysis of the hyperfine splitting 
(HFS) of the radical EPR-spectrum were indecisive whether a deprotonation of aminium 
radical cation int-1.1 took place or a solely electron-transfer from benzylamine (3.1a) 
occurred. An additional small coupling constant of a hydrogen nucleus (AH > 0.4 G) does not 
induce notable changes to the simulated EPR spectrum. 
 
Figure 3.7 EPR spectrum of an irradiated solution 1 containing benzylamine (3.1a) and PrPPT (1.2a); the 
orange line is a simulated spectrum considering a hyperfine splitting from two nonequivalent N (blue line, 
AN1 = 8.25 G and AN2 = 3.25 G) 
Contrarily, the irradiated solution of stilbene (3.2) and deoxygenated photocatalyst 1.2a 
remained EPR-silent. By combining the two facts that stilbene-isomerization was operational 
under reaction conditions and the absence of a radical detection, it quickly becomes obvious 
that the photoisomerization of stilbenes proceeds via an energy transfer from the singlet 
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excited-state of 1.2a*. Thus, the photo-mediated hydroamination of stilbenes proceeds 
most likely via an amine oxidation pathway as depicted in Scheme 3.16. 
3.4 Conclusion 
In conclusion, a metal-free photocatalyzed hydroamination reaction of stilbenes by using 
primary alkyl amines and tetrapropyl pyrimidopteridine-N-oxide as a photocatalyst have 
been developed. A wide range of primary amines comprising linear and branched examples 
as well as functionalized amines were tolerated under the reaction conditions. Also, 
numerous stilbene derivatives, including natural product derived components were 
competent coupling partners. Thus, valuable hydroamination products were obtained 
without the need of any sacrificial additives, especially hydrogen-atom transfer reagents.  
Conducted mechanistic experiments validated the photocatalytic nature of this 
methodology and the involvement of radical electron transfer events. Yet, different possible 
reaction mechanisms became evident while analyzing the reaction and the products. The 
oxidation of primary amines as well as used stilbenes is both thermodynamically feasible. 
Yet, the analysis of EPR experiments favors the amine oxidation pathway. The deprotonation 
of the aminium radical cation, generated in the case of amine oxidation, could not be 
unambigiously disclosed. For the moment, a clear statement about the operating 
mechanisms and the involvement of a neutral aminyl species is difficult to make. Thus, 








4 Fluorescence-based Bioimaging and novel therapeutic 
approaches for the Wilson's disease 
4.1 Introduction 
Copper (Cu) is an essential, ubiquitous, trace metal found in all living organisms. It 
occupies diverse roles in living cell physiology as a catalytic cofactor of various enzymes 
involved in electron transfer reactions, free radical scavenger, and mitochondrial 
processes.[111] Copper, is a redox-active metal that exists in both Cu(II) and Cu(I) states in 
living organisms.[112] Yet, the presence of copper as Cu(I)-ions within cells is more favored 
due to the reductive intracellular environment.[113]  
A delicate and precise balance between intake (influx) and elimination (efflux) of cellular 
copper prevails and maintains a steady copper homeostasis.[112] In case of perturbance of 
this balance, pathological conditions and cytotoxicity are described. An excess of free 
circulating copper is associated with the formation of highly reactive oxygen species (ROS), 
resulting in oxidative stress and cell damage.[114] Oxidation of proteins, lipid peroxidation, 
and subsequent injury and degradation of cell components are often the result of excessive 
copper levels.[115] 
The Wilson's disease is an inherited autosomal recessive genetic disorder of the human 
copper metabolism resulting in accumulation of pathological copper levels.[116] This disorder 
is mainly caused by mutations of the ATP7B gene, which codes for a P-Type copper 
transporting ATPase (Wilson disease protein) in the trans-Golgi network.[116] Consequently, 
misfolded and residual/nonfunctional ATP7B proteins, especially in the liver and brain, are 
responsible for abnormal copper levels leading to a variety of neurological and psychiatric 
symptoms.[117] 
Among numerous cell mechanisms to avert protein misfolding, molecular chaperones in 
addition to the ubiquitin-proteasome system (UPS) adopt a critical function. They comprise a 
family of proteins responsible of protein synthesis regulation, folding into their 
corresponding native fold, unfolding in case of disrupted elements and degradation.[118, 119] 
Molecular chaperones are proteins which are able to bind and stabilize mis- or unfolded 
proteins, facilitating the correct folding of non-native conformations.[119] Also, in case of a 
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defect misfolded protein, a series of ubiquitylation enzymes are activated. These enzymes 
are responsible for the ligation of multiple ubiquitin units adjacent to the misfolded unit. 
Ubiquitin is a regulatory protein found ubiquitously in the organism, marking defective 
proteins for degradation via the proteasome.[120] 
It has been reported that multiple mutations of ATP7B in Wilson's disease show enhanced 
interactions with enzymes responsible for protein ubiquitination and proteosomal 
degradation.[121] Thus, premature breakdown of ubiquitinated, misfolded proteins, 
regardless of the fact that these proteins can effect partial activity and residual functionality, 
is anticipated. 
Given the importance of these mechanisms in relation to the longevity of cells and 
restoration of function, substantial interest in therapeutic intervention evoked.[122, 123] 
Currently, symptomatic therapies are only capable of reducing the abnormal 
concentration of free circulating copper in human body.[124] These therapies consist of zinc 
supplementation as well as copper chelation using triethylentetramine and D-penicillamine 
(Figure 4.1).[125] Despite the importance of current therapies, causal treatment approaches 
directly addressing the misfolded ATP7B protein and restoration of function are not 
available.[126]  
 
Figure 4.1 Copper chelating compounds for treating Wilson's disease and the corresponding copper complex 
structures. 
Thiazolidinediones, also referred to as glitazones, are a class of heterocyclic-, biologically 
active molecules (Figure 4.2).[127] They act by activating the peroxisome proliferator-
activated receptors (PPAR) that constitute a group of nuclear receptors. Especially, the 
subfamily PPAR gamma (PPAR-) is activated by glitazones.[128] Furthermore, dual activation 
of both PPAR gamma and alpha subunits is feasible by novel representatives like 
lobeglitazone (Figure 4.2, right). Upon activation, the receptor-agonist complex in addition 
to the retinoid receptors are capable of modulating the transcription of multiple genes.[129] 
The group of Marfella et al. reported that rosiglitazone (Figure 4.2, left), one of the early 
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representatives of the glitazone family, is able to interrupt the ubiquitin proteasome 
pathway.[130] Also, Lukas et al. revealed an inhibiting effect of rosiglitazone on the 
ubiquitination of -galactosidase A enzyme in the course of Fabry's disease.[131] 
 
Figure 4.2 Molecular structure of two thiazolidinedione representatives: Rosiglitazone (left) and 
Lobeglitazone (right). 
In addition to the targeted and precise treatment of a disease, a correct and accurate 
diagnosis is a crucial prerequisite for a target-oriented therapy.[132] Among several 
methodologies, fluorescence-based bioimaging represents a reliable technique for 
unequivocal diagnosis and non-invasive in cellulo monitoring of different components in 
living cells, especially trace metal ions.[133] This is achieved by using selective fluorescent 
proteins or small molecular dyes.[134] The large Stokes shift of fluorescent probes, manifested 
by a significant difference between absorption- and emission wavelengths with minimal 
interference, renders this method selective and sensitive as well as quantifiable for trace 
metal ion analysis.[135] Beside the intramolecular charge transfer (ICT) and the Förster 
resonance energy transfer (FRET), one of the most common adapted mechanisms for 
fluorescence biosensing is the suppression of photoinduced electron transfer (PET) in 
fluorescent molecules upon interaction with a specific analyte.[136] 
Fluorescent molecular probes consist for the most instances of two main substructures, an 
excitable fluorophore part (acceptor, A) and an electron-rich analyte recognition ionophore 
(donor, D) connected through a spacer (Scheme 4.1).[133] Upon irradiation with a suitable 
light source, an excitation of the fluorophore part (A) takes place as one electron of the 
HOMO of (A) is excited to the corresponding energetically higher lying LUMO. A relaxation of 
the electron of the fluorophore in the excited state back to the corresponding HOMO in 
form of fluorescence is hindered and alternatively quenched by a PET from the donor (D) 
moiety. The quenched state is referred to as the "off-state" of a fluorescent probe 
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(Scheme 4.1, entry A). This form of quenching is thermodynamically favorable since the 
energy level of the HOMO of (D) lies in between the HOMO and LUMO of (A). 
In case of interaction of the donor part (D) with a specific metal (M) in form of e.g. 
coordination, the HOMO energy level of (D) is reduced to a lower energetic level in 
comparison to the HOMO of the acceptor (A) (Scheme 4.1, entry B). Thus, a PET quenching 
from (D) to the HOMO of excited (A) is thermodynamically unfavorable. The resulting 
inhibition leads to a re-establishment of the fluorescence of (A). The latter state is referred 
to as the "on-state" of the fluorescent probe. Thus, the restored fluorescence of the metal-
bound chemosensor can be detected and quantified using fluorescence microscopy. 
 
Scheme 4.1 General scheme of the mode of action of fluorescent probes and the corresponding energy 
diagrams in off and on states. 
In course of the Wilson's disease, the selective detection and quantification of labile 
copper(I) levels are indispensable. This is particularly challenging due to the parallel 
presence of copper in different oxidation states and other cellular divalent metal ions like 
iron, zinc and magnesium.[137] This hurdle is overcome by using a polythioether-rich scaffold 
as an analyte binding domain, commonly bis(2-((2-(ethylthio)ethyl)-thio)ethyl)amine (BETA) 
(Figure 4.3). The high selectivity of Cu(I) for polythioether substructures could be explained 
by the principles of hard and soft bases and acids (HSAB) described by Pearson.[138] Cu(I)-
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ions, as a soft Lewis-acid, are likely to react and form a more stable complex with a soft 
Lewis-base, in this case sulfur atoms of the polythioether moiety.[139] Hence, increased 
interactions of complexed Cu(I)-ions with the nitrogen of BETA leads to a more vigorous 
impact on the acceptors moiety (A) in its excited-state. This scaffold has been adopted in 
various rhodol-based (CPF1) and BODIPY-based (RCS1, CS1 and CS3) Cu(I)-chemosensors 
(Figure 4.3) and is used for copper concentration evaluation in a wide range of living cell 
cultures.[140, 141]  
 
Figure 4.3 Molecular structures of Cu(I)-chemosensors with common polythioether (BETA) acceptor moiety. 
4.2 Objectives 
The Wilson's disease is an autosomal genetic disorder manifested in defective and 
misfolded ATP7B protein, which plays an important role in copper trafficking in human body. 
As a result, excessive harmful amounts of copper accumulate in human body, leading to 
organ failure and even, in severe cases, to death. To establish a valid therapeutic concept, 
diagnosis as well as in vitro cell tests of potential compounds are crucial. Based on former 
reports for the synthesis and application of fluorescent probes for the detection and 
quantification of cellular copper levels, we envisioned to employ two copper-chemosensors, 
CS3 and CPF1, to determine the copper levels in cells with defective ATP7B proteins. 
Therefore, we revised and optimized the synthesis of CS3, CPF1 and its corresponding 
control molecule Ctrl-CPF1. 
Also, assumed from previously noticed effects of two glitazone derivatives on the 
mechanism of protein degradation in cells, we surmise that affected cells showing mutations 
in the ATP7B-gene would benefit from a treatment with glitazones. A possible 
pharmacological interference in the degradation of misfolded, yet partially functional, ATP7B 
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protein could lead to a partial restoration of function. Therefore, we synthesized and revised 
the synthesis of two glitazone derivatives, rosiglitazone and lobeglitazone. 
4.3 Results and discussion 
4.3.1 Fluorescence-based bioimaging of labile cellular copper levels 
The synthesis of BODIPY-based (CS3) as well as the Rhodol-based (CPF1) Chemosensors 
and its corresponding control molecule (Ctrl-CPF1) were conducted and optimized taking 
into account the initial synthetic reports.[140, 142-144] 
4.3.1.1 Synthesis of copper Chemosensor CPF1 and the corresponding control molecule 
ctrl-CPF1 
First, we targeted the synthesis of CPF1 4.20 and the corresponding control molecule 
Ctrl-CPF1 4.21. The synthetic approach to access the fluorescent molecule 4.20 consists of 
the synthesis of two molecular fragments, the rhodol-based chromophore 4.10 (Scheme 4.2) 
and the electron-rich amino polythioether moiety 4.18 (Scheme 4.3). Both fragments are 
combined in the last step to furnish the desired chemosensor 4.20 and control molecule 
4.21 (Scheme 4.4).  
The synthesis of the chromophore Rhodol-based part 4.10 was accessible over 9 steps 
starting from 3-Bromoaniline (4.1) (Scheme 4.2).[142] First, diallylation of the aniline 4.1 
provided 4.2. Next, two diallylated bromo anilines 4.2 were merged via a methylene bridge 
using formaldehyde to afford arene 4.3.[142] Subsequent cyclization with 
dichlorophenylphosphine and following oxidation provided acridophosphine 4.4.[142] The 
oxidation of the benzylic methylene of 4.4 followed by a palladium-catalyzed deprotection of 
the allyl moieties in 4.5 furnished bisaniline derivative 4.6.[142] To access the phenolic form 
4.7, hydrolysis of the intermediate diazonium salt generated from 4.6 was conducted. Then, 
a triflation of the phenolic groups in 4.7 installed a better leaving group, which paved the 
way for the monosubstitution of 4.8 with morpholine affording compound 4.9. Subsequent 
basic cleavage of the sulfone in 4.9 and protection of the intermediate phenol as a silylether 




Scheme 4.2 9-Step synthesis of rhodol-based chromophore (4.10) starting from 3-Bromo aniline (4.1).
[142]
 
On the other hand, thioether-rich receptor 4.18 was accessed over 4 steps (Scheme 4.3). 
The spacer moiety was synthesized starting with the reduction of 4-bromo-3-
(trifluoromethyl)benzoic acid (4.11) to furnish the corresponding benzylic alcohol 4.12. 
Subsequent tosylation of 4.12 allows the installation of a better leaving group in 
intermediate 4.13. On the other hand, the mono alkylation of 1,2-ethandithiol (4.14) and 
successive dialkylation of the formed monoalkyl thioether 4.15 furnished the amino 
polythioether scaffold 4.16. Nucleophilic substitution of the in situ tosylated intermediate 
4.13 with amine 4.16 provided the bridged amino polythioether 4.18. In contrast, the 
synthesis of the control molecule scaffold 4.19 is achieved by replacing amino polythioether 




Scheme 4.3 Synthesis of (4.18) and (4.19) starting from benzoic acid derivative (4.11). 
The last step of the synthesis of 4.20 and the corresponding control molecule 4.21 consists 
of the coupling of 4.10 and, 4.18 for CPF1 or 4.19 for Ctrl-CPF1, mediated by a lithium-
halogen exchange and a subsequent acid-catalyzed dehydration (Scheme 4.4). 
 
Scheme 4.4 Coupling of amino polythioether (4.18) or alkyl amine (4.19) with chromophore (4.10).
[142]
 
First, we tested the effect of different bases on the nucleophilic bisallylation reaction of 
aniline 4.1 (Table 4.1) with allyl bromide (4.1a). Cs2CO3 furnished the highest yield of the 
desired product 4.2 (Table 4.1, entry 1), whereas sodium- and potassium carbonates 
provided 4.2 in slightly diminished yields (Table 4.1, entries 2-3). This can be attributed to 
the fact that cesium-ions, which could behave as a Lewis acid by coordination to the amine 
moiety, increase the acidity of adjacent NH. This facilitates the deprotonation of the amine 
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by the carbonate base and, thus, increases the nucleophilicity of the corresponding 
anion.[145, 146] 
Table 4.1. Base screening in the nucleophilic bisallylation of aniline (4.1). 
 
Entry Base Yield[a] 
1 Cs2CO3 94%  
2 Na2CO3 90%  
3 K2CO3 92%  
4 NaOH 72%  
5 NEt3 29%  
[a]
 Isolated yields are shown. 
Organic amine bases proved to be inadequate for this nucleophilic susbtitution reaction 
due to the competetive formation of quartenary ammonium salts, leading to a 
detetrioration in the yield of 4.2 (Table 4.1, entry 5). Also, due to the strong hygroscopy 
while handling Cs2CO3, especially in multigram-scales, K2CO3 is likely more suitable for this 
reaction. Thus, slightly higher yields of 4.2 compared to the literature yield of 84% were 
achieved (Table 4.1, entry 3).[147] 
In the next step, the feasibility of bridging two molecules of 4.2 with formaldehyde (4.2a) 
in different acidic solvents mixture was explored (Table 4.2). The use of formaldehyde as a 
stock solution (37 wt. % in H2O) in acetic acid as a solvent delivered product 4.3 in 85% yield 
(Table 4.2, entry 1).[147] No desired product was formed when a 0.1 M aq. HCl solution was 
used as a solvent (Table 4.2, entry 2). The elimination of water, critical for the formation of 
4.3, is likely favored when using the more glacial acetic acid. Thus, an equilibrium shift to the 
product side is expected. Additionally, the effect of using paraformaldehyde as a polymer in 
acetic acid was tested (Table 4.2, entry 3). A slight deterioration in the yield of 4.3 was 
observed due to diminished solubility of the polymeric form of formadelhyde. 
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Table 4.2 Optimization of the synthesis of diallylated bisaniline (4.3). 
 
Entry Alteration from std. conditions Yield[a] 
1 none 85%  
2 aq. HCl (0.1 M) instead of AcOH 0%  
3 
Paraformaldehyde (4.2a) in AcOH 
instead of CH2O stock solution 
72%  
[a]
 Isolated yields are shown. 
Notably, the cyclization- and oxidation step of 4.3 to acridophosphine 4.4 was described 
by Yamaguchi with a rather low yield of 28%.[148] Indeed, trials to reproduce the reaction led 
to an initial yield of 15% of 4.4 (Table 4.3, entry 1).  A noticeable improvement in the amount 
of generated 4.4 was achieved through substitution of sec-butyllithium with the more basic 
tert-butyllithium and the incremental increase of the reaction temperature (Table 4.3, 
entries 2-4). Especially, the increase in temperature after the addition of 
dichlorophenylphosphine (4.3a) had a noticeable beneficial influence on the outcome of the 
reaction (Table 4.3, entry 3). 
Table 4.3 Optimization of the synthesis of acridoposphine (4.4). 
 
Entry R-Li[a] T1  T2   Yield
[b] 
      1[148] s-BuLi 78 °C 78 °C 15%  
2 t-BuLi 78 °C 78 °C 17%  
3 t-BuLi 78 °C 78→0 °C 55%  
4 t-BuLi 78→0 °C 78→reflu  61%  
[a] 
s-BuLi: 2.1 equiv.; t-BuLi: 2.5 equiv. 
[b]
 Isolated yields are shown. 
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The sterical hindrance of the second nucleophilic attack of the lithiated arene towards the 
monochlorinated phosphine moiety is likely overcome when increasing the temperature of 
the reaction to reflux (Scheme 4.5). 
 
Scheme 4.5 Sterical hindrance of the second nucleophilic substitution in the synthesis of (4.4). 
Subsequent benzylic oxidation of the methylene bridge was conducted using the 
procedure described by Yamaguchi and co-workers.[148] The tetrachlorinated quinone 
derivative p-chloranil (4.4a), possesing a high reduction potential, served as a sufficient 
redox-active agent to generate oxidized acridophosphine 4.5 (Scheme 4.6) in a reaction 
under atmospheric oxygen pressure. After the formation of a charge-transfer (CT) complex 
between 4.4 and 4.4a, the mechanism of oxidation is thought to proceed over two possible 
pathways: a one-electron oxidation followed by a deprotonation or a hydride abstraction 
from quinone 4.4a.[149] As distinct from the procedure of Yamaguchi and coworkers, 4.13 
was isolated in moderate yields and completely characterized.  
 
Scheme 4.6 Synthesis of (4.5) under atm. oxygen using p-chloranil (4.4a) as an oxidation reagent.
[148]
 
Subsequently, the deprotection of the N,N' bis-allyl protected aniline moieties in 4.5 was 




Scheme 4.7 Palladium catalyzed de-allylation of N,N'-diallyl phosphoacridone (4.5) using sacrificial allyl 
scavenger 1,3-dimethylbarbituric acid (4.5a). 
The corresponding mechanism is depicted in Scheme 4.8, below. The reaction mechanism 
commences with the formation of a -complex through the coordination of the allyl moiety 
in 4.5 to a zerovalent palladium (Scheme 4.8). Then, an oxidative addition and expulsion of 
the anion form of mono-allylated species 4.5b gives access to the 3--allyl-palladium 
complex. Afterwards, anion 4.5b deprotonates the CH acidic sacrificial nucleophile 1,3 
dimethylbarbituric acid (4.5a), which acts as an allyl group scavenger. 
 
Scheme 4.8 Plausible mechanism of the palladium catalyzed deprotection of N,N'-diallyl aniline (4.14).
[150]
 
The strong nucleophilic character of the deprotonated form of 4.5a allows a smooth 
addition to the formed 3--allyl-palladium complex. Reductive elimination regenerates the 
catalyst and closes the catalytic cycle. Thus, a total of four deallylation cycles are required to 
generate the desired 3,7-diamino-5-phenyl-10H-acridophosphin-10-one 5-oxide (4.6) in a 
very good yield of 87%. 
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The synthesis of phenol derivative 4.7 from aniline precursor 4.6 proceeded with a similar 
yield to the one reported by Yamaguchi and co-workers (64%) (Scheme 4.9).[148] A 
nucleophilic attack of the aniline moiety in 4.6 towards the in situ formed nitrosonium 4.6a, 
generated from sodium nitrite under strong acidic conditions, gives access to the diazonium-
intermediate 4.6b after a rearrangement. The elimination of gaseous nitrogen provides 
access to the aryl-cation intermediate 4.6c, prone to nucleophilic attack from H2O, which 
furnishes the desired phenol acridophosphine 4.7 in a good synthetical yield of 67%. 
 
Scheme 4.9 Synthesis of phenol derivative (4.7) from aniline (4.6). 
Next, to render phenol 4.7 susceptible to a nucleophilic substitution at the ipso-position, 
the installation of a good leaving group is essential. This is accomplished by a Hünig-base 
promoted triflation of 4.7 using phenyl triflimide (4.7b) (Scheme 4.10). The corresponding 
product 4.8 was obtained in a very good yield of 92%.[142] Attempts to replace phenyl 
triflimide (4.7b) with triflate anhydride (4.7c) did not lead to any product formation. The 
diminished nucleophilicity of intermediate phenolate 4.7a, due to the enhanced mesomeric 
effect, could reveal the reason why 4.7a only reacted with the more electrophilic phenyl 
triflimide (4.7b). Also, the mesomeric stabilization of the negative charge in the leaving 
group of 4.7b to the adjacent phenyl ring raises the electrophilicity of 4.7b. Hence, less 




Scheme 4.10 Triflation of bisphenol (4.7) using phenyl triflimide (4.7b). 
Afterwards, a nucleophilic monosubstitution of 4.8 using morpholine (4.8a) in DMSO was 
carried out (Scheme 4.11).  
 
Scheme 4.11 Nucleophilic aromatic monosubstitution of (4.8) with morpholine (4.8a). 
Chang and co-workers described the use of one equivalent of nucleophilic 4.8a, which 
yielded monosubtituted product 4.9 in a rather lower yield of 49%.[142] Upon nucleophilic 
attack of the secondary amine 4.8a towards 4.8, rearomatisation and subsequent 
protonation of the elimination product in intermediate 4.8b leads to the formation of 
desired product 4.9. In course of the reaction, triflic acid is formed as a by-product. 
Protonation of secondary amine 4.8a by the generated triflic acid would immensely diminish 
the nucleophilicity in 4.8c and explain the lower yield of 4.9. Hence, we presumed an 
improvement in the formation of 4.9 when using an excess of two equivalents of 4.8a. 
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Indeed, monosubstituted product 4.9 was obtained in a very good yield of 82% with two 
equivalents of 4.8a after 24 hours.  
The last step to access chromophore 4.10 proceeded smoothly using a similar procedure 
described by Chang and co-workers.[142] Nucleophilic aromatic substitution of 4.9 using 
tetrabutylammonium hydroxide (4.9c) as a strong base furnished intermediate phenolate 
4.9a (Scheme 4.12). Intermediate 4.9a was then protected as a TBDMS-ether 4.10, which is 
less prone to hydrolysis under following reaction conditions. The silylation step was 
accessible by employing tert-butyldimethylsilyl chloride (TBDMSCl) and imidazole.[151] The in 
situ formed silyl-imidazolium cation 4.9b participated efficiently in the reaction with 4.9a. In 
contrast to the procedure described by Chang and co-workers, A yield improvement to 
almost quantitative yield of the desired product 4.10 was accomplished when 




Scheme 4.12 Nucleophilic aromatic substitution and silyl protection of triflate derivative (4.9). 
Next, the synthesis of the electron-rich receptor scaffold 4.18 was accomplished in a 
4-step synthesis starting from commercially available 4-bromo-3-(trifluoromethyl)benzoic 
acid (4.11) and 1,2-ethanedithiol (4.14) (Tables 4.4 and 4.5). First, the benzylic alcohol 
derivative 4.12 was obtained by the reduction of the corresponding benzoic acid 4.11 with 
lithium aluminium hydride (4.11a) (Table 4.4). The reduction of precursor 4.11 was 
accomplished by employing modified reaction conditions compared to the described 
procedure by Dodani and co-workers (Table 4.4, entry 2).[143] The use of Et2O as a solvent 
under reflux conditions were indispensable for a good reaction outcome (Table 4.4, entries 1 




Table 4.4 Optimization of the reaction conditions for the reduction of benzoic acid derivative (4.11). 
 
Entry Alteration from std. conditions Yield[a] 
1 none 90%  
2 THF instead of Et2O, room temperature
[143]       21%  
3 room temperature instead of reflux 53%  
[a]
 Isolated yields are shown. 
Moreover, following the modified procedures described by Kimura et al., amino 
polythioether 4.16 was furnished over two steps.[152] 2-(Ethylthio)ethane-1-thiol (4.15) was 
obtained in the first step via a base-promoted nucleophilic substitution of ethyl iodide 
(4.14a) and 1,2-ethanedithiol (4.14) (Scheme 4.13).[152] Undesired over-alkylation of desired 
product 4.15 in course of the reaction and difficulties in purification led to a noticeable 
decrease in the yield of 4.15. Thus, multiple distillations were required to obtain pure 4.15. 
 
Scheme 4.13 Base-promoted monoalkylation of 1,2-ethanedithiol (4.14) with ethyliodide (4.14a).  
Afterwards, a two-fold nucleophilic substitution of bis(2-chloroethyl)amine (4.15a) with 
4.15 afforded the desired electron-rich receptor moiety 4.16 (Table 4.5). The performance of 
different bases during the reaction was investigated and evaluated. Alkoxide bases 
(Table 4.5, entries 1 and 2) as well as sodium carbonate (Table 4.5, entry 3) failed to 
generate the desired product 4.16, whereas sodium hydroxide and cesium carbonate 
delivered 4.16 in very good yields reaching 88% (Table 4.5, entries 4 and 5). Cesium as a 
bulky counter ion (ionic radius of Cs+ = 167 pm)[153] to the deprotonated form of 4.15 is 
known to be more reactive in aprotic polar solvents.[154] Enhanced nucleophilicity and 




Table 4.5 Base screening for the dual nucleophilic substitution reaction of thiol derivative (4.15) and (4.15a). 
 
Entry Base Yield[a] 
1 NaOMe   0% 
2 NaOEt         0%
3 Na2CO3   0% 
4 NaOH   77% 
5 Cs2CO3  88% 
[a]
 Isolated yields are shown. 
Then, receptor fragment 4.16 as well as dioctyl amine (4.17) were merged with the pre-
synthesized bridging scaffold 4.12 (Scheme 4.14). A procedure reported by Dodani et al. 
relied on the chlorination of benzylic alcohol 4.12 and a subsequent nucleophilic substitution 
with amines 4.16 and 4.17 in two consecutive reactions.[143] We presumed that a one-pot in 
situ tosylation of benzylic alcohol 4.12, followed by the nucleophilic base-promoted 
substitution with amines 4.16 and 4.17 would furnish desired products 4.18 and 4.19 
without the need for an intermediate purification and isolation (Scheme 4.14). Indeed, 
benzylic substitution of the in situ formed tosylate 4.12b afforded desired products 4.18 and 
4.19 in yields of 47% and 80%, respectively. The use of two equivalents of sodium hydride as 
a base proved to be sufficient for the deprotonation of benzylic alcohol 4.12 and the amine 




Scheme 4.14 Synthesis of receptor- (4.18) and control molecule scaffold (4.19) from benzylic alcohol 
derivative (4.12). 
In the last step, the desired copper sensor CPF1 4.20 and the corresponding control 
molecule Ctrl-CPF1 4.21 were obtained by the coupling of the synthesized acridophosphine 
chromophore 4.10 with the electron-rich receptor fragment 4.18 and alkyl amine 4.19, 
respectively (Scheme 4.15). Multiple trials to reproduce the procedure described by Chang 
et al. failed.[142] The published procedure consisted of a halogen-metal exchange of 4.18 or 
4.19 with tert-butyllithium (t-BuLi) to generate intermediate 4.18a with a highly polarized 
aryl-carbon-lithium bond. The nucleophilic attack of aryl carbanion from 4.18a to the ketone 
moiety of chromophore 4.10 gives access to the tertiary alcohol 4.10a. Subsequent acid-
catalyzed protonation of the tertiary alcohol and dehydration of 4.10a as well as the 
elimination of the silyl protecting group leads to restoration of the conjugated -system and 
furnishes desired copper chemosensor CFP1 4.20 and its corresponding control molecule 
Ctrl-CPF1 4.21. No product was formed following the procedure described by Chang and co-
workers. We presumed that the order of addition during the reaction could be responsible 
for the lack of formation of 4.20 and 4.21. Indeed, adding lithiated aryl component 4.18a to 
a solution of 4.10 in THF, otherwise than stated by Chang et al., and subsequent raise of the 
reaction mixtures temperature from 78 °C to room temperature revealed an almost 1.5-
2 fold raise in the yields of 4.20 and 4.21. Desired control molecule 4.21 and chemosensor 




Scheme 4.15 Synthesis of copper-sensor (CPF1, 4.20) and control molecule (Ctrl-CPF1, 4.21) by coupling of 
(4.10) and (4.18) or (4.19) and subsequent dehydration/restoration of conjugation. 
4.3.1.2 Synthesis of copper chemosensor CS3 
The Boron-dipyrromethene (BODIPY)-based copper sensor CS3 4.25 was synthesized in a 
similar fashion to chemosensor CPF1 4.20, following the synthesis described by Dodani and 
co-workers (Scheme 4.16 and 4.17).[144] The corresponding chromophore BODIPY-scaffold 
4.24 was obtained over two steps starting from pyrrole derivative 3-ethyl-2,4-dimethyl-1H-
pyrrole (4.22). First, a base-promoted nucleophilic disubstitution of chloroacetyl chloride by 
two equivalents of pyrrole 4.22 followed by a condensation yielded conjugated 
chlorodipyrrole 4.22a. A difluoroborylation using the Lewis-acid-base-adduct boron 
trifluoride diethyl etherate provided intermediate 4.23 in a rather low yield of 43%.[144] 
During the reaction, a variety of side reactions were evident. In addition, challenging 
purification led to diminished yields of 4.23. Nevertheless, synthetically useful amounts 
could be obtained. The substitution of the fluorine moieties in 4.23 with methoxy groups 
was accomplished via a Lewis-acid catalyzed substitution.[144] The sonication of a pre-
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activated mixture of 4.23 with aluminium trichloride, followed by the addition of methanol 
afforded the dimethoxylated diazaborinine derivative 4.24 in a moderate yield of 63%. 
 
Scheme 4.16 Two step synthesis of BODIPY scaffold (4.24) from pyrrole derivative (4.22). 
Finally, the copper chemosensor CS3 (4.25) was obtained through a base-promoted 
nucleophilic substitution of the pre-synthesized amino polythioether 4.16 and the 
chlorinated precursor chromophore 4.24 (Scheme 4.17) in a moderate yield of 43%.[144] 
 




4.3.1.3 Evaluation and application of chemosensors CS3, CPF1, and ctrl-CPF1 in HepG2 
cells 
In cooperation with the group of Dr. Jan Lukas at the Albrecht Kossel institute, CS3 Copper 
sensor 4.25 was applied to cell cultures containing HepG2 cells, a human liver cancer cell 
line. From two tested wildtyp cell cultures (ATP7B+/+), one was treated with a 500 µM 
solution of CuSO4 and incubated for two hours (Figure 4.4, entry B). The control sample was 
measured in the absence of CuSO4 addition (Figure 4.4, entry A). The increase in copper(I)-
concentrations in the investigated cells upon exposure to a copper-rich medium is evident by 
an augmentation of fluorescence through different filters (Figure 4.4, entry B). 
DAPI CS3 CS3 MERGE
DAPI CS3 CS3 MERGE
 
Figure 4.4 CS3 copper sensor in HepG2 cells (A) without and (B) after incubation with a 500 µM CuSO4 
solution. 
Next, the application of CS3 4.25 in the quantification of copper levels in ATP7B deficient 
HepG2 cells (ATP7B-/-) in comparison to the corresponding wildtyp cells (ATP7B+/+) was 
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examined (Figure 4.5). Increased basal copper levels in cells with deficient ATP7B proteins 
were evident after staining with CS3 4.25 in comparison to wildtyp cells (Figure 4.5, A and B). 
In the same context, both cell cultures were treated with a 200 µM solution of CuSO4 for 
24 hours. The treatment resulted in an augmentation of copper levels in wildtyp cells in 
comparison to basal levels in untreated cells, implementing a functional copper trafficking 





























) HepG2 cells with CS3. (B) quantification of fluorescence 
signal generated from (A), (C) quantification of intracellular copper levels by atomic absorption spectroscopy. 
Remarkably, no significant difference was noticed in copper levels of ATP7B deficient cells 
post to treatment compared to basal levels. Thus, CS3 4.25 proved initial functionality in 
copper concentration evaluation in wildtyp- and ATP7B deficient HepG2 cells. In addition, 
intracellular copper levels were measured by atomic absorption spectroscopy (AAS) 
(Figure 4.5, C). In the same context, the employment of CPF1 copper sensor 4.20 and 
ctrl-CPF1 4.21 in HepG2 cell cultures is still a subject of current research in the group of Dr. 
Jan Lukas at the Albrecht Kossel Institute in Rostock.  
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4.3.2 Glitazones as a novel therapeutic approach for the treatment of Wilson's disease 
Rosiglitazone 4.30 and lobeglitazone 4.36, two representatives of the thiazolidinedione 
family, were obtained in a four- and five-step total synthesis, respectively, following 
reported procedures in literature (Figure 4.6).[155-159] 
 
Figure 4.6 Multiple step synthesis of rosiglitazone (4.30) and lobeglitazone (4.36). 
4.3.2.1 Synthesis of rosiglitazone 
The first step in the synthesis of rosiglitazone 4.30 comprised a nucleophilic aromatic 
substitution of 2-chloropyridine (4.26) in neat 2-(methylamino)ethanol (4.26a) at 150 °C 
(Scheme 4.18).[155] Thus, desired product 4.27 was obtained in an excellent yield of 93%. 
 
Scheme 4.18 Nucleophilic aromatic substitution of 2-chloropyridine (4.26) using amine (4.26a). 
Next, 2-(methyl(pyridin-2-yl)amino)ethan-1-ol (4.27) was reacted with 4-
fluorobenzaldehyde (4.27a) in a second nucleophilic aromatic substitution after 
deprotonation with sodium hydride in DMF at 40 °C (Scheme 4.19).[156] The O-arylation 
product 4.28 was obtained in a moderate yield of 57%. The diminished yield of 4.28 is 
probably associated with a competetive base-catalyzed Cannizzaro reaction of non-
enolizable carbonyl educt 4.27a, resulting in a disproportionation of the aldehyde.[160] 
 




Afterwards, a Knoevenagel condensation of 2,4-thiazolidinedione (4.28a) and 4.28 in the 
presence of piperidine and acetic acid in toluene afforded ,-unsaturated carbonyl 
compound 4.29 in a good yield of 82% (Scheme 4.20).[156] Piperidine served as a base for the 
deprotonation of CH-acidic thiazolidinedione 4.28a (pKa  6.24)
[161]. Upon nucleophilic 
attack of deprotonated 4.28a towards the carbonyl moiety in 4.28, subsequent protonation 
and elimination of water generates desired unsaturated precursor 4.29. 
 
Scheme 4.20 Knoevenagel condensation of benzaldehyde derivative (4.28) with thiazolidinedione (4.28a). 
With precursor 4.29 in hand, the unsaturated alkene moiety was reduced via a hydride 
transfer from lithium borohydride (LiBH4) in a mixture of pyridine and THF under reflux  for 
2 hours (Scheme 4.21).[157] Recrystallization of the precipitated solid during the reaction 
afforded the desired rosiglitazone 4.30 in a moderate yield of 61%. 
 
Scheme 4.21 Reduction of ,-unsaturated carbonyl precursor (4.29) to rosiglitazone (4.30) using LiBH4. 
4.3.2.2 Synthesis of lobeglitazone 
In the same context, lobeglitazone 4.36 was synthesized over five-steps starting from 4,6-
dichloropyrimidine (4.31) (Scheme 4.22). In the first step, a nucleophilic aromatic 
monosubstitution of 4.31 was conducted with 4-methoxyphenol (4.31a) after deprotonation 
using sodium hydride in DMF.[158] The fast addition of 4.31 to the reaction mixture was 
crucial. The slow addition of pyrimidine 4.31 at room temperature resulted in a 
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disubstitution of 4.31. By adding 4.31 at once under vigorous stirring to deprotonated 4.31a 
at 0 °C, an excellent yield of 96% of monosubstituted pyrimidine 4.32 was achieved. 
 
Scheme 4.22 Base-promoted monosubstitution of 4,6-dichloropyrimidine (4.31) with (4.31a). 
In a similar procedure to the synthesis of rosiglitazone 4.30, a second nucleophilic 
aromatic substitution of 4.32 with 4.26a under reflux afforded substituted 
N-methylaminoalcohol 4.33 in a quantitative yield after 24 hours (Scheme 4.23).[158] 
 
Scheme 4.23 Nucleophilic aromatic substitution of substituted pyrimidine (4.32) with aminoalcohol (4.26a). 
With N-substituted aminoalcohol 4.33 in hand, a base-promoted nucleophilic aromatic 
substitution of 4-fluorobenzaldehyde (4.27a) using sodium hydride in DMF was 
conducted.[158] The desired benzaldehyde derivative 4.34 was obtained in a good yield of 
85% after 3 hours (Scheme 4.24). In contrast to the similar step in the synthesis of 
Rosiglitazone 4.30, running the reaction at room temperature instead of 40 °C (Scheme 4.19) 
had a positive effect on the yield of the desired product. 
 
Scheme 4.24 Nucleophilic aromatic substitution of 4-fluorobenzaldehyde (4.27a) with N-substituted 
aminoalcohol 4.33. 
Next, the lobeglitazone precursor 4.35 was obtained by a Knoevenagel condensation of 
2,4-thiazolidinedione (4.28a) and benzaldehyde derivative 4.34 in a refluxing mixture of 
piperidine and anhydrous ethanol for 24 hours (Scheme 4.25). The corresponding product 




Scheme 4.25 Knoevenagel condensation of benzaldehyde derivative (4.34) with thiazolidinedione 4.28a.  
The last step to access lobeglitazone 4.36 from precursor 4.35 consisted of the reduction 
of the ,-unsaturated carbonyl bond in 4.35. Literature procedures reported for the 
reduction of 4.35 suffered from diminished yields when employing palladium-catalyzed 
hydrogenation protocols.[158] Thus, a chemoselective procedure described by Nakamura and 
co-workers using diethyl-1,4-dihydro-2,6-dimethyl-3,5-pyridindicarboxylate (4.35a), also 
referred to as Hantzsch-ester, in the presence of silica gel in refluxing toluene was adopted 
(Scheme 4.26).[159, 162] A hydrogen atom transfer from the Hantzsch ester (4.35a) after acidic 
activation of the carbonyl moiety of thiazolidinedione 4.35 with silica, followed by a keto-
enol tautomerization, generated the desired lobeglitazone 4.36 in a very good yield of 90%. 
 
Scheme 4.26 Selective reduction of ,-unsaturated carbonyl precursor (4.35) using Hantzsch ester (4.35a) 
and silica. 
In cooperation with Dr. Jan Lukas, in vitro cell tests investigating the effect of rosiglitazone 
4.30 and lobeglitazone 4.36 on the extent of ubiquitination in modified HEK 297T cells are 




In summary, rhodol-based copper sensor CPF1 and the corresponding control molecule 
ctrl-CPF1 were successfully obtained over a 14-step total synthesis. The optimization of 
intermediate reactions based on early reports mentioned in literature as well as new 
approaches led to a noticeable improvement in yield. In addition, characterization of newly 
isolated intermediates was achieved. In contrast, BODIPY-based copper sensor CS3 was 
obtained based on literature procedures and successfully employed in the quantification of 
copper levels in HepG2 containing cell cultures. Yet, CPF1 and Ctrl-CPF-1 have not been 
tested in vitro and are subject of ongoing research. 
In Addition, two glitazone representatives were synthesized. Rosiglitazone was accessed 
over a four-step synthesis, whereas lobeglitazone was obtained using a five-step procedure. 
Different conditions for similar steps were compared and assessed. In vitro cell tests of both 
potential compounds are still pending and currently being addressed in the group of Dr. Jan 





5 Peptidyl Trifluoromethylketone-based elastase inhibitors in 
acute pancreatitis 
5.1 Introduction 
Protein misfolding and Endoplasmic Reticulum (ER)-stress play a pivotal role in human 
disease pathogenesis.[163, 164] Prevalent examples like Wilson's disease, acute pancreatitis 
and Alzheimer's disease are thought to have their origins in misfolded, aggregated and 
accumulated defective proteins.[118, 122, 165] The presence of distinctive amounts of misfolded 
proteins in ER induces protective intracellular signaling pathways including the unfolded 
protein response (UPR), as well as the ER-associated degradation (ERAD).[166] Those 
responses consist of a group of translational and transcriptional occurrences in order to 
restore the ER functionality and homeostasis.[165] Yet, if high levels of misfolded proteins are 
present and ER stress persists, a terminal UPR pathway is initiated that leads to apoptosis 
induction (programmed cell death) and subsequent loss of functionality of affected cells. 
Acute pancreatitis (AP) is one of the most common gastrointestinal inflammatory 
disorders.[167] Damaged pancreatic acinar cells are believed to trigger inflammatory 
responses that can lead to a severe disorder form and successive high mortality. The most 
common cause of AP are duct obstruction by gallstones and alcohol misuse.[168] As a result, 
digestive zymogens are thought to be subject of premature activation, leading to an 
intracellular autodigestion as well as subsequent pancreatic cell damage.[169] This event is 
often followed by the recruitment and stimulation of different inflammatory cells, especially 
neutrophile granulocytes.[170] 
Among affected enzymes during AP, both pancreatic- and neutrophil elastases are 
considered to play a crucial function in activating and influencing disease severity.[170, 171] In 
this context, the selective inhibition of both enzymes could provide an opportunity for causal 
treatment of AP. Elastase enzymes belong to the class of proteases. This proteolytic enzyme 
group catalyzes the breakdown of proteins peptide bonds into smaller peptide units or 
amino acids via hydrolysis.[172] Proteases, as such, can be grouped as serine-, aspartic-, 
cysteine-, glutamic-, asparagine-, threonine-, or metallo-proteases depending on the 
catalytic mechanism and involved amino acids at the active site of the enzyme.[173] 
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Serine proteases, to which the group of elastase enzymes belong, bear a catalytic triad at 
the enzyme's active site responsible of peptide bond hydrolysis.[174] This triad consists of 
three amino acids with different tasks; aspartic acid, histidine and serine, respectively 
(Scheme 5.1). 
Initially, aspartic acid forms a hydrogen bond with the histidine amine residue and 
stabilizes its positive charge by polarization, thus ensuring proper orientation of the 
imidazole part towards serine. Next, the imidazole moiety of histidine deprotonates and 
polarizes serine, the nucleophilic member of the triad, thereby enhancing the oxygen's 
nucleophilicity. Subsequently, a nucleophilic attack of the generated alkoxide towards the 
positively polarized carbon of the peptide carbonyl group leads to the formation of a 
tetrahedral intermediate. The formed intermediate is stabilized by dipole-charge 
interactions in the oxyanion-hole, consisting of two backbone amide NH's groups of serine 
and glycine. Successive protonation and release of the amine part of the peptide bond 
followed by a hydrolysis of the covalent-acyl-enzyme intermediate via a second tetrahedral 
intermediate furnishes the corresponding carboxylic acid and regenerates the enzyme. 
 
Scheme 5.1 Mechanism of peptide bond cleavage via hydrolysis by serine proteases. 
The inhibition of proteases could be realized by employing transition-state analogs 
inhibitors. These inhibitors resemble the tetrahedral intermediate in structure, preserving 
the hydrogen bonding properties at the enzyme's active site. First trials to inhibit a protease 
by employing transition-state analogues were depicted by Abeles and co-workers.[175] 
Replacing the amide bond of the peptide by a non-hydrolizable bioisostere, for example a 
trifluoromethylketone (TFMK), afforded a selective and reversible inhibition of 
chymotrypsin. The introduction of a strong electron withdrawing group adjacent to the 
ketone's carbonyl moeity, especially a trifluoromethyl group (CF3), leads to remarkable 
amplification of its reactivity. Hence, the enhanced positive charge at the carbonyl carbon 
makes it more susceptible to nucleophilic attacks.[176] Also, TFMK are able to form stable 
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hydrates with improved water solubility. Thus, a stable, yet reversible, hemiketal formation 
of trifluoromethylketone moieties with deprotonated serine alkoxide is reasonable at the 
enzyme's active site (Scheme 5.2).[177] 
 
Scheme 5.2 Reversible inhibition of a serine protease by trifluoromethylketones (TFMK). 
In 1997, peptidyl trifluoromethylketone ZD-0892 5.13 bearing an N-methoxy benzamide 
group was reported by Veale and co-workers as a potent inhibitor of neutrophile-elastase 
(PMN-elastase) (Scheme 5.3).[178] The distinct inhibition capacity of ZD-0892 5.13 in addition 
to its oral availability makes it a potential pharmaceutical candidate for the causal treatment 
of acute pancreatitis.  
5.2 Objectives 
The reported stereoselective synthesis of ZD-0892 5.13, a potent 
peptidyltrifluoromethylketone-based elastase inhibitor, containing three chiral centers, is 
challenging (Scheme 5.3). Early synthetical reports require demanding fractional 
crystallization and handling sensitive and hazardous intermediates.[179] The Optimization of 
the total synthesis of ZD-0892 based on reports from Veale et al. and different approaches 
to access essential intermediates was conducted. A safer and easier total-synthesis protocol 
of ZD-0892 was envisioned with the aim to test 5.13 in vitro in acute pancreatitis cell-
models. 
 
Scheme 5.3 Retrosynthetic analysis of neutrophile-elastase inhibitor ZD-0892 (5.13) and challenging bond 
formations and transformations.  
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5.3 Results and discussion 
First, we started with the synthesis of the peptide core 5.3 of ZD-0892 by a carbodiimide 
5.1b and 1-hydroxybenzotriazole (HOBt) (5.1a) mediated amide bond formation using the 
tert-butyl ester of L-proline (5.1) and Cbz-protected amino acid L-valine (5.2) as coupling 
partners (Scheme 5.4). Initially, the formation of O-acylisourea adduct of free carboxylic acid 
5.2 and N,N'-dicyclohexylcarbodiimide (DCC) (5.1b) takes place.[180] The subsequent addition 
of HOBt 5.1a, a good leaving group, is essential to activate the formed O-acylisourea and 
prevent a transposition of the O-acyl group to the adjacent N-atom.[180] Next, a nucleophilic 
attack of the amine lone-pair of 5.1 towards the carbonyl moiety of the activated carboxylic 
acid ester 5.1c followed by the cleavage of the HOBt subunit generates the desired dipeptide 
5.3 with intact stereochemical centers in an excellent isolated yield of 95%.  
 
Scheme 5.4 Carbodiimide (5.1b) and HOBt (5.1a) mediated peptide-bond formation between -amino 
acids (5.1) and (5.2). 
Following, deprotection of the Cbz-amino protecting group in dipeptide 5.3 was realized in 
methanol using palladium on carbon and atmospheric hydrogen pressure (Scheme 5.5). The 




Scheme 5.5 Deprotection of N-protected dipeptide (5.3) using palladium on carbon and atmospheric 
hydrogen pressure. 
With the dipeptide 5.4 bearing a free amine moiety in hand, we continued with the N-
protection of the free amine in 5.4 using p-anisoyl chloride (5.4a) and stoichiometric 
amounts of triethylamine as a base in THF (Scheme 5.6). The nucleophilic substitution of the 
benzoyl chloride 5.4a by the free amine of 5.4 resulted in the formation of the desired 
benzamide 5.5 and hydrochloric acid as a byproduct. The amine base serves as an acid 
scavenger upon formation of ammonium chloride salts. Due to the diminished solubility of 
ammonium chloride salts in THF, a shift of the reaction equilibrium towards the product side 
translates in an excellent yield of 5.5, accounting up to 90% after one hour. 
 
Scheme 5.6 Base-promoted benzamide formation using didpeptide (5.4) and p-anisoyl chloride (5.4a). 
The cleavage of the tert-butyl ester of 5.5 on a gram-scale was readily achieved by the 
treatment of ester 5.5 with trifluoroacetic acid (5.5a) for 30 minutes (Scheme 5.7). The 
strong acidic trifluoroacetic acid (5.5a) enables the protonation of the carbonyl moiety of 
ester 5.5 followed by a cleavage of the corresponding free carboxylic acid 5.6 and the 




Scheme 5.7 Cleavage of tert-butyl ester in dipeptide (5.5) using trifluoroacetic acid (5.5a). 
Next, we focused on the synthesis of the aminoalcohol (3S)-3-amino-1,1,1-trifluoro-4-
methylpentan-2-ol (5.9) (Scheme 5.8). In a patented procedure by Bergeson and co-workers, 
5.9 was obtained as a threo mixture over a 3-step synthesis starting from 1-iodo-2-
methylpropane (5.7).[181] Due to safety concerns and light sensitivity of nitro containing 
intermediate 5.8 as well as significant difficulty to obtain stereochemical pure 5.9 out of the 
corresponding mixture of isomers following the method of Bergeson et al., we presumed 
that the patented methodology described by Sato and coworkers would ensure a safer and 
easier protocol to access 5.9 as a mixture of only 2 diastereomers.[181, 182] 
Scheme 5.8 Patented methods for the synthesis of (5.9) by (A) Bergeson et al. and (B) Sato et.al..
[181, 182] 
Optical pure oxazolidinone 5.10 was obtained starting from Cbz-L-valine (5.2) via 
introduction of a methylene bridge using paraformaldehyde (4.2a) under acidic conditions 
(Scheme 5.9). Decomposition of paraformaldehyde to formaldehyde under acidic conditions 
using p-toluenesulfonic acid paved the way for two consecutive nucleophilic attacks from 
both amine lone-pair of 5.2 and oxygen lone-paire of the carboxylic acid moiety in 5.2. 
Subsequent elimination of water upon protonation generate optical pure 5.10 in an 




Scheme 5.9 Synthesis of cyclic (5.10) via methylene bridge formation from amino acid (5.2) and 
paraformaldehyde (4.2a) under acidic conditions.  
Afterwards, adopting the procedure described by Sato et al., a one-pot multistep reaction 
including a trifluoromethylation-, reductive CO bond cleavage-, and an elimination step of 
5.10 was conducted (Scheme 5.10).[182] First, a nucleophilic trifluoromethyl anion was 
generated in situ by employing trifluoromethyl trimethylsilane (TMSCF3), also known as 
Ruppert-Prakash reagent, with catalytic amounts of cesium fluoride (CsF) in THF at 0 °C for 
one hour. Subsequently, the highly reactive trifluoromethyl anion attacks the carbonyl group 
of the lactone moiety in 5.10 generating an intermediate alkoxide anion. The latter alkoxide 
anion is quickly silylated by the in situ formed trimethyl silane cation, furnishing acetale 
intermediate 5.10a. Next, cleavage of the trimethyl silane group was accomplished by the 
addition of ethanol as a protic solvent which yielded hemiacetal 5.10b. The addition of 
reducing sodiumborohydride (NaBH4) to the reaction promoted the reductive CO bond 
cleavage in 5.10b, giving access to 5.10c. Subsequent base-promoted elimination of carbon 
dioxide from 5.10c furnishes desired benzyl ((3S)-1,1,1-trifluoro-2-hydroxy-4-methylpentan-
3-yl)carbamate (5.11) in a good synthetic yield of 61%. The existence of (5.11) as a mixture 
of two diastereomers does not affect the optical purity outcome of end-product ZD-0892 
(5.13), since the last step in the total synthesis of 5.13 consists of the oxidation of the 




Scheme 5.10 One-pot synthesis of protected trifluoromethyl amino alcohol (5.11) from cyclic (5.10).
[182]
 
Following, deprotection of benzyl ((3S)-1,1,1-trifluoro-2-hydroxy-4-methylpentan-3-
yl)carbamate (5.11) was enabled by a similar procedure to the reaction of 5.3 to 5.4 
(Scheme 5.5) using palladium(II) hydroxide on carbon and atmospheric hydrogen pressure 
for 24 hours (Scheme 5.11). Upon precipitation with hydrochloric acid, diastereomeric 3-
amino-1,1,1-trifluoro-4-methylpentan-2-ol (5.9) was obtained in a good yield of 80% as a 
hydrochloride.  
 
Scheme 5.11 Palladium-catalyzed cleavage of the Cbz amine protecting group in amino alcohol (5.11). 
Upon deprotonation and crystallization, the structure of the (2R,3S) diastereomeric free 
amine form of product 5.9 was confirmed by X-ray analysis (Figure 5.1). It is worth 
mentioning, that this method offers an easier way to access diastereomeric amino alcohol 
5.9 without the need for multiple crystallization and addition of enantiopure additives.[178] 
 




Afterwards, the coupling of dipeptide 5.6, containing a free carboxylic acid, with 
diastereomeric aminoalcohol salt 5.9 generated the precursor alcohol 5.12 
(Scheme 5.12).[178] The amide bond formation was conducted in a similar procedure to the 
reaction of -amino acids 5.1 and 5.2 to 5.3 using 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCI) (5.12a), 1-hydroxybenzotriazole (5.1a) and 
triethylamine as a base in DMF for 12 hours. The desired peptidyl trifluoromethylalcohol 
5.12 was obtained as a crystalline product in a good yield of 72%.  
 




The last step consisted of a selective oxidation of the secondary alcohol contained in 
precursor 5.12 to the corresponding desired ketone ZD-0892 5.13 using potassium 
permanganate in aqueous basic conditions (Scheme 5.13).[178] Thus, the desired elastase-
inhibitor ZD-0892 5.13 was obtained in quantitative yield after one hour at 0 °C. 
 
Scheme 5.13 Oxidation of secondary alcohol precursor (5.12) to the corresponding peptidyl-
trifluoromethylketone ZD-0892 (5.13) using potassium permanganate.
[178]
 
The application of ZD-0892 5.13 in acute pancreatitis cell models is still a subject of 





In conclusion, an advanced stereoselective synthesis of the peptidyl trifluoromethylketone 
ZD-0892 was accomplished over an optimized 9 step synthesis. A reevaluation of published 
synthetical protocols allowed the establishment of a safer and easier way to access 
stereodemanding intermediates. The in vitro test results regarding the dual inhibition of 
both pancreatic- as well as neutrophil elastase in acinus cells using ZD-0892, which are being 
conducted by the group of Dr. Matthias Sendler in the clinic and polyclinic for internal 
medicine A at the university medical center of Greifswald, are still a subject of ongoing 
research. ZD-0892 could potentially offer a causal treatment of acute pancreatitis. 
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6 Summary and Outlook 
This thesis summarizes initial approaches to access pharmaceutically relevant motifs for 
the individualized therapies of hereditary liver and pancreas diseases. Beside the use of 
different well-established organic chemistry related methods to access literature-known 
compounds, the development of new highly sustainable protocols for the catalytic 
functionalization of organic scaffolds is described. 
An efficient photoredox catalytic decarboxylative methodology to forge new CC bonds 
was described. The photocatalytic decarboxylative Giese-type addition of corresponding 
carboxylic acids to electron-deficient alkenes was accomplished using pyrimidopteridine N-
oxides as photocatalysts. Moreover, the use of catalytic amounts of base and the metal-free 
nature of this protocol offers an environmentally-benign method.  
Also, the photocatalytic hydroamination of different stilbene derivatives using primary 
unprotected amines was showcased. This transformation was accessible using 
pyrimidopteridine N-oxides as photocatalysts in an additive-free setup. Different primary 
unprotected amines proved to be competing coupling partners, giving access to -phenyl 
phenethylamine derivatives, known for their biological activity. 
Moreover, two glitazone derivatives, rosiglitazone and lobeglitazone, as well as two 
different copper chemosensors, CS3 and, CPF1 in addition to the corresponding control 
molecule ctrl-CPF1, were synthesized. Literature reports addressing the total-synthesis of 
latter compounds were re-evaluated. Also, optimization of the reactions during different 
steps of the total-synthesis of CS3, CPF1 and ctrl-CPF1 was achieved. The use of a copper 
chemosensor CS3 for the quantification of labile copper pools in HepG2 cell cultures was 
demonstrated. In the same context, the total-synthesis of a potent peptidyl trifluoromethyl 
ketone elastase-inhibitor ZD-0892 was revised and optimized. The combination of different 
literature known methodologies allowed the establishment of a safer and easier way to 
access ZD-0892. 
The wide variety of synthesized potential bioactive compounds are still under 
investigation and subject of ongoing research within the interdisciplinary research cluster of 
the project. Successfully tested compounds could provide a platform for the treatment of 
hereditary liver and pancreas diseases.  
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7 Experimental section 
7.1 General remarks 
All reactions involving moisture- or air-sensitive reactants or products were performed 
under an atmosphere of dry argon using standard Schlenk techniques and predried 
glassware. Syringes for handling of dry solvents or liquid reactants were flushed with dry 
argon prior to use. All chemicals, unless otherwise indicated, were obtained from 
commercial sources. The synthesis of the starting materials, if not purchased, was carried 
out by literature methods. 
Solvents 
All solvents for reactions containing moisture-sensitive reactants were purchased from 
SIGMA-ALDRICH and ACROS ORGANICS or dried by the usual methods and stored under inert 
atmosphere (argon) according to following standard procedures. Water was degassed by 
bubbling Argon through the solution over 30 minutes and ultrasonication. 
Chromatography  
Analytical thin layer chromatography (TLC) was performed on 0.25 mm silica gel 60F plates 
(MACHEREY-NAGEL) with 254 nm fluorescent indicator from MERCK. Unless otherwise noted, 
plates were visualized under ultraviolet light (254 nm) and developed by treatment with the 
KMnO4 solution. 
  Chromatographic purification of products was accomplished by flash column 
chromatography on Fluka silica gel, grade 60 (0.063-0.200 mm, 70–230 mesh). Solvents used 
for column chromatography were distilled prior of use. 
Analytical Data  
Analytical data of substances that are known in literature (marked by corresponding 
references) were compared with those described in the literature.  
Infrared Spectroscopy  
Infrared spectra were recorded using a Nicolet 550 FT-IR spectrometer with ATR sampling 
technique. Liquid probes were measured as film, solid probes were measured neat. 
Absorption is given in wavenumbers (cm-1). Signal characterization: w = weak, m = medium, 




Nuclear Magnetic Resonance Spectroscopy  
Nuclear magnetic resonance (NMR) spectra were recorded on Bruker AV 300 (300 MHz), 
Bruker AV 400 (400 MHz), and Fourier 300 (300 MHz). For characterization of the observed 
signal multiplicities the following abbreviations were applied: s (singlet), d (doublet), 
t (triplet), q (quartet), m (multiplet). Unless otherwise mentioned, all NMR spectra were 
collected in CDCl3 solution. Chemical shifts are reported as δ-values in ppm relative to the 
residual proton peak of the deuterated solvent or its carbon atom, respectively. Coupling 
constants are indicated as J with residual peaks of CHCl3 at δ = 7.24 ppm, DMSO at δ = 
2.49 ppm, CH2Cl2 at δ = 5.32 ppm, CHD2OD at δ = 3.35 ppm. Coupling constants J are 
reported in Hertz (Hz). Residual carbon peaks are as following: CHCl3 at δ = 77.23 ppm, 
DMSO at δ = 39.51 ppm, CH2Cl2 at δ = 54.00 ppm, CHD2OD at δ = 49.15 ppm. 2D NMR 
techniques (NOESY, COSY, HMBC, HSQC) were performed confirming the structures of the 
synthesized molecules. The spectra were measured with a standard number of scans. 
Mass spectroscopy 
Mass spectra were measured on FINNIGAN MAT 95 (200 eV, EI-MS) or LCQ (70 eV, ESI-MS). 
The ratio of mass to charge are indicated, intensities relative to the base peak (I = 100) are 
written in parentheses. High resolution mass spectras (HRMS) were recorded on BRUKER 
APEX IV (7 T, Transform Ion Cyclotron Resonance (FTICR) mass spectrometer). 
Melting Points 
Melting points were measured using a BÜCHI melting point apparatus. Reported values are 
uncorrected. 
Crystallographic data 
Crystallographic data were collected on a BRUKER KAPPA APEX II DUO diffractometer. The 
structure was solved by direct methods and refined by full-matrix least-squares procedures 
on F2 with the SHELXTL software package (Sheldrick, G. M. Acta Crystallogr. 2008, A64, 112.). 
XP (BRUKER AXS) was used for graphical representation. Displacement ellipsoids are drawn at 
the 30% probability level. 
Photoreactions 
Reactions were performed under Schlenk conditions using a 5 ml reaction vial from 
Biotage® equipped with a NS 14.5 rubber septum. The reaction mixture was then irradiated 
with 2 UV-lamps ONFURO IP66 (30 W) (max = 396 nm) for the indicated time with a distance 
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of 5.7 cm to the nearest- and 10.4 cm to the distant lamp and quenched afterwards upon 
exposure to air. 
7.2 General procedures 
General procedure A: Pyrimidopteridine N-oxide photo-mediated decarboxylative Giese-
type addition 
Unless otherwise mentioned, reactions were performed under Schlenk conditions using a 
5 ml reaction vial equipped with a NS 14.5 rubber septum. To this vial was added the 
appropriate carboxylic acid 2.1 (0.50 mmol, 1.0 equiv.), photocatalyst PrPPTNO 1.2 
(5.0 mol%) and K3PO4 (20.0 mol%). Next, the vial was evacuated and purged with argon for 
3 times. The corresponding olefin 2.4 (1.0 mmol, 2.0 equiv.) was then added to the flask 
under argon. Afterwards, acetonitrile (4.5 ml) and degased water (0.5 ml) were added and 
the reaction mixture was stirred for 2 minutes in the dark. The reaction mixture was then 
irradiated for the indicated time and quenched afterwards upon exposure to air and 
bubbling air through the solution using a pipette. The reaction temperature was monitored 
in an adjacent microwave vial filled with paraffin oil and equipped with a thermal sensor. 
The reaction mixture was concentrated under reduced pressure and the crude mixture was 
purified by column chromatography. 
General procedure B: Pyrimidopteridine N-oxide photo-mediated hydroamination of 
unactivated stilbenes 
Reactions were performed under Schlenk conditions using a 5 ml reaction vial equipped 
with a NS 14.5 rubber septum. The vial containing the corresponding stilbene 3.2 
(0.50 mmol, 1.0 equiv.) and photocatalyst PrPPTNO 1.2 (5.0 mol%) was evacuated for 
5 minutes and purged with argon. Acetonitrile (2.5 ml) was added and the corresponding 
amine 3.1 (2.50 mmol, 5.0 equiv.) was added to the stirring solution. The reaction vial was 
rinsed with acetonitrile (2.5 ml). Next, the reaction mixture was irradiated at 396 nm for 
16-24 h. The reaction temperature was monitored in an adjacent microwave vial filled with 
paraffin oil and equipped with a thermal sensor. A constant temperature of 30 °C was 
measured due to heat emission of the LED. No extra heating or cooling was applied. After 
the indicated time, the reaction was quenched upon exposure to air and bubbling air 
through the solution using a pipette. The reaction was concentrated under reduced pressure 
and the crude product was purified by column chromatography.  
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7.2.1 Experimental section to Chapter 2 
Synthesis of dimethyl 2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)succinate (2.6aa). 
 
Compound 2.6aa was prepared following general procedure A. Dimethyl maleate 2.4a 
(144 mg, 1.0 mmol, 2.0 equiv.) was used. Purification by column chromatography 
(n-pentane: acetone = 40:  →  0: ) yiel e  the title co poun  2.6aa (140 mg, 0.4 mmol, 
88%) as a yellow oil. Analytical data are stated for a mixture of two diastereomers (dr: 1:1). 
Rf = 0.20 (n-pentane:acetone = 10:1, KMnO4). 
1H NMR (300 MHz, CDCl3) δ  4.28 – 3.86 (m, 1H), 3.72 – 3.65 (s, 3H), 3.64 (s, 3H), 3.62– 
3.06 (m, 3H), 2.73 (m, 1H), 2.55 – 2.22 (m, 1H), 1.97 – 1.61 (m, 4H), 1.45 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ  173.8, 173.4, 172.6, 58.5, 57.6, 52.1, 51.9, 47.3, 44.5, 44.1, 
33.8, 28.5, 27.9, 23.6, 22.9. 
MS (EI) m/z relative Intensity: 315 (0.1) [M], 154 (15), 128 (19), 114 (57), 70 (100), 57 (57), 
41 (19). 
HRMS (ESI-TOF, m/z): calcd. for C15H25NO6 [M]
+ 338.1676, found 338.1678. 
IR (ATR, neat, cm-1): 2974 (w), 2955 (w), 2885 (w), 1733 (s), 1689 (s), 1557 (w), 1478 (w), 
1436 (m), 1388 (s), 1366 (s), 1314 (m), 1255 (m), 1157 (s), 1116 (s), 1009 (m), 942 (w), 913 
(m), 873 (m), 846 (m), 772 (m), 675 (w), 544 (w), 509 (w), 462 (w). 
Synthesis of dimethyl 2-((3r,5r,7r)-adamantan-1-yl)succinate (2.6ba) 
 
Compound 2.6ba was prepared following general procedure A. Dimethyl maleate 2.4a 
(144 mg, 1.0 mmol, 2.0 equiv.) was used. Purification by column chromatography 
(n-pentane:EtOAc = 15:1) yielded the title compound 2.6ba (115 mg, 0.41 mmol, 82%) as a 
colorless solid. The analytic data is in correspondence with those reported in literature.[183] 
m.p. 51 °C 
Rf = 0.58 (n-pentane:EtOAc = 10:1, KMnO4) 
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1H NMR (400 MHz, CDCl3) δ  3.64 (s, 3H), 3.60 (s, 3H), 2.70 (m, 1H), 2.45 (m, 2H), 1.96 (m, 
3H), 1.61 (q, J  12.2 Hz, 9H), 1.42 (m, 3H). 
13C NMR (75 MHz, CDCl3) δ  174.3, 173.4, 52.3, 51.8, 51.3, 40,0, 36.8, 34.4, 31.0, 28.5. 
MS (EI) m/z (relative intensity): 280 (1), 248 (13), 145 (7), 135 (100), 107 (6), 93 (12), 79 (14). 
HRMS (ESI-TOF, m/z): calcd. for C16H24O4 [M
+] 280.1669, found 280.1664. 
IR (ATR, neat, cm-1): 2900 (s), 2847 (m), 1725 (s), 1438 (s), 1413 (w), 1366 (m), 1340 (m), 
1304 (m), 1285 (w), 1229 (s), 1208 (s), 1194 (s), 1161 (s), 1119 (m), 1097 (m), 1081 (w), 1011 
(w), 987 (m), 964 (m), 887 (w), 845 (m), 819 (w), 798 (w), 773 (w), 720 (w), 681 (w), 590 (w), 
525 (w), 454 (w). 
Big scale synthesis of dimethyl 2-((3r,5r,7r)-adamantan-1-yl)succinate (2.6ba) 
To a 100 ml flame dried Schlenk flask equipped with a stir bar was added 1-
adamantanecarboxylic acid 2.1b (541 mg, 3.0 mmol, 1.0 equiv.), n-propyl PPTNO 1.2 (65 mg, 
0.150 mmol, 0.05 equiv.) and K3PO4 (127 mg, 0.600 mmol, 0.2 equiv.). The flask was 
evacuated and flushed with argon for 3 times. Afterwards, dimethyl maleate 2.4a (865 mg, 
6.0 mmol, 2.0 equiv.) was added, followed by dry MeCN (27 ml) and degassed water (3 ml) 
under argon. The reaction mixture was allowed to stir in the dark for 2 minutes, then it was 
irradiated for 24 hours. The reaction was quenched by bubbling air through the reaction 
mixture using a pipette. Drying the mixture under vacuum afforded an oil which was purified 
by column chromatography (n-pentane:EtOAc  15:1) and the title compound 2.6ba 
(375 mg, 1.34 mmol, 45%) was obtained as a colorless solid. 
Crystallographic Data of dimethyl 2-((3r,5r,7r)-adamantan-1-yl)succinate (2.6ba) 
Data were collected on a Bruker Kappa APEX II Duo diffractometer using Mo-Ka radiation. 
The structures were solved by direct methods (SHELXS-97: Sheldrick, G. M. Acta Cryst. 2008, 
A64, 112.) and refined by full-matrix least-squares procedures on F2 (SHELXL-2014 and 
SHELXL-2018, resp.: Sheldrick, G. M. Acta Cryst. 2015, C71, 3.). XP (Bruker axs) was used for 











unit cell dimensions    
 a = 9.3426(9) Å  = 90 °
 b = 21.642(2) Å  = 1473.5(2) ° 
 c = 7.3217(7) Å  = 150(2) °
space group P21/c  
Z 4  
 [mm-1] 0.09  
density [g/cm3] 1.264    
no. of reflections measured 27916  
no. of independent reflections 3562 (Rint = 0.028)  
no. of observed reflections (I > 2σ(I)) 2926  
no. of parameters 183  
R1 (I>2(I)) 0.041  
wR2 (all data) 0.116  
Goodness of fit on F2 1.03  











Compound 2.6ca was prepared following general procedure A for 48 h. 18β-Glycyrrhetinic 
acid (enoxolone) 2.1j (235 mg, 0.5 mmol, 1.0 equiv.) was used. Purification by column 
chromatography (n-pentane:EtOAc =  0:  → 5: ) yiel e  the title co poun  2.6ca (223 mg, 
0.391 mmol, 78%) as a colorless thick oil. (mixture of diastereomers) 
Rf = 0.2 (n-pentane:EtOAc = 5:2, UV, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  5.55 (m, 1H), 3.65 (m, 6H), 3.21 (dd, J  10.5, 5.8 Hz, 1H), 2.76 
(m, 2H), 2.58 (m, 1H), 2.46 (ddd, J  16.4, 7.1, 2.8 Hz, 1H), 2.31 (d, J  7.3 Hz, 1H), 2.11 (m, 
1H), 1.90 (m, 3H), 1.60 (m, 5H), 1.38 (m, 10H), 1.15 (m, 8H), 0.96 (m, 9H), 0.81 (d, J  16.2 Hz, 
6H). 
13C NMR (75 MHz, CDCl3) δ  200.4, 200.2, 174.4, 174.3, 173.2, 173.1, 169.7, 169.5, 128.6, 
128.5, 78.8, 61.9, 61.9, 55.0, 53.3, 53.2, 52.0, 51.7, 51.6, 46.9, 45.6, 43.4, 41.8, 40.5, 39.2, 
37.2, 36.1, 35.7, 32.8, 32.4, 32.4, 31.8, 31.8, 31.2, 30.1, 28.7, 28.6, 28.2, 27.4, 26.4, 26.3, 
23.6, 23.5, 18.8, 18.5, 18.5, 17.6, 16.5, 16.4, 15.7. 
MS (EI) m/z (relative intensity): 570 (56) [M], 539 (7), 403 (100), 362 (84), 339 (18), 302 (12), 
235 (15), 217 (15), 193 (16), 188 (11), 175 (71), 161 (10), 135 (46), 121 (17), 95 (19). 
HRMS (ESI-TOF, m/z): calcd. for C35H55O6 [M+H]
+ 571.3998, found 571.4002. 
IR (ATR, neat, cm-1): 3433 (w, br.), 2946 (w), 2926 (w), 2865 (w), 1730 (w), 1655 (w), 
1436 (w), 1195 (w), 1162 (w), 1037 (w), 729 (w). 




Compound 2.6da was prepared following general procedure A. α-(Boc-amino)isobutyric acid 
2.1d  (102 mg, 0.5 mmol, 1.0 equiv.) and dimethyl maleate 2.4a (144 mg, 1.0 mmol, 
2.0 equiv.) were used.  Purification by column chromatography (n-pentane:EtOAc = 9:1) 
yielded the title compound 2.6da (69 mg, 0.222 mmol, 45%) as a colorless oil. The product 
mixture gives multiple sets of NMR signals, owing to the presence of rotamers around the 
amide. 
Rf = 0.47 (n-pentane:EtOAc = 9:2, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  4.72 (br. s, 1H), 3.69 (s, 3H), 3.63 (s, 3H), 3.41 (m, 1H), 2.61 
(m, 2H), 1.42 (m, 9H), 1.32 (s, 3H), 1.26 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 174.2, 172.5, 154.4, 154.4, 79.4, 79.4, 79.3, 53.5, 53.4, 52.0, 
52.0, 51.8, 48.8, 48.8, 32.7, 28.5, 28.3, 25.6, 25.3, 17.5. 
MS (EI) m/z (relative intensity): 230 (4), 216 (6), 198 (5), 172 (7), 155 (21), 128 (19), 114 (21), 
102 (57), 96 (7), 84 (10), 69 (6), 57 (100). 
HRMS (ESI-TOF, m/z): calcd. for C14H25NO6Na [M+Na]
+ 326.1579, found 326.1575. 
IR (ATR, neat, cm-1): 3379 (w), 2977 (w), 2953 (w), 1714 (m), 1510 (m), 1439 (m), 1366 (m), 
1243 (m), 1160 (s), 1074 (m), 1021 (w). 
Synthesis of dimethyl 2-(2-phenoxypropan-2-yl)succinate (2.6ea) 
 
Compound 2.6ea was prepared following general procedure A. Dimethyl maleate 2.4a 
(144 mg, 1.0 mmol, 2.0 equiv.) was used. Purification by column chromatography 
(n-pentane:EtOAc = 9:1) yielded the title compound 2.6ea (37 mg, 0.132 mmol, 26%) as a 
colorless oil.  
Rf = 0.45 (n-pentane:EtOAc = 9:1, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  7.31 (m, 2H), 7.19 (m, 1H), 6.88 (m, 2H), 4.24 (m, 1H), 
3.80 (s, 3H), 3.77 (s, 3H), 3.71 (m, 1H), 3.29 (dd, J  17.5, 11.0 Hz, 1H), 1.55 (s, 3H), 1.26 (s, 
3H). 
13C NMR (75 MHz, CDCl3) δ  172.7, 172.4, 152.5, 129.0, 127.6, 120.9, 118.0, 117.4, 108.5, 
75.0, 52.6, 52.3, 50.8, 42.8, 28.6, 20.9. 
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MS (EI) m/z (relative intensity): 280 (6), 249(4), 220 (14), 188 (16), 166 (23), 161 (17), 
145 (25), 134 (100), 127 (15), 119 (10), 106 (46), 95 (39), 83 (21), 77 (44). 
HRMS (ESI-TOF, m/z): calcd. for C15H21O5 [M+H]
+ 281.1389, found 281.1393. 
IR (ATR, neat, cm-1): 2986 (w), 2955 (w), 1729 (s), 1583 (w), 1436 (w), 1333 (w), 1254 (m), 
1162 (m), 1114 (m), 1018 (w), 943 (w), 765 (m). 
Synthesis of dimethyl 2-(5-(2,5-dimethylphenoxy)-2-methylpentan-2-yl)succinate (2.6fa) 
 
Compound 2.6fa was prepared following general procedure A for 48 h. Dimethyl maleate 
2.4a (144 mg, 1.0 mmol, 2.0 equiv.) was used.  Purification by column chromatography 
(n-pentane:EtOAc = 10:1) yielded the title compound 2.6fa (30 mg, 0.085 mmol, 17%) as a 
colorless oil. 
Rf = 0.42 (n-pentane:EtOAc = 10:1, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  7.00 (d, J  7.5 Hz, 1H), 6.66 (d, J  7.5 Hz, 1H), 6.61 (s, 1H), 
3.91 (m, 2H), 3.69 (s, 3H), 3.66 (s, 3H), 2.82 (m, 2H), 2.48 (m, 1H), 2.31 (s, 3H), 2.17 (s, 3H), 
1.82 (m, 2H), 1.45 (m, 2H), 0.97 (d, J 2.0 Hz, 6H). 
13C NMR (75 MHz, CDCl3) δ  174.8, 173.3, 157.1, 136.6, 130.4, 123.7, 120.8, 112.1, 68.2, 
51.9, 51.6, 49.5, 37.3, 35.1, 32.4, 25.2, 25.0, 24.1, 21.5, 15.9. 
MS (EI) m/z (relative intensity): 350 (37) [M], 229 (100), 197 (10), 179 (11), 169 (15), 165 
(57), 137 (35), 122 (80), 109 (24), 95 (18), 83 (51).  
HRMS (ESI-TOF, m/z): calcd. for C20H31O5 [M+H]
+ 351.2171, found 351.2171. 
IR (ATR, neat, cm-1): 2951 (w), 2873 (w), 1732 (s), 1614 (w), 1509 (w), 1261 (m), 1191 (w), 
1156 (s), 1129 (m), 1008 (w), 504 (w). 





Compound 2.6ga was prepared following general procedure A for 48 h. 2-(4-(2-(4-
chlorobenzamido)ethyl)phenoxy)-2-methylpropanoic acid (Bezafibrate) 2.1g (181 mg, 
0.5 mmol, 1.0 equiv.) was used. Purification by column chromatography 
(n-pentane:acetone = 10:1) yielded the title compound 2.6ga (72 mg, 0.157 mmol, 31%) as a 
white solid. 
m.p.= 172173 °C 
Rf = 0.17 (n-pentane: acetone = 20:3, UV, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  7.63 (m, 2H), 7.36 (m, 2H), 7.08 (m, 1H), 7.02 (m, 1H), 
6.78 (d, J  8.3 Hz, 1H), 6.26 (t, J  5.5 Hz, 1H), 4.17 (d, J  11.8 Hz, 1H), 3.71 (m, 7H), 
3.53 (m, 1H), 3.24 (d, J  11.7 Hz, 1H), 2.81 (m, 2H), 1.50 (s, 3H), 1.22 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ  172.8, 172.3, 166.5, 151.3, 137.7, 133.0, 131.2, 129.4, 128.9, 
128.4, 127.9, 118.3, 117.6, 75.0, 52.6, 52.4, 50.8, 42.7, 41.4, 35.0, 28.5, 21.0. 
MS (EI) m/z (relative intensity): 459 (3) [M], 400 (9), 304 (100), 272 (37), 244 (64), 229 (52), 
199 (24), 171 (22), 159 (10), 139 (45), 128 8), 111 (16). 
HRMS (ESI-TOF, m/z): calcd. for C24H26O6NCl [M+H]
+ 460.1527, found 460.1521. 
IR (ATR, neat, cm-1): 3233 (w), 3083 (w), 2952 (w), 1731 (m), 1630 (w), 1303 (w), 1193 (m), 
847 (w), 737 (w). 
Synthesis of diethyl 2-(1-((3r,5r,7r)-adamantan-1-yl)ethyl)malonate (2.6bb) 
 
Compound 2.6bb was prepared following general procedure A. Diethyl ethylidenmalonate 
2.4b (186 mg, 1.0 mmol, 2.0 equiv.) was used. Purification by column chromatography 
(n-pentane:EtOAc = 20:1) yielded the title compound 2.6bb (148 mg, 0.460 mmol, 92%) as a 
colorless oil. The analytic data is in correspondence with those reported in literature.[183] 
Rf = 0.60 (n-pentane:EtOAc = 10:1, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  4.14 (m, 4H), 3.53 (d, J  5.2 Hz, 1H), 2.03 (qd, J7.3, 5.5 Hz, 
1H), 1.93 (s, 3H), 1.54 (m, 12H), 1.23 (m, 6H), 0.94 (d, J = 7.3 Hz, 3H). 




MS (EI) m/z (relative intensity): 276 (11), 208 (11), 187 (11), 163 (12), 135 (100), 115 (5), 
107 (12), 93 (20), 79 (21), 69 (8). 
HRMS (ESI-TOF, m/z): calcd. for C19H30O4 [M+Na]
+ 345.2041, found 345.2033. 
IR (ATR, neat, cm-1): 2980 (w), 2901 (m), 2848 (w), 1752 (m), 1728 (m), 1448 (w), 1218 
(m), 1138 (m), 1031 (m). 864 (w). 
Synthesis of diethyl 2-(1-(1-methylcyclohexyl)ethyl)malonate (2.6hb) 
 
Compound 2.6hb was prepared following general procedure A. 1-Methyl-1 
cyclohexanecarboxylic acid 2.1h (71 mg, 0.5 mmol, 1.0 equiv.) was used. Purification by 
column chromatography (n-pentane:EtOAc = 100:2) yielded the title compound 2.6hb 
(123 mg, 0.432 mmol, 87%) as a colorless oil. The analytic data is in correspondence with 
those reported in literature.[184] 
Rf = 0.67 (n-pentane:EtOAc 10:1, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  4.12 (m, 4H), 3.52 (d, J  4.7 Hz, 1H), 2.29 (qd, J  7.2, 4.7 Hz, 
1H), 1.31 (m, 17H), 0.96 (d, J  7.2 Hz, 3H), 0.78 (s, J  5.8 Hz, 3H).  
13C NMR (75 MHz, CDCl3) δ  170.4, 169.8, 61.4, 60.9, 52.3, 42.0, 36.3, 35.9, 35.9, 26.3, 22.0, 
21.9, 19.4, 14.1, 11.0. 
MS (EI) m/z (relative intensity): 285 (1), 239 (13), 188 (48), 173 (9), 142 (100), 125 (20), 115 
(87), 109 (6), 97 (71), 87 (27), 81 (25), 69 (53). 
HRMS (ESI-TOF, m/z): calcd. for C13H28O4Na [M+Na]
+ 307.1885, found 307.1886. 
IR (ATR, neat, cm-1): 2979 (w), 2926 (w), 2851 (w), 1729 (s), 1462 (w), 1389 (w), 1296 (m), 
1216 (m), 1143 (m), 1059 (m), 1029 (w), 864 (w). 
Synthesis of diethyl 2-(3,3-dimethylpentan-2-yl)malonate (2.6ib) 
 
Compound 2.6ib was prepared following general procedure A. 2,2-Dimethylbutyric acid 2.1i 
(58 mg, 0.5 mmol, 1.0 equiv.) was used. Purification by column chromatography 
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(n-pentane:EtOAc = 100:2) yielded the title compound 2.6ib (104 mg, 0.403 mmol, 78%) as a 
colorless oil. 
Rf  0.38 (n-pentane:EtOAc = 20:1, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  4.15 (m, 4H), 3.49 (d, J  4.9 Hz, 1H), 2.31 (qd, J 7.2, 4.9 Hz, 
1H), 1.26 (m, 8H), 0.97 (d, J7.2 Hz, 3H), 0.80 (m, 9H). 
13C NMR (75 MHz, CDCl3) δ  170.3, 169.8, 61.4, 61.0, 52.9, 40.4, 36.0, 32.9, 24.2, 24.1, 14.1, 
11.7, 8.2. 
MS (EI) m/z (relative intensity): 229 (25), 213 (27), 188 (35), 173 (9), 169 (8), 155 (46), 
142 (88), 127 (11), 115 (100), 99 (26), 87 (31), 71 (26).  
HRMS (ESI-TOF, m/z): calcd. for C14H26O4Na [M+Na]
+ 281.1728, found 281.1729. 
IR (ATR, neat, cm-1): 2968 (w), 2881 (w), 1752 (w), 1729 (m), 1464 (w), 1369 (w), 1284 (m), 
1143 (m), 1029 (m), 864 (w). 
Synthesis of diethyl 2-(3,3-dimethylbutan-2-yl)malonate (2.6jb) 
 
Compound 2.6jb was prepared following general procedure A. Diethyl ethylidenmalonate 
2.4b (186 mg, 1.0 mmol, 2.0 equiv.) was used. Purification by column chromatography 
(n-pentane:EtOAc = 40:1) yielded the title compound 2.6jb (80 mg, 0.327 mmol, 66%) as 
colorless oil. The analytic data is in correspondence with those reported in literature.[185] 
Rf  0.74 (n-pentane:EtOAc = 10:1, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  4.14 (qd, J  7.1, 3.1 Hz, 4H), 3.48 (d, J5.4 Hz, 1H), 2.20 (m, 
1H), 1.22 (ddd, J  7.1, 5.8, 3.2 Hz, 6H), 0.97 (d, J  7.2 Hz, 3H), 0.86 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ  170.3, 169.6, 61.4, 61.0, 53.4, 42.7, 33.7, 27.6, 14.1, 14.1, 12.1. 
MS (EI) m/z (relative intensity): 245 (1) [M], 229 (9), 199 (28), 188 (26), 173 (7), 155 (39), 
142 (72), 127 (12), 115 (100), 109 (13), 99 (24), 87 (41), 69 (45). 
HRMS (ESI-TOF, m/z): calcd. for C13H25O4 [M+H]
+ 245.1753, found 245.1753. 
IR (ATR, neat, cm-1): 2967 (w), 2907 (w), 1729 (s), 1466 (w), 1368 (m), 1296 (m), 1239 (m), 
1144 (m), 1030 (m), 865 (w), 775 (w). 




Compound 2.6kb was prepared following general procedure A. 3-Hydroxyadamantane-1-
carboxylic acid 2.1k (98 mg, 0.5 mmol, 1.0 equiv.) was used. Purification by column 
chromatography (DCM:MeOH = 100:1) yielded the title compound 2.6kb (142 mg, 
0.420 mmol, 84%) as a colorless oil. The analytic data is in correspondence with those 
reported in literature.[185] 
Rf  0.31 (DCM:MeOH  100:2, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  4.13 (m, 4H), 3.49 (d, J  5.1 Hz, 1H), 2.09 (m, 3H), 1.86 (m, 
1H), 1.57 (m, 4H), 1.36 (m, 8H), 1.21 (td, J  7.1, 4.5 Hz, 6H), 0.94 (d, J  7.3 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ  170.1, 169.5, 68.9, 61.4, 61.0, 52.0, 47.3, 44.7, 44.6, 42.9, 39.2, 
38.2, 37.9, 35.5, 30.6, 30.5, 14.1, 14.0, 10.7. 
MS (EI) m/z (relative intensity): 338 (1) [M], 292 (18), 206 (42), 188 (86), 179 (27), 161 (18), 
151 (72), 142 (100), 133 (16), 121 (10), 115 (69), 109 (13), 107 (27), 95 (58), 93 (59). 
HRMS (ESI-TOF, m/z): calcd. for C19H30O5Na [M+Na]
+ 361.1990, found 361.1990. 
IR (ATR, neat, cm-1): 3399 (w, br.), 2980 (w), 2906 (w), 2852 (w), 1726 (m), 1448 (w), 1297 
(w), 1210 (m), 1138 (m), 1027 (m), 939 (w). 
Synthesis of diethyl 2-(1-(2,2,5-trimethyl-1,3-dioxan-5-yl)ethyl)malonate (2.6lb) 
 
Compound 2.6lb was prepared following general procedure A. 2,2,5-trimethyl-1,3-dioxane-
5-carboxylic acid 2.1l (87 mg, 0.5 mmol, 1.0 equiv.) was used. Purification by column 
chromatography (n-pentane:EtOAc = 20:1) yielded the title compound 2.6lb (46 mg, 
0.145 mmol, 29%) as a colorless oil. 
Rf  0.31 (n-pentane:EtOAc = 10:1, KMnO4) 
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1H NMR (300 MHz, CDCl3) δ  4.17 (m, 4H), 3.74 (dd, J  21.1, 11.5 Hz, 2H), 
3.58 (d, J  5.0 Hz, 1H), 3.46 (ddd, J  11.8, 6.0, 1.1 Hz, 2H), 2.56 (qd, J  7.2, 5.1 Hz, 1H), 1.38 
(d, J  3.7 Hz, 6H), 1.26 (td, J  7.1, 3.5 Hz, 6H), 1.01 (d, J  7.2 Hz, 3H), 0.91 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ  169.7, 169.3, 98.1, 68.7, 68.0, 61.7, 61.2, 52.3, 36.5, 35.5, 24.5, 
23.2, 16.4, 14.1, 11.1. 
MS (EI) m/z (relative intensity): 301 (90), 271 (5), 231 (12), 213 (33), 185 (14), 167 (19), 161 
(24), 155 (100), 136 (18), 127 (18), 109 (18), 99 (11), 69 (21). 
HRMS (ESI-TOF, m/z): calcd. for C16H28O6Na [M+Na]
+ 339.1783, found 339.1789. 
IR (ATR, neat, cm-1): 2984 (w), 2940 (w), 2874 (w), 1728 (s), 1461 (w), 1371 (m), 1202 (m), 
1148 (m), 1085 (m), 1028 (m), 831 (m). 
Synthesis of dimethyl-2-(1-((4-methoxybenzoyl)-L-valyl)pyrrolidin-2-yl)succinate (2.6ma) 
 
Compound 2.6ma was prepared following general procedure A on a 0.2 mmol scale. 
(4-methoxybenzoyl)-L-valylproline 2.1m (52 mg, 0.15 mmol, 1.0 equiv.), dimethyl maleate 
2.4a (45 mg, 0.3 mmol, 2.0 equiv.), PrPPTNO 1.2 (3 mg, 0.01 mmol, 0.05 equiv.) and K3PO4 
(32 mg, 0.2 mmol, 1.0 equiv.) were used in 2 ml of MeCN:H2O (9:1). Purification by column 
chromatography (n-pentane:EtOAc = 2:1) yielded the title compound 2.6ma (51 mg, 
0.114 mmol, 75%) as a light yellow oil. Analytical data are stated for a mixture of two 
diastereomers (dr 1:1). 
Rf  0.17 (n-pentane: acetone  1:1, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  7.77 (dd, J  8.8, 6.8 Hz, 4H), 6.85 (m, 6H), 4.79 (m, 2H), 4.34 
(m, 2H), 3.82 (d, J  3.2 Hz, 6H), 3.67 (d, J  4.0 Hz, 3H), 3.65 (s, 3H), 3.60 (s, 3H), 3.57 (s, 3H), 
3.52 (d, J  4.4 Hz, 3H), 2.41 (m, 8H), 1.89 (m, 8H), 0.99 (m, 12H). 
13C NMR (75 MHz, CDCl3) δ  173.3, 173.0, 172.2, 172.1, 172.0, 171.9, 171.8, 171.4, 171.1, 
171.1, 166.8, 166.8, 166.6, 162.3, 128.9, 126.5, 126.4, 126.3, 113.8, 113.7, 113.7, 77.5, 77.1, 
76.6, 58.8, 58.3, 58.0, 57.7, 56.3, 56.2, 55.9, 55.9, 55.4, 52.1, 52.1, 52.1, 52.0, 52.0, 51.8, 
51.7, 48.1, 47.6, 47.2, 43.3, 42.7, 42.6, 42.3, 42.0, 33.7, 33.4, 31.8, 31.6, 31.5, 31.3, 31.1, 
Experimental section 
113 
31.0, 29.7, 27.3, 27.1, 27.0, 26.4, 25.0, 24.5, 24.3, 24.2, 23.7, 19.8, 19.8, 19.7, 19.6, 18.0, 
18.0, 17.4, 17.3, 17.3, 17.2.  
LCMS (ESI, m/z): 471.2 [M+Na]+ 
HRMS (ESI-TOF, m/z): calcd. for C23H32N2O7 [M] 448.2215, found 448.2216. 
IR (ATR, neat, cm-1): 3323 (w), 2957 w), 1732 (s), 1623 (s), 1606 (s), 1576 (w), 1536 (w), 1500 
(m), 1433 (s), 1308 (m), 1251 (s), 1170 (s), 1121 (m), 1027 (m), 896 (w), 845 (m), 767 (m), 732 
(w), 606 (m), 563 (m), 523 (m). 
Synthesis of dimethyl 2-(1-(((benzyloxy)carbonyl)amino)-2-methylpropyl)succinate (2.6na) 
 
Compound 2.6na was prepared following general procedure A. Dimethyl maleate 2.4a 
(144 mg, 1.0 mmol, 2.0 equiv.) and K3PO4 (80 mg, 0.5 mmol, 1.0 equiv.) were used. 
Purification by column chromatography (n-pentane: acetone = 20:1) yielded the title 
compound 2.6na (120 mg, 0.34 mmol, 68%) as a light-yellow oil. Analytical data are stated 
for a mixture of two diastereomers (dr 1:1). 
Rf  0.28 (n-pentane: acetone  20:1, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  7.33 (m, 5H), 5.28 (m, 1H), 5.10 (m, 2H), 3.67 (d, J6.6 Hz, 
5H), 3.55 (m, 1H), 3.21 (m, 1H), 2.66 (m, 2H), 1.64 (m, 1H), 0.94 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ  174.1, 172.0, 156.7, 136.6, 128.8, 128.6, 128.6, 128.1, 128.0, 
127.9, 66.8, 58.1, 52.0, 52.0, 42.4, 34.9, 32.0, 19.9, 19.4. 
MS (EI) m/z (relative intensity): 308 (6), 204 (23), 114 (6), 91 (100), 79 (4), 65 (6), 55 (6). 
HRMS (ESI-TOF, m/z): calcd. for C18H25NO6 [M
+] 351.1676, found 351.1671. 
IR (ATR, neat, cm-1): 3350 (w), 2957 (w), 1719 (s), 1587 (w), 1527 (m), 1455 (w), 1436 (m), 
1409 (w), 1390 (w), 1343 (m), 1232 (s), 1168 (s), 1116 (m), 1093 (m), 1027 (m), 999 (m), 
912 (w), 889 (w), 844 (w), 772 (w), 739(m), 697 (s), 597 (w), 523 (w), 457 (w). 




Compound 2.6oa was prepared following general procedure A for 24 h. Tetrahydro-2-furoic 
acid 2.1o (216 mg, 1.0 mmol, 2.0 equiv.) , dimethyl maleate 2.4a (144 mg, 0.5 mmol, 
1.0 equiv.) and K3PO4 (32 mg, 0.2 mmol, 0.4 equiv.) were used. Purification by column 
chromatography (n-pentane:EtOAc  3:1) yielded the title compound 2.6oa (57 mg, 
0.26 mmol, 52%) as colorless oil (mixture of diastereomers: 1:1). Diastereomers 2.6oa-1 and 
2.6oa-2 were then separated by column chromatography (n-pentane:EtOAc  3:1). The 
analytical data is in correspondence with those reported in literature.[186] 
2.6oa-1 
Rf 0.59 (n-pentane:EtOAc  3:1, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  4.00 (dd, J  14.1, 6.8 Hz, 1H), 3.76 (m, 5H), 3.67 (s, 3H), 2.82 
(m, 3H), 1.92 (m, 3H), 1.71 (m, 1H). 
13C NMR (75 MHz, CDCl3) δ  173.5, 172.8, 78.8, 68.2, 52.2, 51.9, 46.8, 33.3, 29.8, 25.7. 
MS (EI) m/z (relative intensity): 185 (3), 153 (3), 143 (15), 111 (11), 87 (3), 71 (100), 59 (13).  
HRMS (ESI-TOF, m/z): calcd. for C10H16O5Na [M+Na]
+ 239.0895, found 239.0899. 
IR (ATR, neat, cm-1): 2953 (w), 2874 (w), 1731 (s), 1436 (m), 1358 (m), 1260 (m), 1195 (m), 
1159 (s), 1063 (m), 1030 (m), 922 (w), 890 (w), 849 (m). 
2.6oa-2 
Rf  0.35 (n-pentane:EtOAc 3:1, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  4.05 (m, 1H), 3.85 (m, 1H), 3.73 (m, 4H), 3.67 (s, 3H), 3.08 (m, 
1H), 2.76 (m, 1H), 2.47 (dd, J 16.6, 4.5 Hz, 1H), 1.90 (m, 3H), 1.63 (m, 1H). 
13C NMR (75 MHz, CDCl3) δ  173.4, 172.4, 79.0, 68.6, 52.2, 52.0, 46.2, 32.6, 28.8, 25.8. 
MS (EI) m/z (relative intensity): 185 (4), 153 (2), 143 (14), 111 (10), 87 (2), 71 (100), 59 (13).  
HRMS (ESI-TOF, m/z): calcd. for C10H16O5Na [M+Na]
+ 239.0895, found 239.0894. 
IR (ATR, neat, cm-1): 2953 (w), 2874 (w), 1731 (s), 1436 (m), 1361 (w), 1260 (m), 1194 (m), 
1160 (s), 1065 (m), 1004 (m), 925 (w), 890 (w), 849 (w). 




Compound 2.6pb was prepared following general procedure A. 1,4-Benzodioxane-6-
carboxylic acid 2.1p (90 mg, 0.5 mmol, 1.0 eq.) was used. Purification by column 
chromatography (n-pentane:EtOAc 100:2) yielded the title compound 2.6pb (112 mg, 
0.347 mmol, 70%) as a colorless oil (mixture of diastereomers 1:1). The analytical data is in 
correspondence with those reported in literature.[66] 
Rf 0.31 (n-pentane:EtOAc = 10:1, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  6.83 (m, 4H), 4.23 (m, 6H), 4.01 (m, 1H), 3.75 (dd, J51.8, 
7.1 Hz, 1H), 2.57 (m, 1H), 1.27 (m, 6H), 1.12 (dd, J  19.9, 7.0 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ  169.0, 168.5, 168.4, 168.3, 143.7, 143.4, 143.3, 143.0, 121.6, 
121.5, 121.4, 117.3, 117.1, 117.1, 74.6, 73.7, 66.4, 66.2, 61.7, 61.6, 61.5, 61.3, 54.4, 52.2, 
34.6, 34.4, 14.2, 14.2, 14.2, 14.1, 13.1, 11.9. 
MS (EI) m/z (relative intensity): 322 (34) [M], 277 (17), 231 (10), 162 (100), 147 (19), 
139 (16), 135 (48), 121 (28), 111 (13), 95 (7), 69 (11). 
HRMS (ESI-TOF, m/z): calcd. for C17H22O6Na [M+Na]
+ 345.1313, found 345.1314. 
IR (ATR, neat, cm-1): 2981 (w), 2938 (w), 1727 (m), 1594 (w), 1493 (m), 1369 (w), 1265 (m), 
1252 (m), 1175 (w), 1029 (m), 859 (w). 
Synthesis of diethyl 2-(1-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)ethyl)malonate (2.6qb) 
 
Compound 2.6qb was prepared following general procedure A. Diethyl ethylidenmalonate 
2.4b (186 mg, 1.0 mmol, 2.0 equiv.) was used. Purification by column chromatography 
(n-pentane:EtOAc = 20:1 → 20:3) yielded the title compound 2.6qb (80 mg, 0.225 mmol, 
45%) as translucent oil. The products give multiple sets of NMR signals, owing to the 
presence of rotamers around the amide. Analytical data states for the diastereomeric 
mixture (1:1). The analytic data is in correspondence with those reported in literature.[183] 
Rf  0.23 (n-pentane:EtOAc  10:1, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  4.14 (m, 4H), 3.84 (m, 1H), 3.38 (m, 2H), 3.06 (m, 1H), 2.58 (m, 
1H), 1.81 (m, 4H), 1.46 (d, J  23.9 Hz, 9H), 1.24 (m, 6H), 0.89 (d, J  6.6 Hz, 3H). 
Experimental section 
116 
13C NMR (75 MHz, CDCl3) δ  169.0, 168.4, 155.3, 154.9, 79.8, 79.2, 61.3, 61.2, 60.6, 60.4, 
55.6, 54.8, 54.1, 47.2, 46.9, 37.1, 36.9, 29.3, 28.5, 28.5, 28.3, 28.2, 23.6, 23.4, 14.2, 14.1, 
13.8, 13.6. 
MS (EI) m/z (relative intensity): 301 (13), 255 (16), 227 (4), 187 (65), 181 (8), 160 (19), 
141 (100), 133 (12), 115 (15), 113 (21), 99 (8), 87 (13), 69 (32).  
HRMS (ESI-TOF, m/z): calcd. for C18H31NO6Na [M+Na]
+ 380.2043, found 380.2060. 
IR (ATR, neat, cm-1): 2975 (w), 2936 (w), 1751 (w), 1729 (m), 1689 (m), 1455 (w), 1381 (m), 
1365 (m), 1161 (m), 1105 (m), 1030 (m), 916 (w), 861 (w), 773 (w). 
Synthesis of diethyl 2-(1-cyclobutylethyl)malonate (2.6rb) 
 
Compound 2.6rb was prepared following general procedure A. Cyclobutane carboxylic acid 
2.1r (50 mg, 0.5 mmol, 1.0 equiv.) was used. Purification by column chromatography 
(n-pentane:EtOAc  100:2) yielded the title compound 2.6rb (43 mg, 0.177 mmol, 35%) as a 
colorless oil. The analytical data is in correspondence with those reported in literature.[64] 
Rf  0.45 (n-pentane:EtOAc  20:1, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  4.15 (qt, J  13.7, 6.8 Hz, 4H), 3.20 (d, J  6.3 Hz, 1H), 2.19 (m, 
2H), 1.93 (m, 2H), 1.71 (m, 4H), 1.25 (t, J  7.1 Hz, 6H), 0.90 (d, J  6.5 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ  169.4, 168.8, 61.3, 61.1, 55.1, 40.2, 40.1, 27.4, 27.2, 17.6, 14.2, 
14.2, 14.1. 
MS (EI) m/z (relative intensity): 227 (27), 199 (10), 197 (41), 169 (48), 160 (100), 150 (22), 
141 (92), 133 (38), 122 (22), 115 (57), 105 (9), 95 (34), 87 (25), 83 (21), 69 (30). 
HRMS (ESI-TOF, m/z): calcd. for C13H22O4Na [M+Na]
+ 265.1415, found 265.1418. 
IR (ATR, neat, cm-1): 2974 (w), 2938 (w), 1729 (s) 1463 (w), 1369 (w), 1242 (m), 1174 (m), 
1148 (m), 1031 (m), 862 (w). 




Compound 2.6sb was prepared following general procedure A for 24 h. Diethyl 
ethylidenmalonate 2.4b (93 mg, 0.5 mmol,  1.0 equiv.), cyclohexanecarboxylic acid 2.1s 
(128 mg, 1.0 mmol, 2.0 equiv.) and K3PO4 (43 mg, 0.2 mmol, 0.4 equiv.) were used. 
Purification by column chromatography (n-pentane:EtOAc  40:1) yielded the title 
compound 2.6sb (50 mg, 0.185 mmol, 37%) as colorless oil. The analytical data is in 
correspondence with those reported in literature.[66] 
Rf  0.34 (n-pentane:EtOAc  40:1, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  4.17 (m, 4H), 3.37 (d, J  9.1 Hz, 1H), 2.32 – 2.06 (m, 1H), 
1.80 – 1.51 (m, 5H), 1.38 – 1.00 (m, 12H), 0.88 (d, J  7.0 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 169.4, 169.2, 61.2, 61.2, 55.9, 40.4, 38.7, 31.6, 27.5, 26.9, 26.7, 
26.6, 14.2, 13.0. 
MS (EI) m/z (relative intensity): 271 (1) [M+H], 225 (11), 187 (42), 160 (100), 141 (31), 
133 (50), 115 (54), 105 (13), 88 (18), 81 (33), 69 (60).  
HRMS (ESI-TOF, m/z): calcd. for C15H26O4Na [M+Na]
+ 293.1728, found 293.1727. 
IR (ATR, neat, cm-1): 2979 (w), 2925 (m), 2853 (w), 1153 (w), 1730 (m), 1463 (w), 1448 (w), 
1149 (w), 1032 (w). 
Synthesis of diethyl 2-(1-(tetrahydrofuran-2-yl)ethyl)malonate (2.6tb) 
 
Compound 2.6tb was prepared following general procedure A for 24 h. Tetrahydro-2-furoic 
acid (116 mg, 1.0 mmol, 2.0 equiv.) and diethyl ethylidenmalonate 2.4b (93 mg, 0.5 mmol, 
1.0 equiv.) were used. Purification by column chromatography (n-pentane:EtOAc  20:1) 
yielded the title compound 2.6tb (44 mg, 0.170 mmol, 34%) as a colorless oil (mixture of 
diastereomers 1:1.3). The analytical data is in correspondence with those reported in 
literature.[187] 
Rf  0.14 (n-pentane:EtOAc  20:1, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  4.17 (qdd, J  7.1, 2.6, 2.0 Hz, 4H), 3.75 (m, 3H), 
3.59 (d, J  6.4 Hz, 0.52H), 3.40 (d, J  8.6 Hz, 0.43H), 2.47 (m, 0.43H), 2.27 (m, 0.56H), 1.90 
(m, 3H), 1.53 (m, 1H), 1.25 (m, 6H), 0.96 (dd, J  6.9, 4.0 Hz, 3H). 
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13C NMR (75 MHz, CDCl3) δ  169.4, 169.0, 168.9, 168.9, 81.4, 80.5, 68.4, 67.9, 61.3, 61.3, 
61.2, 61.1, 55.1, 54.5, 39.2, 37.5, 30.1, 28.6, 26.1, 26.0, 14.2, 14.2, 14.2, 13.6, 12.4. 
MS (EI) m/z (relative intensity): 257 (1) [M], 213 (17), 189 (11), 167 (16), 139 (11), 115 (7), 98 
(76), 71 (100). 
HRMS (ESI-TOF, m/z): calcd. for C13H22O5Na [M+Na]
+ 281.1364, found 281.1369. 
IR (ATR, neat, cm-1): 2977 (w), 2940 (w), 2875 (w), 1728 (s), 1464 (w), 1265 (m), 1174 (m), 
1153 (m), 1065 (m), 1030 (m), 863 (w). 
Synthesis of diethyl 2-(3-methylpentan-2-yl)malonate (2.6ub) 
 
Compound 2.6ub was prepared following general procedure A. 2,2-Dimethylbutyric acid 
2.1u (51 mg, 0.5 mmol, 1.0 equiv.) was used. Purification by column chromatography 
(n-pentane:EtOAc = 100:2) yielded the title compound 2.6ub (35 mg, 0.143 mmol, 29%) as a 
colorless oil. The analytical data is in correspondence with those reported in literature.[185] 
Rf  0.43 (n-pentane:EtOAc  20:1, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  4.17 (m, 4H), 3.33 (dd, J  21.7, 9.9 Hz, 1H), 2.28 (m, 1H), 
1.30 (m, 9H), 0.92 (m, 10H). 
13C NMR (75 MHz, CDCl3) δ  169.4, 169.2, 169.1, 61.3, 61.2, 57.0, 56.2, 38.9, 37.0, 36.6, 
36.2, 28.1, 23.8, 17.5, 14.2, 13.5, 12.6, 12.2, 12.1, 11.2. 
MS (EI) m/z (relative intensity): 199 (17), 187 (10), 160 (100), 141 (14), 133 (39), 115 (41), 
105 (8), 87 (24), 69 (28), 55 (10). 
HRMS (ESI-TOF, m/z): calcd. for C13H24O4Na [M+Na]
+ 267.1572, found 267.1570. 
IR (ATR, neat, cm-1): 2964 (w), 2936 (w), 1754 (m), 1730 (s), 1463 (w), 1368 (w), 1274 (w), 
1191 (m), 1129 (m), 1096 (w), 1031 (m), 860 (w). 





Compound 2.6vb was prepared following general procedure A. Boc-L-Phenylalanine 2.1v 
(133 mg, 0.5 mmol, 1.0 equiv.) and diethyl ethylidenmalonate 2.4b (186 mg, 1.0 mmol, 
2.0 equiv.) was used. Purification by column chromatography (n-pentane:EtOAc = 8:1) 
yielded the title compound 2.6vb (61 mg, 0.150 mmol, 30%) as a pale yellow oil (mixture of 
diastereomers). The analytical data is in correspondence with those reported in literature.[64] 
Rf  0.44 (n-pentane:EtOAc  8:2, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  7.26 (m, 2H), 7.15 (m, 3H), 4.51 (d, J  9.4 Hz, 0.39H), 4.21 
(m, 5.88H), 3.77 (m, 0.53H), 3.48 (d, J  6.8 Hz, 0.52H), 3.34 (m, 0.48H), 2.99 (m, 0.53H), 2.76 
(d, J  6.7 Hz, 0.76H), 2.62 (m, 0.54H), 2.45 (m, 1.08H), 1.28 (m, 15.88H), 1.11 (m, 1.77H), 
0.92 (t, J  7.2 Hz, 1.41H). 
13C NMR (75 MHz, CDCl3) δ  169.6, 169.0, 168.4, 155.6, 155.3, 138.0, 129.4, 129.2, 128.5, 
128.5, 126.5, 79.3, 79.1, 61.6, 61.4, 61.3, 61.2, 55.6, 55.4, 55.2, 54.3, 52.8, 39.9, 39.1, 37.2, 
35.8, 28.3, 28.0, 15.1, 14.2, 14.1, 11.1. 
MS (EI) m/z (relative intensity): 334 (2), 316 (18), 288 (4), 262 (17), 216 (100), 198 (16), 
170 (32), 142 (27), 131 (16), 124 (49), 96 (17), 91 (33), 69 (10), 57 (52).  
HRMS (ESI-TOF, m/z): calcd. for C13H24O4Na [M+Na]
+ 430.2205, found 430.2217. 
IR (ATR, neat, cm-1): 2978 (w), 2936 (w), 1726 (w), 1700 (w), 1497 (w), 1455 (w), 1389 (w), 
1366 (w), 1168 (w), 1028 (w), 700 (w). 
Synthesis of diethyl 2-(1-((tert-butoxycarbonyl)amino)propan-2-yl)malonate (2.6wb) 
 
Compound 2.6wb was prepared following general procedure A. Boc-glycine 2.1w (88 mg, 
0.5 mmol, 1.0 equiv.) and diethyl ethylidenmalonate 2.4b (186, 1.0 mmol, 2.0 equiv.) were 
used.Purification by column chromatography (n-pentane:EtOAc = 8:1) yielded the title 
compound 2.6wb (29 mg, 0.091 mmol, 18%) as a colorless oil. The analytical data is in 
correspondence with those reported in literature.[64] 
Rf  0.26 (n-pentane:EtOAc  8:1, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  4.72 (br. s, 1H), 4.19 (qd, J  7.1, 1.3 Hz, 4H), 
3.30 (d, J  7.4 Hz, 1H), 3.15 (m, 2H), 2.44 (dt, J  13.5, 6.7 Hz, 1H), 1.42 (s, J  6.3 Hz, 9H), 
1.27 (m, 6H), 1.00 (d, J  6.9 Hz, 3H). 
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13C NMR (75 MHz, CDCl3) δ  168.9, 168.7, 156.1, 79.4, 61.6, 61.5, 55.2, 34.2, 28.5, 15.7, 
14.2, 14.2. 
MS (EI) m/z (relative intensity): 260 (3), 244 (13), 216 (36), 198 (19), 172 (22), 160 (34), 
152 (12), 142 (28), 126 (29), 115 (32), 101 (27), 87 (23), 69 (22), 57 (100). 
HRMS (ESI-TOF, m/z): calcd. for C15H27NO6Na [M+Na]
+ 340.1735, found 340.1736. 
IR (ATR, neat, cm-1): 3399 (w), 2978 (w), 2936 (w), 1715 (m), 1513 (w), 1366 (m), 1254 (m), 
1162 (s), 1114 (m), 1029 (m), 994 (w), 861 (w). 
Synthesis of diethyl 2-(1-(cyclohexyloxy)propan-2-yl)malonate (2.6xb) 
 
Compound 2.6xb was prepared following general procedure A. 2-(cyclohexyloxy)acetic acid  
2.1x (79 mg, 0.5 mmol, 1.0 equiv.) and diethyl ethylidenmalonate 2.4b (186, 1.0 mmol, 
2.0 equiv.) were used. Purification by column chromatography (n-pentane:EtOAc = 20:1) 
yielded the title compound 2.6xb (32 mg, 0.107 mmol, 21%) as a colorless oil. 
Rf  0.65 (n-pentane:EtOAc  10:1, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  4.17 (qd, J  7.1, 1.6 Hz, 4H), 3.48 (d, J  7.4 Hz, 1H), 3.37 (m, 
2H), 3.16 (dt, J  8.6, 4.0 Hz, 1H), 2.47 (m, 1H), 1.76 (m, 4H), 1.47 (m, 1H), 1.23 (m, 11H), 1.01 
(d, J  6.9 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 169.2, 169.0, 77.6, 70.4, 61.2, 61.1, 54.3, 34.3, 32.1, 26.0, 24.1, 
14.8, 14.2, 14.2. 
MS (EI) m/z (relative intensity): 217 (3), 201 (14), 173 (100), 161 (38), 145 (35), 140 (78), 
133 (16), 127 (64), 115 (38), 109 (5), 82 (61), 69 (17). 
HRMS (ESI-TOF, m/z): calcd. for C16H28O5Na [M+Na]
+ 323.1833, found 323.1835. 
IR (ATR, neat, cm-1): 2980 (w), 2932 (w), 2856 (w), 1730 (s), 1450 (w), 1367 (w), 1258 (m), 
1176 (m), 1094 (s), 1029 (m), 947 (w). 




Compound 2.6yc was prepared following general procedure A. 2-(2-fluoro-[1,1'-biphenyl]-4-
yl)propanoic acid (flurbiprofen) 2.6y (122 mg, 0.5 mmol, 1.0 equiv.) and Dimethyl maleate 
2.4a (172 mg, 1.0 mmol, 2.0 equiv.) were used. The reaction mixture of two vials with the 
same content was combined, dried under reduced pressure and purified by column 
chromatography (n-pentane:EtOAc = 50:1) which yielded the title compound 2.6yc (33 mg, 
165 µmol, 17%) as a colorless oil. 
Rf  0.70 (n-pentane:EtOAc  50:1, UV, KMnO4) 
1H NMR (300 MHz, CDCl3) δ   7.64 – 7.52 (m, 2H), 7.48 – 7.41 (m, 2H), 7.40 – 7.31 (m, 2H), 
7.10 – 6.71 (m, 2H), 2.95 – 2.31 (m, 2H), 1.40 – 0.85 (t, J  7.6, 7.6 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ  161.5, 158.2, 146.1, 146.0, 130.6, 130.6, 129.1, 129.1, 128.5, 
127.5, 126.4, 126.3, 124.0, 124.0, 115.7, 115.6, 28.5, 28.5, 15.4. 
19F NMR (282 MHz, CDCl3) δ  118.81 (dd, J  11.5 Hz, 8.3 Hz). 
MS (EI) m/z (relative intensity): 200 (50) [M], 185 (100), 165 (17), 157 (4), 133 (9), 92 (5), 
63 (5). 
HRMS (ESI-TOF) m/z: calcd. for C14H13F1 [M]
+ 200.0996, Found 200.0996. 
IR (ATR, neat, cm-1): 2996 (w), 2873 (w), 1625 (w), 1483 (m), 1416 (m). 1266 (w), 1128 (w), 
1011 (w), 911 (m), 763 (m), 695 (s). 
Synthesis of diethyl 2-((3r,5r,7r)-adamantan-1-yl)succinate (2.9c) 
 
Compound 2.9c was prepared following general procedure A. Diethyl maleate 2.4c (172 mg, 
1.0 mmol, 2.0 equiv.) was used. Purification by column chromatography 
(n-pentane:EtOAc = 100:3) yielded the title compound 2.9c (128 mg, 0.415 mmol, 83%) as a 
colorless oil. 
Rf  0.58 (n-pentane:EtOAc  10:1, KMnO4) 
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1H NMR (300 MHz, CDCl3) δ 4.12 (m, 4H), 2.72 (dd, J  16.9, 12.2 Hz, 1H), 
2.46 (dt, J  11.7, 3.1 Hz, 2H), 1.96 (s, 3H), 1.64 (m, 9H), 1.44 (m, 3H), 1.24 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ  173.9, 173.0, 60.6, 60.2, 52.4, 40.1, 36.9, 34.5, 31.4, 28.6, 14.4, 
14.3. 
MS (EI) m/z (relative intensity): 308 (1) [M], 263 (16), 235 (11), 193 (3), 173 (17), 135 (100), 
119 (2), 107 (6), 93 (11), 79 (12).  
HRMS (ESI-TOF, m/z): calcd. for C18H28O4Na [M+Na]
+ 331.1885, found 331.1883. 
IR (ATR, neat, cm-1): 2980 (w), 2902 (m), 2849 (w), 1726 (s), 1447 (w), 1369 (w), 1188 (m), 
1156 (s), 1028 (m). 
Synthesis of di-tert-butyl 2-((3r,5r,7r)-adamantan-1-yl)succinate (2.9d) 
 
Compound 2.9d was prepared following general procedure A. Di-tert-butyl fumarate 2.4d 
(228 mg, 1.0 mmol, 2.0 equiv.) was used. Purification by column chromatography 
(n-pentane:EtOAc = 100:2) yielded the title compound 2.9d (97 mg, 0.266 mmol, 53%) as a 
white solid. 
m.p. 64-66 °C 
Rf  0.12 (n-pentane:EtOAc  100:2, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  2.42 (m, 3H), 1.94 (m, 3H), 1.62 (m, 9H), 1.48 (m, 3H), 
1.43 (s, 9H), 1.40 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ  172.9, 172.4, 80.4, 80.3, 53.4, 40.2, 37.0, 34.4, 32.6, 28.7, 28.2, 
28.2. 
MS (EI) m/z (relative intensity): 308 (1), 252 (26), 234 (10), 207 (15), 165 (2), 135 (100), 
107 (3), 93 (6), 79 (6), 57 (24).  
HRMS (ESI-TOF, m/z): calcd. for C22H36O4Na [M+Na]
+ 387.2510, found 387.2507. 
IR (ATR, neat, cm-1): 2976 (w), 2903 (m), 2849 (w), 1720 (m), 1365 (m), 1247 (w), 1141 (s), 
1119 (m), 849 (m). 




Compound 2.9e was prepared following general procedure A. 2-Cyclopentenon 2.4e (82 mg, 
1.0 mmol, 2.0 equiv.) was used. Purification by column chromatography 
(n-pentane:EtOAc = 20:1) yielded the title compound 2.9e (97 mg, 0.444 mmol, 89%) as a 
colorless oil. The analytical data is in correspondence with those reported in literature.[188] 
Rf  0.50 (n-pentane:EtOAc  10:1, KMnO4) 
1H NMR (400 MHz, CDCl3) δ  2.28 (m, 1H), 2.11 (m, 2H), 1.93 (m, 5H), 1.81 (m, 1H), 
1.70 (m, 3H), 1.61 (m, 4H), 1.49 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ  220.1, 48.9, 40.1, 39.2, 38.9, 37.3, 33.5, 28.5, 22.5. 
MS (EI) m/z (relative intensity): 218 (6) [M], 135 (100), 105 (3), 93 (14), 79 (15), 53 (3).  
HRMS (ESI-TOF, m/z): calcd. for C15H22O1 [M]
+ 218.1665, found 218.1672. 
IR (ATR, neat, cm-1): 2898 (m), 2845 (m), 1739 (s), 1449 (w), 1404 (w), 1171 (w), 1131 (w), 
1099 (w), 499 (w). 
Synthesis of 3-((3r,5r,7r)-adamantan-1-yl)cyclohexan-1-one (2.9f) 
 
Compound 2.9f was prepared following general procedure A. 2-cyclohexenone 2.4f (96 mg, 
1.0 mmol, 2.0 equiv.) was used. Purification by column chromatography 
(n-pentane:EtOAc = 15:1) yielded the title compound 2.9f (94 mg, 0.405 mmol, 81%) as a 
white solid. The analytical data is in correspondence with those reported in literature.[188] 
Rf  0.61 (n-pentane:EtOAc  10:1, KMnO4) 
m.p. = 6465 °C 
1H NMR (300 MHz, CDCl3) δ  2.36 (m, 2H), 2.20 (m, 1H), 2.06 (m, 2H), 1.92 (m, 4H), 
1.61 (m, 6H), 1.48 (m, 7H), 1.27 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ  213.5, 49.8, 42.2, 41.7, 37.3, 34.6, 28.7, 25.8, 24.7. 
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MS (EI) m/z (relative intensity): 232 (3), 135 (100), 107 (10), 93 (19), 79 (23), 69 (4).  
HRMS (ESI-TOF, m/z): calcd. for C16H24O [M
+] 232.1822, found 232.1821. 
IR (ATR, neat, cm-1): 2964 (s), 2843 (s), 1708 (m), 1448 (w), 1346 (w), 1316 (w), 1228 (w), 
1167 (w), 1034 (w), 923 (w). 
Synthesis of 3-((3r,5r,7r)-adamantan-1-yl)cycloheptan-1-one (2.9g) 
 
Compound 2.9g was prepared following general procedure A. 2-Cyclohepten-1-one 2.4g 
(110 mg, 1.0 mmol, 2.0 equiv.) was used. Purification by column chromatography 
(n-pentane:EtOAc = 97:3) yielded the title compound 2.9g (23 mg, 0.093 mmol, 19%) as a 
white solid. 
m.p. 7173 °C 
Rf  0.23 (n-pentane:EtOAc  20:1, KMnO4) 
1H NMR (400 MHz, CDCl3) δ  2.46 (m, 3H), 2.30 (dd, J  14.2, 11.5 Hz, 1H), 1.98 (m, 5H), 1.89 
(m, 1H), 1.57 (m, 13H), 1.27 (m, 2H), 1.01 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ  216.1, 46.5, 44.5, 43.4, 39.2, 37.3, 35.4, 29.7, 29.6, 28.8, 25.4. 
MS (EI) m/z (relative intensity): 246 (11) [M], 228 (10), 135 (100), 107 (7), 93 (13), 79 (13), 
67 (5), 54 (1).  
HRMS (ESI-TOF, m/z): calcd. for C17H26O1 [M]
+ 246.1978, found 246.1984. 
IR (ATR, neat, cm-1): 2897 (m), 2846 (m), 1697 (m), 1446 (w), 1346 (w), 1131 (w), 1005 (w). 
Synthesis of 3-((3r,5r,7r)-adamantan-1-yl)-2-methylcyclopentan-1-one (2.9h) 
 
Compound 2.9h was prepared following general procedure A. 2-Methyl-2-cyclopenten-1-one 
2.4h (96 mg, 1.0 mmol, 2.0 equiv.) was used. Purification by column chromatography 
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(n-pentane:EtOAc = 40:1) yielded the title compound 2.9h (66 mg, 0.284 mmol, 57%) as a 
colorless oil (mixture of diastereomers 1:2.3). 
Rf = 0.70 (n-pentane:EtOAc = 10:1, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  2.28 (m, 1H), 2.10 (m, 1H), 2.00 (m, 4H), 1.84 (m, 1H), 
1.57 (m, 14H), 1.12 (m, 3H). 
13C NMR (75 MHz, CDCl3) δ  222.8, 222.6, 55.5, 52.7, 45.8, 44.1, 41.3, 40.4, 37.5, 37.4, 37.3, 
37.3, 34.5, 28.7, 28.7, 20.9, 19.8, 17.7, 13.2. 
MS (EI) m/z (relative intensity): 232 (9) [M], 135 (100), 119 (1), 107 (10), 93 (17), 79 (19), 
67 (7), 55 (7), 41 (9). 
HRMS (ESI-TOF, m/z): calcd. for C16H24ONa [M+Na]
+ 255.1724, found 255.1725. 
IR (ATR, neat, cm-1): 2963 (w), 2892 (s), 2845 (m), 1729 (s), 1445 (w), 1404 (w), 1268 (w), 
1132 (w), 981 (w), 824 (w). 
Synthesis of 2-((1S,3s)-adamantan-1-yl)chroman-4-one (2.9i) 
 
Compound 2.9i was prepared following general procedure A. 4H-chromen-4-one 2.4i 
(146 mg, 1.0 mmol, 2.0 equiv.) was used. Purification by column chromatography 
(n-pentane:EtOAc = 90:5) yielded the title compound 2.9i (54 mg, 0.191 mmol, 39%) as a 
colorless solid. The analytical data is in correspondence with those reported in literature.[66] 
m.p. 103105 °C 
Rf  0.26 (n-pentane:EtOAc  90:3, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  7.85 (m, 1H), 7.45 (m, 1H), 6.97 (m, 2H), 
3.90 (dd, J  13.5, 3.1 Hz, 1H), 2.66 (qd, J  16.5, 8.3 Hz, 2H), 2.05 (m, 3H), 1.67 (m, 12H). 
13C NMR (75 MHz, CDCl3) δ  193.9, 162.4, 135.9, 127.0, 121.0, 118.0, 85.6, 37.9, 37.2, 37.2, 
36.0, 28.3. 
MS (EI) m/z (relative intensity): 282 (68) [M], 164 (3), 147 (49), 135 (100), 121 (13), 93 (17), 
79 (16), 67 (6). 
HRMS (ESI-TOF, m/z): calcd. for C19H23O2 [M+H]
+ 283.1698, found 283.1693. 
IR (ATR, neat, cm-1): 2897 (m), 2848 (m), 1689 (m), 1604 (m), 1472 (m), 1462 (m), 1306 (m), 
1233 (m), 1147 (w), 753 (m). 
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Synthesis of 2-((1S,3s)-adamantan-1-yl)-6-fluorochroman-4-one (2.9j) 
 
Compound 2.9j was prepared following general procedure A. 6-fluoro-4H-chromen-4-one 
2.4j (164 mg, 1.0 mmol, 2.0 equiv.) was used. Purification by column chromatography 
(n-pentane:EtOAc = 90:5) yielded the title compound 2.9j (43 mg, 0.143 mmol, 29%) as a 
white solid. 
m.p.= 120122 °C 
Rf  0.61 (n-pentane:EtOAc  10:1, UV, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  7.49 (m, 1H), 7.17 (ddd, J  9.0, 7.8, 3.2 Hz, 1H), 6.95 (m, 1H), 
3.88 (dd, J  12.9, 3.8 Hz, 1H), 2.65 (m, 2H), 2.06 (m, 3H), 1.68 (m, 12H). 
13C NMR (75 MHz, CDCl3) δ  193.1, 193.1, 158.7, 158.7, 158.6, 155.5, 123.6, 123.3, 121.4, 
121.3, 119.7, 119.6, 112.0, 111.7, 86.0, 37.8, 37.1, 37.0, 36.0, 28.2. 
19F NMR (282 MHz, CDCl3) δ  122.04, 122.06, 122.07, -122.09, 122.10, 122.11. 
MS (EI) m/z (relative intensity): 300 (36) [M], 191 (1), 165 (74), 139 (15), 135 (100), 119 (3), 
110 (20), 93 (28), 82 (10), 79 (40), 67 (13), 41 (19). 
HRMS (ESI-TOF, m/z): calcd. for C19H22O2F [M+H]
+ 301.1604, found 301.1605. 
IR (ATR, neat, cm-1): 2893 (m), 2851 (w), 1686 (m), 1618 (w), 1478 (m), 1450 (w), 1292 (w), 
1273 (w), 1164 (w), 1001 (w), 881 (w). 
Synthesis of 2-((1S,3s)-adamantan-1-yl)-6-chlorochroman-4-one (2.9k) 
 
Compound 2.9k was prepared following general procedure A. 6-chloro-4H-chromen-4-one 
2.4k (181 mg, 1.0 mmol, 2.0 equiv.) was used. Purification by column chromatography 
(n-pentane:EtOAc = 90:5) yielded the title compound 2.9k (70 mg, 0.221 mmol, 44%) as a 
light yellow solid. 
m.p. 152154 °C 
Rf  0.63 (n-pentane:EtOAc  10:1, UV, KMnO4) 
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1H NMR (300 MHz, CDCl3) δ  7.81 (m, 1H), 7.39 (dd, J  8.8, 2.7 Hz, 1H), 6.96 (m, 1H), 
3.88 (dt, J  21.8, 10.9 Hz, 1H), 2.67 (qd, J  16.6, 8.4 Hz, 2H), 2.08 (m, 3H), 1.71 (m, 12H). 
13C NMR (75 MHz, CDCl3) δ  192.7, 160.8, 135.7, 126.5, 126.2, 121.7, 119.7, 85.9, 37.8, 37.1, 
36.9, 36.0, 28.2. 
MS (EI) m/z (relative intensity): 316 (25) [M], 183 (21), 181 (65), 154 (17), 135 (100), 
126 (19), 107 (13), 98 (5), 93 (27), 79 (38), 67 (14). 
HRMS (ESI-TOF, m/z): calcd. for C19H22O2Cl [M+H]
+ 317.1308, found 317.1303. 
IR (ATR, neat, cm-1): 2899 (w), 2848 (w), 1694 (w), 1602 (w), 1469 (w), 1270 (m), 1222 (w), 
997 (w), 819 (w), 797 (w). 
Synthesis of 2-((1S,3s)-adamantan-1-yl)-6-bromochroman-4-one (2.9l) 
 
Compound 2.9l was prepared following general procedure A. 6-bromo-4H-chromen-4-one 
2.4l (225 mg, 1.0 mmol, 2.0 equiv.) was used. Purification by column chromatography 
(n-pentane:EtOAc = 95:5) yielded the title compound 2.9l (100 mg, 0.277 mmol, 55%) as a 
white solid. 
m.p. 195196 °C 
Rf  0.91 (n-pentane:EtOAc  9:1, UV, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  7.93 (m, 1H), 7.50 (dd, J  8.8, 2.6 Hz, 1H), 6.87 (m, 1H), 
3.87 (dd, J  12.9, 3.8 Hz, 1H), 2.64 (qd, J  16.6, 8.3 Hz, 2H), 2.05 (m, 3H), 1.69 (m, 12H). 
13C NMR (75 MHz, CDCl3) δ  192.5, 161.2, 138.5, 129.4, 122.2, 120.1, 113.7, 85.9, 37.8, 37.1, 
36.9, 36.0, 28.4, 28.2, 28.0. 
MS (EI) m/z (relative intensity): 361 (11) [M], 281 (2), 227 (53), 2100 (10), 172 (6), 146 (2), 
135 (100), 118 (8), 93 (16), 79 (20), 63 (8).  
HRMS (ESI-TOF, m/z): calcd. for C19H22O2Br [M-H]
+ 359.0647, found 359.0648. 
IR (ATR, neat, cm-1): 2898 (w), 2847 (w), 1693 (m), 1597 (w), 1465 (w), 1414 (w), 1267 (m), 
1221 (w), 989 (w), 818 (m). 




Compound 2.9m was prepared following general procedure A. Phenyl vinyl sulfone 2.4m 
(168 mg, 1.0 mmol, 2.0 equiv.) was used. Purification by column chromatography 
(n-hexane:EtOAc = 30:1) yielded the title compound 2.9m (105 mg, 0.345 mmol, 69%) as a 
colorless thick oil. The analytical data is in correspondence with those reported in 
literature.[66] 
Rf  0.10 (n-hexane:EtOAc  97:3, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  7.89 (m, 2H), 7.64 (m, 1H), 7.55 (m, 2H), 3.04 (m, 2H), 
1.91 (s, 3H), 1.58 (m, 6H), 1.45 (m, 2H), 1.38 (d, J = 2.6 Hz, 6H). 
13C NMR (75 MHz, CDCl3) δ  139.3, 133.7, 129.3, 128.1, 51.3, 42.0, 36.9, 35.9, 31.9, 28.5. 
MS (EI) m/z (relative intensity): 304 (1) [M], 276 (2), 239 (2), 163 (2), 135 (100), 107 (5), 
93 (9), 77 (15), 67 (3). 
HRMS (ESI-TOF, m/z): calcd. for C18H25O2S [M+H]
+ 305.1575, found 305.1574. 
IR (ATR, neat, cm-1): 2898 (m), 2845 (m), 1584 (w), 1447 (m), 1322 (m), 1150 (s), 1099 (m), 
995 (w) 778 (m), 730 (m), 532 (s). 
Synthesis of 3-((3r,5r,7r)-adamantan-1-yl)propanenitrile (2.9n) 
 
Compound 2.9n was prepared following general procedure A. Acrylonitrile 2.4n (53 mg, 
1.0 mmol, 2.0 equiv.) was used. Purification by column chromatography 
(n-pentane:EtOAc = 10:1) yielded the title compound 2.9n (38 mg, 0.201 mmol, 40%) as a 
white solid. The analytical data is in correspondence with those reported in literature.[189] 
m.p.  4344 °C 
Rf  0.55 (n-pentane:EtOAc  10:1, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  2.26 (m, 2H), 1.97 (s, 3H), 1.62 (m, 6H), 1.47 (m, 8H). 
13C NMR (75 MHz, CDCl3) δ  121.0, 41.7, 39.6, 36.9, 32.2, 28.5, 11.1. 
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MS (EI) m/z (relative intensity): 189 (4) [M], 135 (100), 107 (7), 93 (12), 79 (12), 67 (4).  
HRMS (ESI-TOF, m/z): calcd. for C13H20N [M+H]
+ 190.1595, found 190.1597. 
IR (ATR, neat, cm-1): 2896 (m), 2846 (m), 2242 (w), 1448 (w), 1360 (w), 1345 (w), 1100 (w), 
973 (w), 812 (w). 
Synthesis of 3-((3r,5r,7r)-adamantan-1-yl)butanal (2.9o) 
 
Compound 2.9o was prepared following general procedure A. Crotonaldehyde 2.4o (70 mg, 
1.0 mmol, 2.0 equiv.) was used. Purification by column chromatography 
(n-pentane:EtOAc = 100:2) yielded the title compound 2.9o (33 mg, 0.160 mmol, 32%) as a 
white solid. The analytical data is in correspondence with those reported in literature.[66] 
m.p.  101103 °C 
Rf  0.29 (n-pentane:EtOAc  100:2, KMnO4) 
1H NMR (300 MHz, CDCl3) δ 9.73 (dd, J  3.4, 1.3 Hz, 1H), 2.57 (m, 1H), 2.02 (m, 4H), 
1.65 (m, 7H), 1.48 (m, 6H), 0.86 (m, 3H). 
13C NMR (75 MHz, CDCl3) δ  204.1, 45.7, 39.5, 37.9, 37.3, 34.4, 28.7, 14.0. 
MS (EI) m/z (relative intensity): 188 (2), 135 (100), 107 (8), 93 (13), 91 (6), 79 (13), 67 (4), 
53 (2). 
HRMS (ESI-TOF, m/z): calcd. for C14H21O1 [M-H]
+ 205.1587, found 205.1590. 
IR (ATR, neat, cm-1): 2901 (m), 2885 (m), 2849 (m), 1699 (m), 1448 (w), 1352 (w), 1305 (m), 
1208 (w), 967 (w). 
Synthesis of ethyl 3-((3r,5r,7r)-adamantan-1-yl)propanoate (2.9p) 
 
Compound 2.9p was prepared following general procedure A. Ethylacrylat 2.4p (100 mg, 
1.0 mmol, 2.0 equiv.) and K2CO3 (69 mg, 0.5 mmol, 1.0 equiv.) were used. Purification by 
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column chromatography (n-pentane:diethylether  200:1) yielded the title compound 2.9p 
(32 mg, 0.135 mmol, 27%) as a colorless oil. The analytical data is in correspondence with 
those reported in literature.[190] 
Rf  0.61 (n-pentane:EtOAc  20:1, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  4.11 (q, J  7.1 Hz, 2H), 2.24 (m, 2H), 1.94 (s, 3H), 1.62 (m, 6H), 
1.42 (m, 8H), 1.25 (t, J  7.1 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ  174.9, 60.4, 42.2, 39.1, 37.2, 32.1, 28.7, 28.4, 14.4. 
MS (EI) m/z (relative intensity): 236 (7) [M], 191 (9), 135 (100), 119 (1), 107 (6), 93 (11), 
79 (12), 67 (4).  
HRMS (ESI-TOF, m/z): calcd. for C15H25O2 [M+H]
+ 237.1854, found 237.1852. 
IR (ATR, neat, cm-1): 2949 (w), 2898 (m), 2846 (m), 1734 (m), 1450 (w), 1376 (w), 1301 (w), 
1188 (m), 1150 (m), 1103 (w). 
Synthesis of benzyl 3-((3r,5r,7r)-adamantan-1-yl)propanoate (2.9q) 
 
Compound 2.9q was prepared following general procedure A. Benzylacrylat 2.4q (162 mg, 
1.0 mmol, 2.0 equiv.) was used. Purification by column chromatography 
(n-pentane:toluene  5:2) yielded the title compound 2.9q (41 mg, 0.137 mmol, 27%) as a 
colorless oil. The analytical data is in correspondence with those reported in literature.[191] 
Rf  0.32 (n-pentane:toluene  1:1, KMnO4) 
1H NMR (400 MHz, CDCl3) δ  7.35 (m, 5H), 5.11 (s, 2H), 2.32 (m, 2H), 1.95 (s, 3H), 
1.63 (m, 6H), 1.45 (m, 8H). 
13C NMR (101 MHz, CDCl3) δ  174.7, 136.3, 128.7, 128.4, 128.3, 66.3, 42.2, 39.0, 37.2, 32.0, 
28.7, 28.3. 
MS (EI) m/z (relative intensity): 298 (4), 207 (66), 189 (16), 161 (6), 147 (16), 135 (74), 
107 (18), 91 (100), 81 (8), 79 (35), 65 (17). 
HRMS (ESI-TOF, m/z): calcd. for C20H26O2Na [M+Na]
+ 321.1830, found 321.1828. 
IR (ATR, neat, cm-1): 2898 (m), 2845 (M), 1734 (m), 1451 (w), 1140 (m), 979 (w), 696 (m). 




Compound 2.9r was prepared following general procedure A. Phenylacrylat 2.4r (148 mg, 
1.0 mmol, 2.0 equiv.) was used. Purification by column chromatography 
(n-pentane:EtOAc   00: → 00:5) yiel e  the title co poun  2.9r (37 mg, 0.130 mmol, 
26%) as a white solid. The analytical data is in correspondence with those reported in 
literature.[192] 
m.p. 4546 °C 
Rf  0.41 (n-pentane:EtOAc  100:2, KMnO4) 
1H NMR (400 MHz, CDCl3) δ  7.55 (m, 2H), 7.39 (m, 1H), 7.25 (m, 2H), 2.69 (m, 2H), 
2.16 (s, 3H), 1.84 (m, 6H), 1.73 (m, 8H). 
13C NMR (101 MHz, CDCl3) δ  173.3, 150.9, 129.5, 125.8, 121.7, 42.2, 39.0, 37.2, 32.2, 28.7, 
28.5. 
MS (EI) m/z (relative intensity): 284 (2) [M], 191 (100), 173 (18), 163 (9), 147 (5), 135 (61), 
121 (3), 94 (19), 79 (19).  
HRMS (ESI-TOF, m/z): calcd. for C19H24O2Na [M+Na]
+ 307.1674, found 307.1675. 
IR (ATR, neat, cm-1): 2897 (m), 2843 (m), 1753 (m), 1591 (w), 1492 (w), 1452 (w), 1381 (w), 
1195 (m), 1124 (m), 1103 (m), 930 (m). 
Synthesis of 2-((3r,5r,7r)-adamantan-1-yl)butane-1,4-diol (2.10) 
 
Compound 2.10 was prepared in a similar fashion to the procedure described in 
literature.[193]  A solution of diester 2.6ba (100 mg, 0.357 mmol, 1.0 equiv.) in THF (0.5 ml) 
was added dropwise under argon to a stirred suspension of LiAlH4 (27 mg, 0.713 mmol, 
2.0 equiv.) in THF (1.15 ml) at 0 °C over 5 minutes. The cooling bath was removed, and the 
mixture was stirred at room temperature for 24 h. Then, the reaction mixture was quenched 
with water (0.5 ml) and 10% aqueous NaOH (0.1 ml) at 0 °C and stirred for further 
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15 minutes. Afterwards, the reaction mixture was extracted with 3 x 10 ml of CH2Cl2 and the 
combined organic fractions were dried over Na2SO4 and filtered. The filtrate was dried under 
reduced pressure and purified by column chromatography (DCM:EtOAc  1:1) to give diol 
2.10 (74 mg, 0.330 mmol, 93%) as a colorless oil. 
Rf  0.36 (DCM:EtOAc  1:2, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  3.82 (m, 4H), 3.53 (ddd, J  10.5, 8.8, 4.1 Hz, 1H), 
3.41 (dd, J  10.3, 8.7 Hz, 1H), 1.88 (m, 4H), 1.60 (m, 12H), 1.40 (m, 1H), 1.15 (m, 1H). 
13C NMR (75 MHz, CDCl3) δ  62.9, 62.8, 50.0, 34.0, 37.3, 34.9, 30.4, 28.7. 
MS (EI) m/z (relative intensity): 224 (1) [M], 176 (3), 165 (4), 152 (34), 135 (100), 119 (2), 
107 (9), 93 (18), 81 (5), 79 (19), 67 (7). 
HRMS (ESI-TOF, m/z): calcd. for C14H24O2Na [M+Na]
+ 247.1673, found 247.1677. 
IR (ATR, neat, cm-1): 3261 (br., w.), 2902 (w), 2844 (w), 1443 (w), 1347 (w), 1192 (w), 
1103 (w), 1021 (w), 879 (w). 
Synthesis of 4-((3r,5r,7r)-adamantan-1-yl)-5,5-dimethyldihydrofuran-2(3H)-one (2.11) 
 
Diester 2.6ba (100 mg, 0.357 mmol, 1.0 equiv.) was dissolved in dry THF (4.0 ml) under 
argon. The reaction mixture was then cooled to 0 °C and MeMgBr (3.0 M in diethylether) 
(490 µl, 1.46 mmol, 4.1 equiv.) was added dropwise over 5 minutes. Subsequently, the 
cooling bath was removed, and the mixture was stirred at room temperature for further 
24 h. Then, the reaction mixture was quenched at 0 °C with a sat. ammonium chloride 
solution and diluted with diethylether (10 ml). The aqueous phase was extracted with 
diethylether (2 x 10 ml). Afterwards, combined organic phases were washed with brine, 
dried over Na2SO4, and concentrated under vacuum. Purification by column chromatography 
(n-pentane:EtOAc  100:2) afforded product 2.11 (77 mg, 0.310 mmol, 87%) as a white solid. 
m.p. 110113 °C 
Rf  0.10 (n-pentane:EtOAc100:2, KMnO4) 
1H NMR (300 MHz, CDCl3) δ 2.43 (dd, J  12.2, 9.2 Hz, 1H), 1.91 (m, 8H), 1.67 (m, 6H), 
1.48 (m, 3H), 1.41 (s, 3H), 1.32 (s, 3H). 
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13C NMR (75 MHz, CDCl3) δ  176.4, 80.6, 50.7, 39.3, 36.9, 36.2, 33.9, 28.9, 28.4, 27.2. 
MS (EI) m/z (relative intensity): 248 (5) [M], 192 (9), 147 (4), 135 (100), 105 (8), 91 (16), 
79 (20), 67 (9), 55 (11).  
HRMS (ESI-TOF, m/z): calcd. for C16H25O2 [M+H]
+ 249.1854, found 249.1847. 
IR (ATR, neat, cm-1): 2978 (w), 2909 (m), 2847 (w), 1747 (m), 1451 (w), 1385 (w), 1286 (w), 




Compound 2.12 was prepared in a similar fashion to the procedure described in 
literature.[194] Sodium (54 mg, 2.36 mmol, 3.1 equiv.) was dissolved in absolute ethanol 
(1 ml) in a 25 ml flame dried flask equipped with a reflux condenser. A solution of diester 
2.6bb (245 mg, 760 µmol, 1.0 equiv.) in 1 ml of absolute ethanol was added followed by a 
solution of dimethyl urea (35 mg, 752 µmol, 1.0 equiv) in 0.7 ml of absolute ethanol. The 
reaction mixture was then refluxed for 23 h and cooled to room temperature. Afterwards, 
the reaction was quenched with water (2 ml) and the reaction solution was acidified by 
adding conc. HCl (0.3 ml). The aqueous phase was extracted with 3 x dichloromethane 
(15 ml) and the combined organic phases were dried over Na2SO4 and filtered. Afterwards, 
the filtrate was dried under vacuum and the crude material was purified by column 
chromatography (n-pentane:EtOAc  15:1) which afforded desired product 2.12 (81 mg, 
0.254 mmol, 33%) as a white solid. 
m.p. 195198 °C 
Rf  0.44 (n-pentane:EtOAc  5:1, UV, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  3.71 (d, J  2.0 Hz, 1H), 3.28 (d, J  5.6 Hz, 6H), 2.04 (m, 4H), 
1.64 (m, 12H), 0.90 (d, J  7.4 Hz, 3H). 




MS (EI) m/z (relative intensity): 318 (1) [M], 182 (6), 135 (100), 119 (1), 107 (6), 93 (10), 
79 (11), 69 (4), 55 (2).  
HRMS (ESI-TOF, m/z): calcd. for C18H27O3N2 [M+H]
+ 319.2021, found 319.2016. 
IR (ATR, neat, cm-1): 2965 (w), 2896 (w), 2848 (w), 1668 (w), 1416 (w), 1368 (w), 1122 (w), 
1086 (w), 755 (w). 
Deuterium incorporation experiments. 
Deuterium incorporation experiments (Scheme S2.1) were performed under Schlenk 
conditions using a 5 ml process vial equipped with a NS 14.5 rubber septum. To this vial was 
added 1-adamantanecarboxylic acid 2.1b (45 mg, 0.25 mmol, 1.0 equiv.), photocatalyst 1.2 
(5 mg, 125 µmol ,0.05 equiv.) and K3PO4 (11 mg, 0.05 mmol, 0.2 equiv.). Next, the vial was 
evacuated and purged with argon for 3 times. Diethyl ethylidenmalonate 2.4b (93 mg, 
0.5 mmol, 2.0 equiv.) was then added to the flask under argon. Afterwards, 5 ml of (a) 
D3CN:H2O (9:1) or (b) MeCN:D2O (9:1) were added and the reaction mixture was stirred for 
2 minutes in the dark. The reaction mixture was then irradiated for 16 h and quenched 
afterwards upon exposure to air and bubbling air through the solution using a pipette. The 
reaction was concentrated under reduced pressure and the crude product was purified by 
column chromatography (n-pentane:EtOAc  20:1) yielding the title compound 2.6bb as a 
colorless oil.  
 





Figure S1.1 1H NMR of product 2.6bb using conditions (a). 
 




Figure S2.3 1H NMR of product 2.6bb using conditions (b). 
 
Figure S2.4 HRMS spectrum of 2.6bb using conditions (b). 
TEMPO quenching experiment 
TEMPO quenching experiment (Scheme S2.2) was performed under Schlenk conditions using 
a 5 ml process vial equipped with a NS 14.5 rubber septum. To this vial was added 1-
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adamantanecarboxylic acid carboxylic acid 2.1b (90 mg, 0.5 mmol, 1.0 equiv.), photocatalyst 
1.2 (10.8 mg, 0.05 equiv.), 2,2,6,6-Tetramethylpiperidin-1-yl)oxyl (98 mg, 0.625 mmol, 
1.25 equiv.) and K3PO4 (21 mg, 0.2 mmol, 0.2 equiv.). Next, the vial was evacuated and 
purged with argon for 3 times followed by the addition of Diethyl ethylidenmalonate 2.4b 
(93 mg, 0.5 mmol, 2.0 equiv.) under argon. Afterwards, 4.5 ml of MeCN and 0.5 ml degassed 
H2O were added and the reaction mixture was irradiated for 16 h. Subsequently, 0.5 ml 
sample was taken and measured by LC-MS (Figure S2.5).   
 
Scheme S2.2 TEMPO quenching experiment. 
 
 





7.2.2 Experimental section to Chapter 3 
This project was conducted with Richy Hauptmann.  
The letter (a) and (b) stated after the compound numbers during the experimental section to 
chapter 3 (e.g. X.Xma or X.Xmb) correspond to different possible regioisomers. 
Synthesis of N-benzyl-1,2-diphenylethan-1-amine (3.3a) 
 
Compound 3.3a was prepared following general procedure B. Purification by column 
chromatography (n-pentane:EtOAc  20:1) yielded the title compound 3.3a (95 mg, 
0.33 mmol, 66%) as a colorless solid. 
m.p.  52–54 °C. 
Rf  0.3 (n-pentane:EtOAc 9:1, KMnO4). 
1H NMR (400 MHz, CDCl3) δ  7.29 – 7.19 (m, 4H), 7.19 – 7.06 (m, 7H), 
7.00 (dt, J  7.9, 1.4 Hz, 4H), 3.79 (dd, J  8.5, 5.5 Hz, 1H), 3.56 (d, J  13.5 Hz, 1H), 
3.36 (d, J = 13.5 Hz, 1H), 2.97 – 2.70 (m, 2H), 1.64 (s, 1H).  
13C NMR (101 MHz, CDCl3) δ  143.8, 140.6, 138.9, 129.4, 128.5, 128.5, 128.4, 128.0, 127.5, 
127.2, 126.8, 126.5, 63.7, 51.5, 45.4. 
MS (EI) m/z (relative intensity): 286 (1), 197 (15), 196 (100), 91 (87).    
HRMS (EI, m/z): calcd. for C21H22N [M+H]
+ 288.1752, found 288.1759. 
IR (ATR, neat, cm-1): 2704 (w), 1952 (w), 1871 (w), 1813(w), 1601 (w), 1582 (w), 1491 (m), 
1452 (m), 1398 (w), 1357 (w), 1315 (w), 1288 (w), 1269 (w), 1227 (w), 1195 (w), 1179 (w), 
1162 (w), 1153 (w), 1120 (m), 1068 (m), 1028 (m), 1000 (w), 988 (w), 946 (w), 911 (w), 832 
(w), 820(w), 793 (w), 758 (m), 741 (m), 728 (s), 695 (s), 635 (m), 619 (w), 579 (w), 547 (s), 
506 (m), 460 (m). 




Compound 3.3b was prepared following general procedure B. Purification by column 
chromatography (n-pentane:EtOAc  20:1) yielded the title compound 3.3b (63 mg, 
0.25 mmol, 50%) as a yellow oil. 
Rf  0.4 (n-pentane:EtOAc  9:1, KMnO4). 
1H NMR (300 MHz, CDCl3) δ  7.22 (d, J  4.3 Hz, 4H), 7.18 – 7.08 (m, 4H), 7.07 – 
7.01 (m, 2H), 3.75 (dd, J  8.0, 6.0 Hz, 1H), 2.93 – 2.72 (m, 2H), 2.41 – 2.15 (m, 2H), 
1.39 (s, 1H), 1.33 – 1.19 (m, 2H), 1.19 – 1.01 (m, 2H), 0.72 (t, J  7.2 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ  144.1, 139.1, 129.4, 128.4, 128.4, 127.4, 127.1, 126.4, 65.0, 
47.6, 45.5, 32.3, 20.4, 14.0. 
MS (EI) m/z (relative intensity): 252 (1), 163 (12), 162 (100), 106 (17), 91 (10). 
HRMS (ESI-TOF, m/z): calcd. for C18H24N [M+H]
+ 254.1908, found 254.1911. 
IR (ATR, neat, cm-1): 3062 (w), 3028 (w), 2956 (w), 2928 (w), 2869 (w), 2795 (w), 2727 (w), 
2565 (w), 2461 (w), 1721 (w), 1674 (w), 1601 (w), 1585 (w), 1494 (w), 1454 (m), 1377 (w), 
1314 (w), 1244 (w), 1212 (w), 1141 (w), 1127 (w), 1072 (w), 1028 (w), 1001 (w), 984 (w), 
922 (w), 879 (w), 839 (w), 793 (w), 770 (w), 758 (m), 739 (m), 697 (s), 613 (w), 563 (w), 
507 (w), 473 (w), 447 (w). 
Synthesis of N-(1,2-diphenylethyl)cyclohexanamine (3.3c) 
 
Compound 3.3c was prepared following general procedure . Purification by column 
chromatography (n-pentane:EtOAc  20:1) yielded the title compound 3.3c (73 mg, 
0.25 mmol, 50%) as yellow oil. 
Rf  0.2 (n-pentane:EtOAc  9:1, KMnO4). 
m.p.  53–55 °C. 
1H NMR (300 MHz, CDCl3) δ  7.31 – 7.15 (m, 8H), 7.08 (ddt, J  7.3, 1.5, 0.7 Hz, 2H), 
4.02 (dd, J  8.1, 6.0 Hz, 1H), 2.95 – 2.75 (m, 2H), 2.19 (tt, J  10.0, 3.7 Hz, 1H), 
1.82 (d, J  12.4 Hz, 1H), 1.69 – 1.39 (m, 4H), 1.30 – 1.18 (m, 1H), 1.14 – 0.92 (m, 4H), 0.87 – 
0.69 (m, 1H). 
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13C NMR (75 MHz, CDCl3) δ  144.7, 139.2, 129.4, 128.4, 128.3, 127.4, 126.9, 126.4, 61.3, 
53.6, 45.8, 34.9, 32.8, 26.2, 25.3, 24.9. 
MS (EI) m/z (relative intensity): 188 (100), 106 (67), 103 (11), 91 (50), 79 (14), 77 (13), 
65 (10), 55 (15), 41 (13). 
HRMS (ESI-TOF, m/z): calcd. for C20H26N [M+H]
+ 280.2065, found 280.2066. 
IR (ATR, neat, cm-1): 3083 (w), 3061 (w), 3026 (w), 2922 (m), 2850 (w), 1602 (w), 1584 (w), 
1493 (w), 1451 (m), 1359 (w), 1345 (w), 1307 (w), 1259 (w), 1181 (w), 1143 (w), 1120 (w), 
1070 (w), 1028 (w), 976 (w), 911 (w), 889 (w), 846 (w), 804 (w), 779 (w), 756 (m), 696 (s), 
624 (w), 565 (m), 532 (m), 500 (w), 464 (w), 417 (w). 
Synthesis of N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1,2-diphenylethan-1-amine (3.3d) 
 
Compound 3.3d was prepared following general procedure B. Purification by column 
chromatography (n-pentane:EtOAc  20:1) yielded the title compound 3.3d (70 mg, 
0.20 mmol, 40%) as colorless solid. 
Rf  0.6 (n-pentane:EtOAc  9:1, KMnO4). 
1H NMR (300 MHz, CDCl3) δ  7.28 – 7.05 (m, 10H), 3.81 (dd, J  8.3, 5.6 Hz, 1H), 3.61 – 3.47 
(m, 2H), 2.97 – 2.74 (m, 2H), 2.49 – 2.33 (m, 2H), 1.96 (s, 1H), 0.74 (d, J  0.7 Hz, 9H), 0.08 – 
0.16 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ  144.0, 138.9, 129.4, 128.5, 128.4, 127.5, 127.1, 126.5, 64.7, 
62.4, 49.8, 45.6, 26.0, 18.3, -5.3. 
MS (EI) m/z (relative intensity): 354 (1), 265 (36), 264 (100), 248 (14), 166 (10), 165 (10), 105 
(13), 103 (14), 91 (25), 73 (21).   
HRMS (EI, m/z): calcd. for C22H32NOSi [M-H] 354.2239, found 354.2248. 
IR (ATR, neat, cm-1): 3084 (w), 3062 (w), 3027 (w), 2952 (w), 2927 (w), 2855 (w), 1602 (w), 
1494 (w), 1462 (w), 1453 (m), 1388 (w), 1360 (w), 1309 (w), 1253 (m), 1226 (w), 1085 (m), 
1020 w), 1006 (w), 957 (w), 939 (w), 888 (w), 832 (s), 811 (m), 775 (s), 756 (s), 697 (s), 662 
(m), 629 (w), 568 (w), 548 (w), 512 (w), 450 (w). 




Compound 3.3e was prepared following general procedure B. Purification by column 
chromatography (n-pentane:EtOAc  20:1) yielded the title compound 3.3e (40 mg, 
169 µmol, 34%) as colorless oil. 
Rf = 0.4 (n-pentane:EtOAc  9:1, KMnO4). 
1H NMR (300 MHz, CDCl3) δ  7.28 – 7.09 (m, 8H), 7.08 – 7.01 (m, 2H), 
5.68 (dddd, J  17.6, 9.7, 6.6, 5.3 Hz, 1H), 5.00 – 4.86 (m, 2H), 3.82 (dd, J  8.0, 6.1 Hz, 1H), 
3.01 (ddt, J  14.3, 5.3, 1.6 Hz, 1H), 2.93 – 2.76 (m, 3H), 1.46 (s, 1H). 
13C NMR (75 MHz, CDCl3) δ  143.7, 138.9, 136.9, 129.4, 128.5, 128.4, 127.5, 127.2, 126.5, 
115.7, 64.0, 50.1, 45.3. 
MS (EI) m/z (relative intensity): 236 (1), 147 (13), 146 (100), 91 (17), 41 (17).  
HRMS (EI, m/z): calcd. for C17H18N [M-H] 236.1430, found 236.1434. 
IR (ATR, neat, cm-1): 3062 (w), 3026 (w), 2977 (w), 2918 (w), 2845 (w), 1948 (w), 1879 (w), 
1808 (w), 1642 (w), 1602 (w), 1584 (w), 1494 (w), 1453 (m), 1417 (w), 1355 (w), 1328 (w), 
1308 (w), 1229 (w), 1208 (w), 1180 (w), 1141 (w), 1109 (w), 1070 (w), 1028 (w), 993 (w), 
914 (m), 844 (w), 794 (w), 756 (m), 742 (m), 696 (s), 625 (w), 591 (w), 562 (m), 547 (m), 503 
(w), 444 (w). 
Synthesis of N-benzyl-1-phenyl-2-(p-tolyl)ethan-1-amine (3.3fa) and N-benzyl-2-phenyl-1-
(p-tolyl)ethan-1-amine (3.3fb) 
 
Compounds 3.3fa and 3.3fb were prepared following general procedure B with a reaction 
time of 16 h. Purification by column chromatography (n-pentane:EtOAc  10:1) yielded the 
title compounds as inseparable mixture (101 mg, 0.34 mmol, 67%, 3.3fa:3.3fb = 61:39) as a 
colorless oil. 
Rf 0.3 (n-pentane:EtOAc 9:1, KMnO4). 
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1H NMR (300 MHz, CD2Cl2) δ  7.46 – 7.00 (m, 14H), 3.91 (ddd, J  8.0, 6.0, 4.0 Hz, 1H), 
3.65 (dd, J  13.5, 0.8 Hz, 1H), 3.49 (dd, J  13.4, 1.7 Hz, 1H), 3.03 – 2.83 (m, 2H), 
2.36 (d, J  12.5 Hz, 3H), 1.71 (s, 1H). 
13C NMR (75 MHz, CD2Cl2) δ  144.6, 141.3, 141.3, 139.6, 137.0, 136.2, 129.7, 129.5, 129.4, 
129.4, 128.7, 128.7, 128.6, 128.3, 127.8, 127.7, 127.4, 127.0, 126.6, 64.3, 63.9, 51.8, 51.7, 
45.6, 45.2, 21.3, 21.2. 
MS (EI) m/z (relative intensity): 300 (1), 210(27), 197 (12), 196 (76), 105 (11), 91 (100), 
65 (11). 
HRMS (EI, m/z): calcd. for C22H24N [M+H]
+ 302.1909, found 302.1910. 
IR (ATR, neat, cm-1): 3025 (w), 2918 (w), 1513 (w), 1493 (w), 1452 (w), 1109 (w), 1027 (w), 
732 (m), 696 (s), 547 (m). 
Synthesis of ethyl -4-(1-(benzylamino)-2-phenylethyl)benzoate (3.3ga) and ethyl 4-(2-
(benzylamino)-2-phenylethyl)benzoate (3.3gb) 
 
Compounds 3.3ga and 3.3gb were prepared following general procedure B with a reaction 
time of 16 h. Purification by column chromatography (n-pentane:EtOAc  9:1) yielded the 
title compounds (61 mg, 0.17 mmol, 34%, 3.3ga:3.3gb = 67:33) as a colorless oil. Analytically 
pure samples of each regioisomere were obtained by flash chromatography 
(n-pentane:EtOAc  9:1). When the reaction was run for 24 h, the products 3.3ga and 3.3gb 
(73 mg, 0.20 mmol, 40%, 3.3ga:3.3gb = 66:34) were obtained as colorless oil.  
3.3ga: 
Rf  0.4 (n-pentane:EtOAc  5:1, KMnO4). 
1H NMR (300 MHz, CDCl3) δ  8.11 – 8.01 (m, 2H), 7.51 – 7.41 (m, 2H), 7.33 – 7.20 (m, 6H), 
7.17 – 7.05 (m, 4H), 4.42 (q, J  7.1 Hz, 2H), 3.99 (dd, J  7.9, 6.2 Hz, 1H), 3.68 (d, J  13.5 Hz, 
1H), 3.49 (d, J = 13.5 Hz, 1H), 3.04 – 2.89 (m, 2H), 1.91 (s, 1H), 1.44 (t, J = 7.1 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ  168.3, 148.8, 141.3, 138.3, 129.9, 129.6, 129.4, 128.6, 128.5, 
128.1, 127.6, 127.0, 126.7, 63.1, 58.4, 50.8, 43.2, 13.5. 
MS (EI) m/z (relative intensity): 358 (1), 314 (1), 268 (42), 91 (100), 65 (9).   
HRMS (ESI-TOF, m/z): calcd. for C24H26NO2 [M+H]
+ 360.1964, found 360.1969. 
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IR (ATR, neat, cm-1): 3084 (w), 2980 (w), 2927 (w),1712 (s), 1609 (w), 1577 (w), 1494 (w), 
1453 (m), 1415 (w), 1390 (w), 1366 (w), 1307 (w), 1270 (s), 1199 (w), 1172 (m), 1099 (s), 
1019 (m), 979 (w), 909 (w), 858 (w), 769 (m), 742 (m), 696 (s), 657 (w), 621 (w), 604 (w), 
572 (w), 550 (m), 482 (w). 
3.3gb: 
Rf  0.3 (n-pentane:EtOAc  5:1, KMnO4). 
1H NMR (400 MHz, CD2Cl2) δ  7.93 – 7.86 (m, 2H), 7.38 – 7.10 (m, 12H), 4.34 (q, J  7.1 Hz, 
2H), 3.93 (dd, J  7.4, 6.7 Hz, 1H), 3.64 (d, J  13.4 Hz, 1H), 3.49 (d, J  13.4 Hz, 1H), 3.07 – 
2.94 (m, 2H), 1.68 (s, 1H), 1.37 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CD2Cl2) δ  166.7, 144.8, 143.8, 141.0, 129.9, 129.7, 129.7, 129.1, 128.7, 
128.6, 128.3, 127.8, 127.6, 127.1, 64.0, 51.7, 45.5, 14.5. 
MS (EI) m/z (relative intensity): 358 (1), 314 (1), 197 (11), 196 (72), 91 (100), 65 (9).  
HRMS (ESI-TOF, m/z): calcd. for C24H26NO2 [M+H]
+ 360.1964, found 360.1958. 
IR (ATR, neat, cm-1): 3327 (w), 3061 (w), 3027 (w), 2980 (w), 2926 (w), 2850 (w), 1947 (w), 
1809 (w), 1714 (s), 1610 (w), 1575 (w), 1493 (w), 1453 (m), 1415 (w), 1391 (w), 1366 (w), 
1309 (w), 1274 (s), 1199 (w), 1178 (m), 1103 (s), 1022 (m), 974 (w), 912 (w), 854 (w), 
762 (m), 699 (s), 651 (w), 638 (w), 612 (w), 584 (w), 553 (w), 500 (w), 462 (w), 426 (w). 
Synthesis of 4-(1-(benzylamino)-2-phenylethyl)benzonitrile (3.3ha) and 4-(2-
(benzylamino)-2-phenylethyl)benzonitrile (3.3hb) 
 
Compounds 3.3ha and 3.3hb were prepared following general procedure B with a reaction 
time of 16 h. Purification by column chromatography (n-pentane:EtOAc  10:1) yielded the 
title compounds (58 mg, 0.19 mmol, 37%, 3.3ha:3.3hb = 74:26) as a colorless oil. Yield of 
3.3h after 24 h (46 mg, 0.15 mmol, 29%, 3.3ha:3.3hb = 74:26). Analytically pure samples of 
each regioisomere were obtained by flash chromatography (n-pentane:EtOAc 20:1). 
3.3ha: 
Rf  0.3 (n-pentane:EtOAc  9:1, KMnO4). 
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1H NMR (400 MHz, CDCl3) δ  7.65 (d, J  8.4 Hz, 2H), 7.50 (d, J  8.3 Hz, 2H), 7.36 – 7.16 (m, 
7H), 7.11 (ddt, J  14.0, 5.5, 1.7 Hz, 4H), 3.98 (dd, J  8.2, 6.0 Hz, 1H), 3.66 (d, J  13.5 Hz, 
1H), 3.49 (d, J = 13.5 Hz, 1H), 3.00 – 2.85 (m, 2H), 1.80 (s, 1H). 
13C NMR (101 MHz, CDCl3) δ  149.6, 140.0, 137.8, 132.4, 129.3, 128.7, 128.5, 128.3, 127.9, 
127.1, 126.9, 119.2, 111.0, 63.6, 51.6, 45.2. 
MS (EI) m/z (relative intensity): 222 (16), 221 (82), 92 (15), 91 (100), 65 (24). 
HRMS (EI, m/z): calcd. for C22H21N2 [M+H]
+ 313.1705, found 313.1710. 
IR (ATR, neat, cm-1): 3326 (w), 3084 (w), 3061 (w), 3027 (w), 2919 (w), 2840 (w), 2226 (m), 
1950 (w), 1808 (w), 1647 (w), 1605 (w), 1583 (w), 1494 (m), 1453 (m), 1411 (w), 1349 (w), 
1301 (w), 1200 (w), 1177 (w), 1155 (w), 1103 (w), 1076 (w), 1028 (w), 1019 (w), 971 (w), 
909 (w), 832 (m), 733 (s), 696 (s), 647 (w), 626 (w), 605 (w), 584 (m), 562 (s), 514 (m), 
479 (m).   
3.3hb: 
Rf  0.1 (n-pentane:EtOAc  9:1, KMnO4). 
1H NMR (400 MHz, CDCl3) δ  7.41 (d, J  8.3 Hz, 1H), 7.30 – 7.09 (m, 11H), 7.09 – 6.99 (m, 
4H), 3.78 (dd, J  7.0 Hz, 1H), 3.73 (s, 1H), 3.58 (d, J  13.4 Hz, 1H), 3.41 (d, J 13.3 Hz, 1H), 
3.00 – 2.83 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ  144.6, 142.7, 140.4, 140.3, 132.1, 130.3, 128.7, 128.5, 128.5, 
128.3, 128.1, 127.6, 127.4, 127.1, 119.1, 110.3, 63.4, 53.3, 51.4, 45.2. 
MS (EI) m/z (relative intensity): 221 (1), 197 (9), 196 (59), 116 (10), 91 (100), 89 (11), 65 (13). 
HRMS (EI, m/z): calcd. for C22H21N2 [M+H]
+ 313.1705, found 313.1705. 
IR (ATR, neat, cm-1): 3084 (w), 3061 (w), 3027 (w), 2923 (w), 2850 (w), 2226 (w), 1641 (w), 
1606 (w), 1493 (w), 1453 (m), 1413 (w), 1358 (w), 1331 (w), 1307 (w), 1199 (w), 1177 (w), 
1155 (w), 1113 (w), 1074 (w), 1027 (w), 1002 (w), 970 (w), 912 (w), 848 (w), 823 (m), 
733 (m), 697 (s), 616 (w), 587 (w), 562 (m), 547 (m), 486 (w), 462 (w), 426 (w). 





Compounds 3.3ia and 3.3ib were prepared following general procedure B, with a reaction 
time of 16 h. Purification by column chromatography (n-pentane:EtOAc 20:1) yielded the 
title compound (57 mg, 0.16 mmol, 32%, 3.3ia:3.3ib = 68:32; after 24h: 49 mg, 0.14 mmol, 
28%, 3.3ia:3.3ib = 69:31) as colorless oil. Analytically pure samples were obtained by flash 
chromatography (n-pentane:EtOAc  20:1). 
3.3ia: 
Rf 0.2 (n-pentane:EtOAc 10:1, KMnO4). 
1H NMR (300 MHz, CDCl3) δ  7.61 (d, J  8.1 Hz, 2H), 7.50 (d, J  8.1 Hz, 2H), 7.27 (dqt, J  
5.5, 3.8, 1.9 Hz, 6H), 7.18 – 7.02 (m, 4H), 3.97 (dd, J  8.4, 5.7 Hz, 1H), 3.66 (d, J  13.5 Hz, 
1H), 3.47 (d, J  13.6 Hz, 1H), 3.05 – 2.81 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ  148.1, 140.2, 138.2, 129.4, 129.3, 128.7, 128.5, 128.0, 127.9, 
127.0, 126.8, 125.5, 125.5, 63.4, 51.5, 45.3. 
19F NMR (282 MHz, CDCl3) δ 62.30. 
MS (EI) m/z (relative intensity): 354 (1), 264 (82), 91 (100), 65 (10).  
HRMS (ESI-TOF, m/z): calcd. for C22H21NF3 [M+H]
+ 356.1626, found 356.1631. 
IR (ATR, neat, cm-1): 3330 (w), 3085 (w), 3063 (w), 3028 (w), 2920 (w), 2846 (w), 1948 (w), 
1807 (w), 1618 (w), 1603 (w), 1585 (w), 1495 (w), 1454 (w), 1417 (w), 1322 (s), 1161 (m), 
1118 (s), 1065 (s), 1029 (w), 1017 (m), 976 (w), 909 (w), 834 (m), 734 (m), 696 (s), 649 (w), 
609 (m), 565 (w), 543 (m), 515 (w), 473 (w).   
3.3ib: 
Rf  0.1 (n-pentane:EtOAc  10:1, KMnO4). 
1H NMR (300 MHz, CDCl3) δ  7.53 – 7.45 (m, 2H), 7.38 – 7.21 (m, 9H), 7.15 (dddd, J  9.5, 
7.6, 1.8, 1.1 Hz, 4H), 3.88 (t, J  7.0 Hz, 1H), 3.67 (d, J  13.4 Hz, 1H), 3.49 (d, J  13.4 Hz, 1H), 
2.99 (d, J = 7.0 Hz, 2H). 
13C NMR (75 MHz, CDCl3) δ  143.1, 140.4, 129.8, 128.6, 128.5, 128.1, 127.5, 127.5, 127.0, 
125.3, 125.3 (q, J  3.8 Hz), 63.5, 51.5, 45.1. 
19F NMR (282 MHz, CDCl3) δ  62.30. 
MS (EI) m/z (relative intensity): 354 (1), 196 (50), 91 (100), 65 (10).  
HRMS (ESI-TOF, m/z): calcd. for C22H21NF3 [M+H]
+ 356.1626, found 356.1631. 
IR (ATR, neat, cm-1): 3085 (w), 3063 (w), 3028 (w), 2920 (w), 2846 (w), 1948 (w), 1807 (w), 
1618 (w), 1603 (w), 1585 (w), 1495 (w), 1454 (w), 1417 (w), 1322 (s), 1161 (m), 1118 (s), 
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1065 (s), 1029 (w), 1017 (m), 976 (w), 909 (w), 834 (m), 734 (m), 696 (s), 649 (w), 609 (m), 
565 (w), 543 (m), 515 (w), 473 (w).  
Synthesis of (R)-N-benzyl-2-(4-methoxyphenyl)-1-phenylethan-1-amine (3.3k) 
 
Compound 3.3k was prepared following general procedure B with a reaction time of 16 h. 
Purification by column chromatography (n-pentane:EtOAc  10:1) yielded the title 
compounds (18 mg, 0.06 mmol, 12%, 3.3ka:3.3kb = 93:7; after 24 h: 33 mg, 0.10 mmol, 20%, 
3.3ka:3.3kb = 93:7) as a colorless oil. 
Rf  0.1 (n-pentane:EtOAc  10:1, KMnO4). 
1H NMR (300 MHz, CDCl3) δ  7.30 – 7.06 (m, 8H), 7.06 – 6.87 (m, 4H), 6.82 – 6.65 (m, 2H), 
3.83 – 3.62 (m, 4H), 3.57 (d, J  13.5 Hz, 1H), 3.37 (d, J  13.5 Hz, 1H), 2.96 – 2.54 (m, 2H), 
1.65 (s, 1H). 
13C NMR (75 MHz, CDCl3) δ  172.1, 171.2, 159.4, 153.9, 152.3, 149.9, 144.2, 143.6, 142.7, 
141.8, 141.6, 141.3, 140.8, 140.4, 140.1, 139.7, 128.1, 77.2, 75.9, 68.2, 64.8, 64.7, 58.8, 57.8.  
MS (EI) m/z (relative intensity): 316 (1), 226 (5), 197 (15), 196 (100), 194 (9), 121 (6), 91 (67). 
HRMS (EI, m/z): calcd. for C22H24NO [M+H]
+ 318.1858, found 318.1858. 
IR (ATR, neat, cm-1): 3322 (w), 3083 (w), 3060 (w), 3027 (w), 3001 (w), 2931 (w), 2913 (w), 
2834 (w), 1947 (w), 1885 (w), 1810 (w), 1611 (w), 1583 (w), 1510 (s), 1493 (m), 1453 (m), 
1356 (w), 1300 (m), 1245 (s), 1176 (m), 1109 (m), 1073 (w), 1034 (m), 975 (w), 912 (w), 




Compound 3.2h was synthesized using a modified literature procedure.[107] Potassium (E)-
trifluoro(styryl)-borane[195] (167 mg, 0.80 mmol, 1.6 equiv.) and estrogen 
trifluoromethanesulfonate[196] (200 mg, 0.50 mmol), Pd(OAc)2 (11 mg, 0.05 mmol, 
0.10 equiv.), PCy3 (28 mg, 0.10 mmol, 0.2 equiv.) and Cs2CO3 (486 mg, 1.50 mmol, 3.0 equiv.) 
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in THF:H2O (10:1, 10 ml) was stirred at 80 °C over night. The mixture was allowed to cool to 
room temperature and filtered through a plug of celite and washed with EtOAc. The filtrate 
was concentrated under reduced pressure and purified by column chromatography 
(n-pentane:EtOAc = 20:1). (8R,9S,13S,14S)-8,13-dimethyl-3-((E)-styryl)-6-9,11-16-decahydro-
17H-cyclopenta[a]phenanthren-17-one 3.2h (157 mg, 0.44 mmol, 89%) was obtained as a 
pale yellow crystalline solid. 
m.p.  184187 °C. 
Rf  0.3 (n-pentane:EtOAc  9:1, UV). 
1H NMR (300 MHz, CDCl3) δ 7.58 – 7.48 (m, 2H), 7.43 – 7.23 (m, 6H), 7.10 (s, 2H), 3.05 – 
2.89 (m, 2H), 2.63 – 2.28 (m, 3H), 2.27 – 1.93 (m, 4H), 1.79 – 1.39 (m, 6H), 0.95 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ  220.9, 139.5, 137.5, 136.7, 134.9, 128.7, 128.4, 128.1, 127.5, 
127.1, 126.4, 125.7, 124.0, 50.5, 48.0, 44.5, 38.2, 35.9, 31.6, 29.5, 26.5, 25.7, 21.6, 13.9. 
MS (EI) m/z (relative intensity): 357 (29), 356 (100), 232 (12), 229 (13), 22 (11), 215 (20), 
202 (16), 178 (12), 165 (11), 153 (14), 128 (12), 115 (15), 91 (27), 77 (12), 55 (15), 41 (16).  
HRMS (EI, m/z): calcd. for C26H28O [M
+] 356.2135, found 356.2140.  
IR (ATR, neat, cm-1): 3447 (w), 3058 (w), 3021 (w), 2953 (w), 2927 (w), 2877 (w), 2858 (w), 
2828 (w), 2312 (w), 1730 (w), 1633 (w), 1594 (w), 1574 (w), 1557 (w), 1495 (w), 1469 (w), 
1448 (w), 1425 (w), 1402 (w), 1372 (w), 1338 (w), 1297 (w), 1286 (w), 1257 (w), 1192 (w), 
1157 (w), 1135 (w), 1114 (w), 1082 (m), 1051 (w), 1026 (w), 1003 (m), 983 (w), 959 (s), 
920 (w), 906 (m), 894 (w), 842 (w), 818 (m), 784 (m), 759 (s), 742 (s), 722 (w), 709 (m), 691 
(s), 667 (w), 631 (w), 612 (w), 586 (w), 578 (m), 565 (m), 529 (m), 510 (m), 492 (w), 471 (w), 
447 (w), 437 (m). 
Synthesis of (8S,9R,13R,14R)-3-(2-(benzylamino)-2-phenylethyl)-13-methyl-






Compound 3.3m was prepared following general procedure B. Purification by column 
chromatography (n-pentane:EtOAc = 20:1) yielded the title compound (146 mg, 0.31 mmol, 
63%, 3.3ma:3.3mb = 74:26) as colorless viscous oil. The regioisomers were separated using 
n-heptane:EtOAc  8:1(+0.1% NH3
.H2O) as eluent. The epimers were not separated. 
3.3ma: 
Rf  0.30 (n-heptane:EtOAc  2:1, KMnO4). 
1H NMR (400 MHz, CDCl3) δ  7.41 (dt, J  8.1, 1.5 Hz, 2H), 7.36 (dd, J  8.3, 6.6 Hz, 2H), 
7.31 – 7.11 (m, 8H), 6.94 (ddd, J  11.9, 7.9, 2.0 Hz, 1H), 6.87 (dd, J  8.5, 1.9 Hz, 1H), 
3.90 (ddd, J  9.3, 4.8, 2.3 Hz, 1H), 3.67 (d, J  13.7 Hz, 1H), 3.46 (dd, J  13.7, 2.0 Hz, 1H), 
2.99 – 2.75 (m, 4H), 2.52 (dd, J  18.7, 8.6 Hz, 1H), 2.47 – 2.35 (m, 1H), 2.34 – 2.25 (m, 1H), 
2.21 – 1.95 (m, 4H), 1.72 (d, J  2.7 Hz, 1H), 1.70 – 1.40 (m, 7H), 0.93 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ  221.1 (Cq), 144.1 (Cq), 140.7 (Cq), 138.0 (Cq), 136.6 (Cq), 
136.3 (Cq), 130.0 (CH), 129.9 (CH), 128.5 (CH), 128.3 (CH), 128.0 (CH), 128.0 (CH), 127.5 (CH), 
127.2 (CH), 126.8 (CH), 126.8 (CH), 126.7 (CH), 125.5 (CH), 63.4 (CH), 51.4 (CH2), 50.6 (CH), 
48.1 (CH2), 44.9 (Cq), 44.4 (CH), 38.3 (CH), 36.0 (CH2), 31.7 (CH2), 29.5 (CH2), 26.7 (CH2), 
25.9 (CH2), 21.7 (CH2), 14.0 (CH3). 
MS (EI) m/z (relative intensity): 463 (0) [M], 429 (1), 341 (2), 281 (5), 196 (100), 141 (3), 
91 (75). 
HRMS (ESI-TOF, m/z): calcd. for C33H38NO [M+H]
+ 464.2953, found 464.2952. 
IR (ATR, neat, cm-1): 3324 (w), 3059 (w), 3025 (w), 2918 (w), 2855 (w), 1950 (w), 1878 (w), 
1736 (s), 1602 (w), 1584 (w), 1494 (m), 1452 (m), 1406 (w), 1372 (w), 1340 (w), 1258 (w), 
1213 (w), 1168 (w), 1156 (w), 1113 (w), 1083 (w), 1052 (w), 1027 (w), 1007 (m), 982 (w), 
965 (w), 910(w), 819 (w), 782 (w), 731 (s), 698 (s), 657 (w), 621 (w), 579 (m), 559 (w), 540 
(w), 501 (w), 443 (w).  
3.3mb: 
Rf  0.27 (n-heptane:EtOAc  2:1, KMnO4). 
1H NMR (300 MHz, CDCl3) δ = 7.3 – 7.0 (m, 13H), 3.8 (dd, J  9.4, 4.7 Hz, 1H), 3.7 (d, 
J  13.6 Hz, 1H), 3.4 (d, J  13.6 Hz, 1H), 3.1 – 2.7 (m, 5H), 2.7 – 2.4 (m, 2H), 2.4 – 2.3 (m, 1H), 
2.3 – 1.9 (m, 3H), 1.8 – 1.4 (m, 7H), 0.9 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ  221.1 (Cq), 141.4 (Cq), 140.7 (Cq), 139.2 (Cq), 138.7 (Cq), 136.6 
(Cq), 129.4 (CH), 128.6 (CH), 128.5 (CH), 128.4 (CH), 128.1 (CH), 128.0 (CH), 128.0 (CH), 127.5 
(CH), 127.2 (CH), 126.8 (CH), 126.5 (CH), 125.5 (CH), 125.5 (CH), 124.9 (CH), 63.4 (CH2), 63.3 
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(CH2), 63.2 (CH2), 51.2 (Cq), 50.7 (CH2), 48.2 (Cq), 45.4 (Cq), 44.6 (CH2), 38.3 (CH2), 36.0 (Cq), 
31.8 (Cq), 29.6 (Cq), 25.9 (Cq), 21.8 (Cq), 14.0 (CH2). 
MS (EI) m/z (relative intensity): 462 (1), 373 (10), 372 (35), 128 (2), 115 (2), 91 (100).  
HRMS (ESI-TOF, m/z): calcd. for C33H38NO [M+H]
+ 464.2953, found 464.2951. 
IR (ATR, neat, cm-1): 3330 (w), 3085 (w), 3063 (w), 3028 (w), 2920 (w), 2846 (w), 1948 (w), 
1807 (w), 1618 (w), 1603 (w), 1585 (w), 1495 (w), 1454 (w), 1417 (w), 1322 (s), 1161 (m), 
1118 (s), 1065 (s), 1029 (w), 1017 (m), 976 (w), 909 (w), 834 (m), 734 (m), 696 (s), 649 (w), 
609 (m), 565 (w), 543 (m), 515 (w), 473 (w). 
Synthesis of (6aR,10aR)-3-(2-(benzylamino)-2-phenylethyl)-6,6,9-trimethyl-6a,7,8,10a-





S1 was synthesized according to literature procedure.[107] (S)-cis-Verbenol (1.00 g, 
6.57 mmol, 1.0 equiv.) and phloroglucinol (4.14 g, 32.8 mmol, 5.0 equiv.) were dissolved in a 
mixture of dry MeNO2 (80 ml) and dry THF (20 ml). The solution was cooled to 0 °C and 
trimethylsilyl trifluoromethanesulfonate (1.53 g, 6.90 mmol, 1.05 equiv.) was added 
dropwise. The reaction mixture was stirred at 0 °C for 30 min. The reaction was quenched 
upon addition of a saturated aqueous solution of NaHCO3 (20 ml). The organic layer was 
separated, and the aqueous layer was extracted with CH2Cl2 (3 x 25 ml). The combined 
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organic layer was washed with brine and dried over Na2SO4. The crude product was 
concentrated under reduced pressure and purified by column chromatography 
(CH2Cl2:acetone  20:1). The title compound S1 (1.37 g, 5.26 mmol, 80%) was isolated as a 
yellow solid. 
m.p.  7881 °C. 
Rf = 0.2 (CH2Cl2:acetone  20:1, KMnO4). 
1H NMR (300 MHz, CDCl3) δ  5.94 (d, J  2.4 Hz, 1H), 5.86 (d, J  2.4 Hz, 1H), 5.43 – 5.35 (m, 
1H), 3.21 – 3.08 (m, 1H), 2.63 (td, J  11.0, 4.8 Hz, 1H), 2.10 (ddd, J  12.4, 5.0, 2.7 Hz, 1H), 
1.77 (td, J  10.7, 4.5 Hz, 3H), 1.67 (d, J  1.5 Hz, 3H), 1.35 (s, 3H), 1.08 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ  156.2, 155.6, 154.9, 134.9, 119.3, 106.6, 97.1, 96.2, 50.9, 45.0, 
36.2, 31.4, 28.0, 27.5, 23.6, 18.6. 
MS (EI) m/z (relative intensity): 260 (22), 217 (13), 192 (17), 178 (11), 177 (100), 139 (20), 
119 (10), 91 (17), 79 (11), 77 (16), 69 (27), 67 (12), 55 (14), 53 (14), 43 (17), 41 (26), 39 (17).  
HRMS (EI, m/z): calcd. for C16H20O3 [M
+] 260.1407, found 260.1408. 
IR (ATR, neat, cm-1): 3355 (w), 2974 (w), 2931 (w), 2913 (w), 2889 (w), 2843 (w), 1701 (w), 
1601 (s), 1509 (w), 1444 (m), 1405 (w), 1384 (m), 1370 (m), 1302 (w), 1261 (s), 1180 (m), 
1146 (s), 1127 (s), 1111 (s), 1083 (s), 1051 (m), 1032 (s), 1010 (s), 961 (w), 938 (w), 907 (m), 
849 (m), 818 (s), 789 (m), 765 (w), 732 (s), 703 (m), 684 (m), 629 (m), 538 (m), 527 (m), 
475 (m).  
Synthesis of (6aR,10aR)-1-hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-
benzo[c]chromen-3-yl trifluoromethanesulfonate (S2) 
 
N-Phenyl-bis(trifluoromethanesulfonimide) (3.52 g, 9.85 mmol, 1.0 equiv.) and (6aR,10aR)-
6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene- 1,3-diol S1 (2.56 g, 
9.85 mmol, 1.0 equiv.) were dissolved in dry THF (70 ml). The mixture was cooled to 0 °C and 
a solution of lithium bis(trimethylsilyl)amide in THF (1.0 M, 9.85 ml, 1.0 equiv.) was added 
dropwise. The reaction mixture was stirred for 90 min. at 0 °C and then concentrated under 
reduced pressure. The product was purified by column chromatography 
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(n-pentane:EtOAc:MeOH = 100:2:0.5). The title compound S2 (2.83 g, 7.22 mmol, 73%) was 
isolated as colorless oil. 
Rf  0.3 (n-pentane:EtOAc  20:1, UV). 
1H NMR (300 MHz, CDCl3) δ 6.37  (d, J  2.5 Hz, 1H), 6.23 (d, J  2.5 Hz, 1H), 5.44 (ddd, J 
5.0, 2.4, 1.2 Hz, 1H), 3.26 – 3.08 (m, 1H), 2.70 (td, J  11.1, 4.8 Hz, 1H), 2.24 – 2.05 (m, 1H), 
1.91 – 1.73 (m, 3H), 1.69 (d, J  2.0 Hz, 3H), 1.39 (s, 3H), 1.10 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ  156.0, 156.0, 148.2, 134.6, 119.40, 118.8 (q, J = 320.9 Hz), 
113.9, 103.50, 100.8, 78.1, 44.6, 35.6, 31.7, 27.9, 27.4, 23.5, 18.6. 
19F NMR (282 MHz, CDCl3) δ  73.01. 
MS (EI) m/z (relative intensity): 393 (13) [M+H], 392 (66), 377 (11), 349 (55), 324 (16), 311 
(11), 310 (13), 309 (100), 216 (11), 191 (29), 176 (13), 91 (12), 69 (30). 
HRMS (EI, m/z): calcd. for C17H19O5F3S [M
+] 392.0900, found 392.0900. 
IR (ATR, neat, cm-1): 3546 (w), 3386 (w), 2977 (w), 2894 (w), 2846 (w), 1597 (m), 1498 (w), 
1419 (m), 1387 (w), 1375 (w), 1334 (w), 1244 (m), 1207 (m), 1179 (m), 1137 (m), 1100 (m), 
1085 (m), 1051 (w), 1035 (m), 1020 (w), 982 (s), 941 (w), 909 (w), 898 (w), 862 (m), 842 (m), 
827 (m), 794 (m), 757 (w), 720 (w), 678 (w), 643 (w), 611 (m), 595 (m), 566 (w), 515 (m), 




Compound S3 was synthesized using a modified literature procedure.[107] Potassium (E)-
trifluoro(styryl)-borane (437 mg, 2.08 mmol, 1.6 equiv.) and (6aR,10aR)-1-hydroxy-6,6,9-
trimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-3-yl trifluoromethanesulfonate (S2) 
(510 mg, 1.30 mmol, 1.0 equiv.), Pd(OAc)2 (30 mg, 0.13 mmol, 0.10 equiv.), PCy3 (73 mg, 
0.26 mmol, 0.20 equiv.) and Cs2CO3 (1.27 g, 3.90 mmol, 3.0 equiv.) in THF:H2O (10:1, 10 ml) 
was stirred at 80 °C for 22 h. The mixture was allowed to cool to room temperature and 
filtered through a plug of celite and washed with EtOAc. The filtrate was concentrated under 




S3 (399 mg, 1.15 mmol, 88%) was obtained as an off-white solid. 
m.p.  6264 °C. 
Rf = 0.5 (n-pentane:EtOAc 9:1, UV). 
1H NMR (300 MHz, CDCl3) δ  7.50 – 7.44 (m, 2H), 7.41 – 7.20 (m, 3H), 7.02 (d, J  16.3 Hz, 
1H), 6.91 (d, J  16.3 Hz, 1H), 6.63 (d, J  1.7 Hz, 1H), 6.44 (d, J 1.7 Hz, 1H), 5.52 – 5.34 (m, 
1H), 4.93 (s, 1H), 3.31 – 3.14 (m, 1H), 2.76 (s, 1H), 1.98 – 1.78 (m, 3H), 1.72 (d, J  1.7 Hz, 3H), 
1.41 (s, 3H), 1.13 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ  155.4, 155.3, 137.4, 137.0, 134.8, 129.8, 128.8, 128.8, 128.2, 
127.8, 127.7, 126.6, 123.9, 119.5, 113.3, 108.7, 105.7, 45.0, 36.0, 32.0, 28.0, 27.7, 23.6, 18.6. 
MS (EI) m/z (relative intensity): 346 (49), 303 (13), 278 (13), 264 (19), 263 (100), 225 (20), 
165 (11), 91 (15). 
HRMS (EI, m/z): calcd. for C24H26O2 [M
+] 346.1927, found 346.1930. 
IR (ATR, neat, cm-1): 3351 (w), 3025(w), 2971 (w), 2887 (w), 2840 (w), 1700 (w), 1614 (w), 
1566 (w), 1542 (w), 1508 (w), 1496 (w), 1474 (w), 1447 (w), 1419 (w), 1383 (w), 1370 (w), 
1360 (w), 1345 (w), 1325 (m), 1258 (m), 1182 (s), 1152 (m), 1128 (m), 1111 (m), 1081 (s), 
1048 (w), 1031 (s), 1017 (m), 957 (s), 907 (m), 893 (m), 862 (m), 842 (m), 818 (m), 788 (m), 
767 (w), 748 (s), 730 (m), 690 (s), 621 (m), 602 (m), 578 (m), 565 (m), 556 (m), 540 (m), 513 
(m), 487 (m), 473 (m), 446 (m), 434 (m). 
Synthesis of (6aR,10aR)-6,6,9-trimethyl-3-((E)-styryl)-6a,7,10,10a-tetrahydro-6H-
benzo[c]chromen-1-yl acetate (3.2g) 
 
Acetic anhydride (250 µl, 2.5 mmol, 1.25 equiv.) was added dropwise to a stirring solution of 
S3 (693 mg, 2.0 mmol, 1.0 equiv.), NEt3 (350 µl, 2.50 mmol, 1.25 equiv.) and DMAP (25 mg, 
0.02 mmol, 0.1 equiv.) in dichloromethane (20 ml). The reaction mixture was stirred for 3 h 
at ambient temperature. The crude reaction mixture was concentrated under reduced 
pressure and purified by column chromatography (n-pentane:EtOAc  20:1). The title 
compound 3.2g (639 mg, 1.65 mmol, 83%) was isolated as a colorless solid. 
m.p.  5458 °C. 
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Rf = 0.3 (n-pentane:EtOAc 20:1, UV). 
1H NMR (300 MHz, CDCl3) δ  7.52 – 7.45 (m, 2H), 7.39 – 7.31 (m, 2H), 7.30 – 7.22 (m, 1H), 
7.10 – 6.93 (m, 2H), 6.90 (d, J  1.7 Hz, 1H), 6.76 (d, J  1.8 Hz, 1H), 5.51 – 5.39 (m, 1H), 
2.83 – 2.54 (m, 2H), 2.32 (s, 3H), 2.25 – 2.08 (m, 1H), 2.00 – 1.75 (m, 3H), 1.75 – 1.67 (m, 3H), 
1.41 (s, 3H), 1.13 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ  168.9, 155.1, 150.3, 137.2, 137.1, 133.8, 129.3, 128.7, 127.7, 
127.6, 126.6, 119.8, 118.5, 113.4, 112.5, 77.1, 44.6, 36.1, 32.1, 27.7, 27.4, 23.6, 21.3, 18.6. 
MS (EI) m/z (relative intensity): 389 (29), 388 (100), 347 (10), 346 (40), 345 (14), 329 (15), 
305 (30), 303 (32), 278 (22), 264 (20), 263 (100), 225 (26), 91 (12), 43 (22). 
HRMS (EI, m/z): calcd. for C26H28O3 [M
+] 388.2033, found 388.2032. 
IR (ATR, neat, cm-1): 3026 (w), 2973 (w), 2931 (w), 2891 (w), 2841 (w), 1764 (w), 1677 (w), 
1617 (w), 1558 (w), 1496 (w), 1481 (w), 1447 (w), 1420 (m), 1384 (w), 1368 (m), 1338 (w), 
1315 (w), 1259 (w), 1200 (s), 1179 (s), 1156 (m), 1127 (m), 1078 (m), 1033 (s), 1018 (m), 984 
(w), 958 (m), 900 (m), 846 (m), 826 (w), 789 (w), 749 (m), 691 (s), 640 (w), 617 (w), 582 (w), 
572 (w), 547 (w), 535 (w), 512 (w), 493 (w), 473 (w), 434 (w). 
Synthesis of (6aR,10aR)-3-((S)-2-(benzylamino)-2-phenylethyl)-6,6,9-trimethyl-6a,7,10,10a-
tetrahydro-6H-benzo[c]chromen-1-yl acetate (3.3la) and (6aR,10aR)-3-((R)-1-
(benzylamino)-2-phenylethyl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-
benzo[c]chromen-1-yl acetate (3.3lb) 
 
Compound 3.3l was prepared following general procedure B. Purification by column 
chromatography (n-pentane:EtOAc  20:1) yielded the title compound (156 mg, 0.34 mmol, 
69%, 3.3la:3.3lb = 68:32) as brownish viscous oil. The regioisomers were separated using 
n-heptane:i-PrOH = 30:1(+0.1% NEt3) as eluent. The diastereomers were not separated. 
3.3la: 
d.r.  60:40. 
Rf  0.53 (n-heptane:EtOAc)  1:1, KMnO4). 
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m.p.  6769 °C. 
1H NMR (400 MHz, CDCl3) δ  7.46 (ddd, J = 7.4, 4.5, 1.8 Hz, 2H), 7.43 – 7.31 (m, 2H), 
7.35 -7.26 (m, 1H), 7.26 – 7.11 (m, 3H), 7.00 (ddd, J  17.9, 5.4, 1.7 Hz, 2H), 6.24 (d, 
J  1.6 Hz, 1H, CH i1), 6.20 (d, J  1.6 Hz, 1H, CHi2), 6.15 (d, J  1.7 Hz, 1H, CHi1), 6.06 (d, 
J  1.7 Hz, 1H, CHi2), 5.46 (d, J  5.0 Hz, 1H), 3.86 (dd, J  10.3, 3.8 Hz, 1H), 3.70 (dd, J  13.7, 
10.7 Hz, 1H), 3.47 – 3.33 (m, 2H), 2.91 – 2.60 (m, 3H), 2.21 – 2.11 (m, 1H), 1.96 – 1.77 (m, 
2H), 1.75 (d, J  6.1 Hz, 3H), 1.41 (d, J 2.1 Hz, 3H), 1.34 – 1.22 (m, 1H), 1.16 (d, J  27.4 Hz, 
3H). 
 13C NMR (101 MHz, CDCl3) δ  156.5, 156.4, 155.6, 142.7, 142.4, 139.2, 138.9, 138.1, 137.8, 
135.2, 135.1, 128.7, 128.5, 128.5, 128.3, 128.2, 128.0, 127.8, 127.6, 127.6, 127.2, 119.5, 
119.3, 112.1, 112.1, 109.8, 109.0, 108.6, 76.8, 64.1, 63.1, 51.3, 50.8, 45.2, 45.0, 44.5, 44.4, 
36.2, 35.9, 32.0, 31.9, 28.1, 27.8, 27.8, 23.8, 23.8, 18.8, 18.6. 
MS (EI) m/z (relative intensity): 452 (1), 374 (1), 257 (1), 197 (15), 186 (88), 174 (6), 123 (3), 
91 (100).  
HRMS (ESI-TOF, m/z): calcd. for C33H38NO3 [M+H]
+ 454.2746, found 454.2747. 
IR (ATR, neat, cm-1): 3273 (w), 3027 (w), 2971 (w), 2913 (w), 2841 (w), 2638 (w), 2324 (w), 
1618 (w), 1578 (w), 1511 (w), 1495 (w), 1424 (m), 1382 (m), 1368 (m), 1358 (m), 1340 (m), 
1280 (w), 1259 (m), 1182 (m), 1153 (w), 1129 (m), 1112 (m), 1085 (m), 1053 (w), 1035 (m), 
1001 (m), 909 (m), 895 (w), 843 (m), 789 (m), 758 (m), 729 (m), 696 (s), 603 (m), 550 (w), 
526 (w), 508 (w), 485 (w), 474 (w), 464 (w), 435 (w).   
3.3lb: 
d.r.  54:46. 
Rf 0.44 (n-heptane:EtOAc)  1:1, KMnO4). 
m.p.  4647 °C. 
1H NMR (400 MHz, CDCl3) δ  7.28 – 7.16 (m, 6H), 7.16 – 7.02 (m, 4H), 6.53 – 6.29 (m, 2H), 
5.44 (d, J  5.0 Hz, 1H), 3.71 (ddd, J = 13.7, 8.1, 3.9 Hz, 2H), 3.47 (d, J  13.6 Hz, 1H), 3.32 – 
3.21 (m, 1H), 2.95 (ddd, J  13.1, 8.0, 4.9 Hz, 1H), 2.83 (ddd, J  13.7, 9.2, 7.2 Hz, 1H), 
2.73 (td, J  10.7, 4.5 Hz, 1H), 2.15 (dt, J  15.3, 8.8 Hz, 1H), 1.93 – 1.76 (m, 3H), 1.71 (s, 3H), 
1.40 (d, J  2.6 Hz, 3H), 1.28 (d, J 15.7 Hz, 2H), 1.13 (d, J  11.5 Hz, 3H), 1.01 – 0.79 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ  155.8, 155.8, 155.1, 155.1, 143.3, 143.2, 140.2, 140.1, 139.0, 
139.0, 135.0, 129.4, 129.4, 128.7, 128.6, 128.5, 128.4, 128.4, 128.1, 128.1, 127.2, 126.9, 
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126.9, 126.5, 126.5, 119.4, 112.5, 112.4, 109.6, 109.4, 106.1, 106.0, 76.8, 63.5, 63.3, 53.2, 
51.5, 51.4, 45.0, 45.0, 44.8, 36.1, 36.1, 32.0, 28.1, 27.7, 23.7, 18.7, 18.6. 
MS (EI) m/z (relative intensity): 362 (M-Bn, 100), 318 (1), 228 (4), 207 (4), 188 (4), 91 (83), 
69 (11). 
HRMS (EI, m/z): calcd. for C33H38NO3 [M+H]
+ 454.2746, found 454.2747. 
IR (ATR, neat, cm-1): 3286 (w), 3060 (w), 3027 (w), 2970 (w), 2916 (w), 2889 (w), 2842 (w), 
1619 (w), 1580 (m), 1495 (w), 1453 (m), 1426 (s), 1382 (m), 1358 (m), 1330 (m), 1263 (m), 
1181 (m), 1153 (w), 1131 (w), 1112 (w), 1084 (m), 1051 (w), 1034 (m), 986 (w), 960 (w), 
940 (w), 908 (m), 846 (m), 823 (m), 787 (w), 745 (m), 696 (s), 657 (m), 602 (w), 579 (m), 555 
(w), 540 (w), 477 (m), 436 (w). 
On-Off-Experiment 
In a preheated dry Schlenk-tube, E-stilbene 3.2a (90 mg, 0.5 mmol, 1.0 equiv.), PrPPTNO 1.2 
(11 mg, 25 µmol, 0.05 equiv.) and biphenyl (39 mg, 0.25 mmol, 0.5 equiv.) were added under 
argon. The Schlenk tube was evacuated and purged with argon 3 times. Next, benzylamine 
(3.1a) (0.27 ml, 2.5 mmol, 5.0 equiv.) and dry acetonitrile (5.0 ml) were added under argon 
and the reaction mixture was stirred for 5 minutes at room temperature. The reaction 
mixture was irradiated for 2 h, then the light source was switched off for 2 consecutive 
hours. This process was repeated alternately for 16 h. A 0.1 ml Sample was taken every 
2 hours from the reaction mixture, quenched with air and analyzed with calibrated GC. The 
final areas represent the average of 3 measurements per sample. 
Kinetic Experiments 
Kinetic experiments were performed under standard conditions on a 0.5 mmol-scale, using 
biphenyl as internal standard. Samples of 0.1 ml were taken in one-hour intervals under an 
argon atmosphere, quenched with air and analyzed by calibrated GC. Initial rates were 
determined within the first 4 hours at conversions below 20%. 
Rate of formation of 3.3a from (E)-stilbene (3.2a): 









               
       

















Rate of isomerization from (E)-stilbene (3.2a) to (Z)-stilbene (3.2i): 







               
       






















Rate of formation of 3.3a from (Z)-stilbene (3.2i): 







                  
        


















Rate of isomerization from (Z)-stilbene (3.2i) to (E)-stilbene (3.2a): 
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Rate of formation of 3.3g from 3.2c: 







                  
        





















Rate of isomerization from 3.2c to the (Z)-isomer of stilbeneethylester: 







               
       































7.2.3 Experimental section to chapter 4 
Fluorescence measurements and in vitro cell-tests were conducted in cooperation with 
the group of Dr. Jan Lukas from the translational neurodegeneration section of the Albrecht-
Kossel institute in Rostock. 
Synthesis of N,N-diallyl-3-bromoaniline (4.2): 
 
4.2 was prepared following a modified literature procedure.[147] 3-bromoaniline 4.1 
(98% purity, 33.0 µl, 291 µmol, 1.0 equiv.) and allyl bromide (98% purity, 80.0 µl, 901 µmol, 
3.1 equiv.) were added to a suspension/homogeneous mixture of K2CO3 (84 mg, 610 µmol, 
2.1 equiv.) in dry acetonitrile (1 ml) at room temperature. The mixture was stirred for 
20 hours at 80 °C and allowed to cool to room temperature. The suspension was filtered 
through a pad of Celite, extracted with ethyl acetate (3 x 5 ml). The combined organic layers 
were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced 
pressure. The resulting residue was purified by column chromatography 
(n-pentane:EtOAc  50:1) yielding the desired product 4.2 (69 mg, 274 µmol, 94%) as a 
colorless oil. 
Rf  0.71 (n-hexane:EtOAc  20:1, KMnO4). 
1H NMR (400 MHz, CDCl3) δ  7.04 (dd, J  8.4, 7.7 Hz, 1H), 6.90 – 6.76 (m, 2H), 6.61 (ddd, J  
8.5, 2.5, 0.9 Hz, 1H), 5.84 (ddt, J  16.7, 10.8, 4.8 Hz, 2H), 5.27 – 5.09 (m, 4H), 3.91 (dt, 
J = 4.8, 1.7 Hz, 4H). 
13C-NMR (101 MHz, CDCl3) δ  150.0, 133.3, 130.4, 123.4, 119.1, 116.4, 115.1, 110.9, 52.8. 
MS (EI) m/z (relative intensity): 252 (25) [M+], 251 (81), 224 (97), 210 (18), 184 (34), 157 (49), 
145 (30), 130 (100), 82 (13), 77 (28).  
HRMS (ESI-TOF, m/z): calculated for C12H14N1Br [M]
+: 251.0304, found: 251.0302. 
IR (ATR, neat, cm-1): 3081 (w), 2980 (w), 2862 (w), 1587 (s), 1487 (s), 1355 (w), 1232 (m), 
981 (m), 755 (s). 




Compound 4.3 was prepared following a literature procedure.[147] To a stirred solution of 
N,N-diallyl-3-bromoaniline 4.2 (52 mg, 204 µmol, 1.0 equiv.) in acetic acid (1 ml) was added a 
solution of formaldehyde (36% wt., 76.0 µl, 992 µmol, 5.0 equiv.) at room temperature. The 
mixture was heated at 80 °C for 2 hours and cooled to room temperature. Next, the reaction 
mixture was neutralized with a saturated solution of aqueous NaHCO3 (10 ml) and extracted 
with dichloromethane (3 x 20 ml). The combined organic layers were dried over anhydrous 
sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue 
was purified by column chromatography (n-pentane:EtOAc  50:1) yielding the desired 
product 4.3 (45 mg, 87 µmol, 85%) as a light pale yellow oil. 
Rf  0.65 (n-hexane:EtOAc  10:1, UV, KMnO4). 
1H NMR (300 MHz, CDCl3) δ  6.91 (d, J  2.7 Hz, 2H), 6.83 (d, J  8.6 Hz, 2H), 
6.56 (dd, J  8.6, 2.7 Hz, 2H), 5.83 (m, 4H), 5.17 (m, 8H), 3.97 (s, 2H), 3.88 (m, 8H). 
13C-NMR (75 MHz, CDCl3) δ 148.2, 133.6, 130.9, 125.7, 116.5, 116.1, 111.8, 52.9, 39.9. 
MS (EI) m/z (relative intensity): 516 (100) [M+], 435 (5), 419 (5), 273 (4), 266 (20), 245 (7), 
218 (12), 198 (24), 165 (6), 109 (4).  
HRMS (ESI-TOF, m/z): calculated for C25H28N2Br2 [M]
+ : 514.0614, found: 514.0612. 
IR (ATR, neat, cm-1): 3078 (w), 2978 (w), 1602 (s), 1497 (s), 1385 (w), 1229 (m), 1019 (m), 
915 (s), 803 (m). 
Synthesis of 3,7-bis(diallylamino)-5-phenyl-10H-acridophosphine 5-oxide (4.4): 
 
4.4 was prepared following a modified literature procedure.[148] To a stirred solution of 4,4'-
methylenebis(N,N-diallyl-3-bromoaniline) (4.3) (203 mg, 394 µmol, 1.0 equiv.) in anhydrous 
THF (2 ml) was added a solution of tert-butyllithium in pentane (1.9 M, 510 µl, 969 µmol, 
2.5 equiv.) dropwise at 78 °C. The mixture was stirred for further 10 min. at78 °C and 
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warmed slowly to 0 °C and stirred for another 1 hour. The reaction mixture was then cooled 
again to 78 °C and dichlorophenylphosphine 4.4a (97% purity, 81 µl, 581 µmol, 1.5 equiv.) 
was added dropwise to the reaction mixture over 1 minute. The resulting solution was 
warmed to room temperature and refluxed afterwards at 70 °C for 2 hours. After cooling to 
0 °C, a 30% aqueous solution of hydrogen peroxide (0.3 ml) was added dropwise and the 
solution was further stirred at room temperature for 2 hours. The reaction mixture was then 
extracted using dichloromethane (3 x 15 ml). The combined organic layers were dried over 
anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The formed 
residue was purified by column chromatography (dichloromethane:EtOAc  6:1) yielding the 
desired product 4.4 (116 mg, 241 µmol, 61%) as a viscous yellow oil. 
Rf  0.41 (dichloromethane:EtOAc  1:1, UV, KMnO4). 
1H NMR (300 MHz, CDCl3) δ   7.53 – 7.40 (m, 4H), 7.39 – 7.24 (m, 3H), 7.16 (dd, J  8.5, 
5.9 Hz, 2H), 6.76 (dd, J  8.5, 2.8 Hz, 2H), 5.93 – 5.67 (m, 4H), 5.21 – 5.05 (m, 8H), 4.05 – 
3.77 (m, 9H), 3.64 (dd, J  18.2, 3.6 Hz, 1H). 
13C-NMR (75 MHz, CDCl3) δ  147.4 (d, J  12.7 Hz), 134.5 (d, J  104.3 Hz), 133.5, 131.1 
(d, J  2.7 Hz), 130.8 (d, J  10.5 Hz), 129.7 (d, J  78.9 Hz), 129.0 (d, J  12.4 Hz), 
128.9 (d, J  11.6 Hz), 128.3 (d, J  12.1 Hz), 116.3, 115.6 (d, J  2.6 Hz), 113.9 (d, J  8.2 Hz), 
52.8, 35.3 (d, J  9.5 Hz). 
31P-NMR (122 MHz, CDCl3) δ  13.86. 
LCMS (ESI, m/z): 481 [M+H]+.  
HRMS (ESI-TOF, m/z): calculated for C31H34N2OP [M+H]
+: 481.2407, found: 481.2409. 
IR (ATR, neat, cm-1): 2923 (w), 1578 (s), 1387 (m), 1303 (m), 1230 (m), 1148 (m), 919 (m), 830 
(m), 716 (m). 
Synthesis of 3,7-bis(diallylamino)-5-phenyl-10H-acridophosphin-10-one 5-oxide (4.5): 
 
Compound 4.5 was prepared following a literature procedure.[148] To a solution of 3,7-
bis(diallylamino)-5-phenyl-10H-acridophosphine 5-oxide 4.4 (2.54 g, 5.28 mmol, 1.0 equiv.) 
in dichloromethane (50 ml) was added p-chloranil 4.4a (3.90 g, 15.84 mmol, 3.0 equiv.) at 
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room temperature. The reaction mixture was stirred overnight open to air at room 
temperature and was then quenched with an aqueous solution of Na2SO3. Subsequently, the 
crude mixture was extracted with dichloromethane (3 x 30 ml). The combined organic layers 
were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced 
pressure. The resulting residue was purified by flash column chromatography 
(dichloromethane:EtOAc  7:1) yielding the desired product 4.5 (1.55 g, 3.13 mmol, 59%) as 
a yellow oil. 
Rf  0.48 (dichloromethane:EtOAc  1:1, UV, KMnO4). 
1H NMR (300 MHz, CDCl3) δ 8.26 (dd, J 9.0, 6.0 Hz, 2H), 7.64 – 7.50 (m, 2H), 7.41 – 7.23 
(m, 3H), 7.13 (dd, J  14.8, 2.7 Hz, 2H), 6.85 (dd, J  9.0, 2.6 Hz, 2H), 5.77 (m, 4H), 5.29 – 
4.99 (m, 8H), 3.99 (m, 8H). 
13C-NMR (75 MHz, CDCl3) δ  180.2 (d, J  8.7 Hz), 151.5 (d, J  12.7 Hz), 
134.9 (d, J  106.8 Hz), 134.7 (d, J  97.2 Hz), 132.2, 131.4 (d, J  10.0 Hz), 
130.7 (d, J  10.2 Hz), 128.5 (d, J  12.4 Hz), 124.9 (d, J  6.7 Hz), 117.1, 115.2 (d, J  2.3 Hz), 
112.6 (d, J  7.9 Hz), 52.7. 
31P-NMR (122 MHz, CDCl3) δ  6.24. 
HRMS (ESI-TOF, m/z): calculated for C31H32N2O2P [M+H]
+: 495.2201, found: 495.2209. 
IR (ATR, neat, cm-1): 3313 (m), 2927 (w), 1475 (m), 1314 (m), 1167 (m), 1097 (s), 1018 (m), 
813 (m), 654 (m). 
Synthesis of 3,7-diamino-5-phenyl-10H-acridophosphin-10-one 5-oxide (4.6): 
 
Compound 4.6 was prepared following a literature procedure.[148] To a solution of 3,7-
bis(diallylamino)-5-phenyl-10H-acridophosphine 5-oxide 4.5 (477 mg, 965 µmol, 1.0 equiv.) 
in 1,2-dichloroethane (18 ml) was added Tetrakis(triphenylphosphane)palladium (145 mg, 
125 µmol, 0.13 equiv.) and 1,3-dimethylbarbituric acid (699 mg, 4.28 mmol, 4.4 equiv.) at 
room temperature. The reaction mixture was stirred at 80 °C for 24 hours and was then 
cooled down to room temperature. Subsequently, the crude mixture was filtered through 
Celite and the solvent was removed under reduced pressure. The resulting residue was 
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purified by flash column chromatography (dichloromethane:MeOH  20:1) yielding the 
desired product 4.6 (281 mg, 841 µmol, 87%) as a yellow solid. 
Rf  0.23 (dichloromethane:methanol  12:1, UV, KMnO4). 
1H NMR (400 MHz, CD3OD) δ  8.26 (dd, J  9.0, 6.0 Hz, 2H), 7.64 – 7.50 (m, 2H), 7.41 – 7.23 
(m, 3H), 7.13 (dd, J  14.8, 2.7 Hz, 2H), 6.85 (dd, J  9.0, 2.6 Hz, 2H), 5.77 (ddt, J  17.0, 9.9, 
4.8 Hz, 4H), 5.29 – 4.99 (m, 8H), 3.99 (m, 8H). 
13C-NMR (101 MHz, CD3OD) δ  181.3 (d, J  8.9 Hz), 154.8 (d, J  13.1 Hz), 
135.1 (d, J  98.0 Hz), 134.4 (d, J  108.9 Hz), 133.3 (d, J  2.9 Hz), 132.6 (d, J  10.3 Hz), 
131.6 (d, J  10.6 Hz), 129.9 (d, J  12.8 Hz), 125.5 (d, J  7.0 Hz), 118.5 (d, J  2.3 Hz), 
115.2 (d, J  7.3 Hz). 
31P-NMR (162 MHz, CD3OD) δ  8.78. 
HRMS (ESI-TOF, m/z): calculated for C19H16N2O2P [M+H]
+: 335.0949, found: 335.0949. 
IR (ATR, neat, cm-1): 3349 (w), 3207 (w), 1621 (w), 1580 (m), 1435 (w), 1302 (m), 1143 (m), 
913 (w). 
Synthesis of 3.7-Dihydroxy-5-phenylacridophosphin-10(5H)-on-5-oxid (4.7) 
 
Compound 4.7 was prepared following a literature procedure.[148] To a solution of 4.6 
(450 mg, 1.35 mmol, 1.0 equiv.) in 96% H2SO4 (17 ml) was added sodium nitrite (326 mg, 
4.58 mmol, 3.4 equiv.) at 0 °C under air. after stirring for 3 hours at room temperature, the 
mixture was slowly poured to ice and stirred at 110 °C for 1 hour. The resulting precipitate 
was filtrated, washed with distilled water and dispersed in methanol. the filtrate was dried 
under vacuum and purified by column chromatography 
(dichloromethane:MeOH 100:3 → 100:5) yielding product 4.7 (303 mg, 901 µmol, 67%) as 
a yellow solid. 
Rf  0.42 (dichloromethane:methanol 12:1, UV, KMnO4). 
1H NMR (400 MHz, CD3OD) δ   7.15 (ddd, 2H, J  8.6, 2.5, 0.8 Hz), 7.21 (ddd, 2H, J  14.2, 
2.5, 0.4 Hz), 7.40 – 7.63 (m, 5H), 8.31 (dd, 1H, J  8.6, 0.4 Hz), 8.33 (dd, 1H, J  8.8, 0.3 Hz). 
13C-NMR (101 MHz, CD3OD) δ  117.6 (d, J  6.8 Hz), 121.5 (d, J  2.1 Hz), 129.1 
(d, J  6.7 Hz), 130.2 (d, J  12.8 Hz), 131.7 (d, J  10.7 Hz), 133.3 (d, J  10.3 Hz), 
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133.6 (d, J  109.9 Hz), 133.7 (d, J  2.7 Hz), 135.6 (d, J  98.0 Hz), 163.9 (d, J  13.8 Hz), 
181.4 (d, J  8.9 Hz). 
31P-NMR (162 MHz, CD3OD) δ  7.3. 
LCMS (ESI, m/z): 337 [M+H]+.  
HRMS (ESI-TOF, m/z): calculated for C19H14O4P [M+H]
+ 337.0630, found 337.0633. 
IR (ATR, neat, cm-1): 3053 (br. w), 2683 (w), 2292 (w), 1586 (m), 1565 (m), 1292 (m), 
1134 (m), 909 (w), 881 (w). 
Synthesis of 5-oxido-10-oxo-5-phenyl-10H-acridophosphine-3,7-diyl 
bis(trifluoromethanesulfonate) (4.8) 
 
Compound 4.8 was synthesized according to a literature procedure.[142] A solution of 4.7 
(253 mg, 752 µmol, 1.0 equiv.), phenyl triflimide (823 mg, 2.3 mmol, 3.0 equiv.) and DIPEA 
(770 µl, 4.5 mmol, 6.0 equiv.) in anhydrous DMF (5 ml) was stirred at room temperature 
overnight. The reaction was diluted with H2O (15 ml) and extracted with EtOAc (3x 20 ml), 
dried over sodium sulfate and dried under vacuum. The resulted residue was purified by 
column chromatography (n-pentane:EtOAc 7:1) which yielded desired product 4.8 
(414 mg, 690 µmol, 92%) as a white solid. 
Rf  0.26 (dichloromethane:methanol 200:1, UV, KMnO4). 
1H NMR (400 MHz, CDCl3) δ   7.40 – 7.59 (m, 5H), 7.67 (ddd, 2H, J  8.8, 2.5, 0.6 Hz), 
7.92 (dd, 2H, J  13.0, 2.5 Hz), 8.56 (ddd, 2H, J  8.8, 5.2, 0.4 Hz). 
13C NMR (101 MHz, CDCl3) δ  118.7 (q, J  320 Hz), 124.0 (d, J  7.4 Hz), 126.2 (d, J  1.4 Hz), 
129.5 (d, J  13.0 Hz), 130.8 (d, J  10.6 Hz), 130.9 (d, J  111.2 Hz), 132.8 (d, J  9.4 Hz), 
133.2 (d, J  2.8 Hz), 134.9 (d, J  5.5 Hz), 136.5 (d, J  96.1 Hz), 153.1 (d, J  15.1 Hz), 
180.1 (d, J 8.9 Hz). 
31P NMR (162 MHz, CDCl3) δ  2.4. 
19F NMR (376 MHz, CDCl3) δ  72.6. 
LCMS (ESI, m/z): 601 [M+H]+.  
HRMS (ESI-TOF, m/z): calculated for C21H11F6O8PS2 [M]
+ 600.9615, found 600.9612. 
Experimental section 
166 
IR (ATR, neat, cm-1): 3105 (w), 2924 (w), 1672 (w), 1589 (w), 1424 (s), 1204 (s), 1134 (s), 
926 (m), 804 (m), 717 (m). 
Synthesis of 7-morpholino-5-oxido-10-oxo-5-phenyl-10H-acridophosphin-3-yl 
trifluoromethanesulfonate (4.9) 
 
Compound 4.9 was synthesized according to a modified literature procedure.[142] 
Morpholine (10 mg, 113 µmol, 2.0 equiv.) was diluted in anhydrous DMSO (1 ml). The 
resulting solution was added to a mixture of 4.8 in DMSO (1 ml) at room temperature. Next, 
the reaction mixture was heated to 90 °C overnight and cooled afterwards to room 
temperature. The reaction mixture was diluted with H2O (2 ml) and extracted with 
EtOAc (3 x 5 ml), dried over sodium sulfate and dried under reduced pressure. the crude 
residue was purified by column chromatography (dichloromethane:EtOAc  1:1) yielding 
desired 4.9 (25 mg, 47 µmol, 82%) as a solid. 
Rf  0.34 (dichloromethane/EtOAc  1:1, UV, KMnO4). 
1H NMR (400 MHz, CDCl3) δ   3.33 – 3.48 (m, 4H), 3.77 – 3.87 (m, 4H), 7.12 (dd, 1H, J  9.1, 
2.7 Hz), 7.32 (dd, 1H, J  15.3, 2.8 Hz), 7.36 – 7.60 (m, 6H), 7.88 (dd, 1H, J  12.7, 2.6 Hz), 
8.35 (dd, 1H, J  9.0, 6.0 Hz), 8.52 (ddd, 1H, J  8.8, 5.2, 0.4 Hz). 
13C NMR (101 MHz, CDCl3) δ  46.9, 66.4, 114.2 (d, J 8.2 Hz), 117.1 (d, J  2.1 Hz), 123.4 (d, 
J  6.4 Hz), 125.4 (d, J  6.9 Hz), 125.5 (d, J  1.8 Hz), 129.2 (d, J 12.7 Hz), 130.7 
(d, J  10.6 Hz), 132.0, 132.1 (d, J  1.5 Hz), 132.3, 132.5 (d, J  2.8 Hz), 133.5, 133.9, 135.2, 
135.9 (d, J  6.0 Hz), 136.2, 137.5, 153.1 (d, J  121.4 Hz), 153.3 (d, J 119.5 Hz), 
179.7 (d, J  8.3 Hz). 
31P NMR (122 MHz, CDCl3) δ  4.0. 
19F NMR (282 MHz, CDCl3) δ  72.7. 
LCMS (ESI, m/z): 538 [M+H]+.  
HRMS (ESI-TOF, m/z): calculated for C24H20NO6F3PS [M+H]
+ 538.0701, found 538.0704. 





10-one 5-oxide (4.10) 
 
Compound 4.10 was synthesized according to a modified literature procedure.[142] A solution 
of 4.9 (54 mg, 12 µmol, 1.0 equiv.) in dioxane (3 ml) was treated with a solution of tetrabutyl 
ammonium hydroxide (40% w/w in H2O) (130 mg, 201 µmol, 2.0 equiv.). The reaction 
mixture was stirred at room temperature for 2.5 hours. the resulting mixture was then dried 
under reduced pressure and re-dissolved in dichloromethane (3 ml). After cooling the 
solution to 0 °C, imidazole (35 mg, 502 µmol, 5.0 equiv.) was added to the solution followed 
by TBDMSCl (77 mg, 502 µmol, 5.0 equiv.).  After stirring the solution for 4 hours at room 
temperature, the reaction mixture was diluted with DCM (5 ml) and washed with H2O (5 ml). 
The organic fractions were dried over sodium sulfate and dried under reduced pressure. the 
crude residue was purified by column chromatography (dichloromethane:EtOAc  2:1) which 
afforded desired product 4.10 (51 mg, 99 µmol, 98%) as a white solid. 
Rf  0.21 (dichloromethane/EtOAc1:1, UV, KMnO4). 
1H NMR (300 MHz, CDCl3) δ  0.18 (d, 6H, J  3.8 Hz), 0.93 (s, 9H), 3.35 (dd, 4H, J  5.9, 
3.8 Hz), 3.80 (t, 4H, J  4.7 Hz), 7.05 – 7.11 (m, 2H), 7.27 – 7.45 (m, 5H), 7.50 – 7.62 (m, 2H), 
8.29 – 8.38 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ  4.3 (d, J  7.3 Hz), 18.3, 25.6, 47.0, 66.4, 114.3 (d, J  7.8 Hz), 
117.0 (d, J  1.9 Hz), 121.7 (d, J  6.3 Hz), 124.2, (d, J  2.2 Hz), 126.4 (d, J  6.8 Hz), 
128.8 (d, J  12.8 Hz), 129.8 (d, J  6.3 Hz), 130.6 (d, J  10.5 Hz), 131.6 (d, J  10.0 Hz), 
131.8 (d, J  4.9 Hz), 131.9 (d, J  2.7 Hz), 133.7 (d, J  83.9 Hz), 134.7 (d, J  8.8 Hz), 
135.8 (d, J  31.9 Hz), 153.6 (d, J  12.4 Hz), 160.3 (d, J  14.0 Hz), 180.6 (d, J  9.1 Hz). 
31P NMR (122 MHz, CDCl3) δ  4.8. 
LCMS (ESI, m/z): 520 [M+H]+.  
HRMS (ESI-TOF, m/z): calculated for C29H34NO4PSi [M+H]
+ 520.2073, found 520.2078. 





Synthesis of (4-bromo-3-(trifluoromethyl)phenyl)methanol (4.12) 
 
Compound 4.12 was prepared following a modified literature procedure.[197] A solution of 4-
bromo-3-(trifluoromethyl)benzoic acid 4.11 (2.0 g, 7.43 mmol, 1.0 equiv.) in dry diethyl ether 
(15 ml) was added dropwise to a suspension of LiAlH4 (97% purity, 597 mg, 15.3 mmol, 
2.05 equiv.) in dry diethyl ether (10 ml) at 0 °C. The reaction mixture was stirred at 48 °C for 
3 hours and was allowed to cool down to room temperature. Subsequently, the reaction was 
quenched with water (15 ml) at 0 °C and acidified with 0.5 M aqueous HCl (10 ml). The crude 
mixture was extracted with dichloromethane (3 x 30 ml). The combined organic layers were 
dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. 
The resulting residue was purified by column chromatography (n-pentane:EtOAc  5:1) 
yielding the desired product 4.12 (1.692 g, 6.39 mmol, 89%) as a sticky pale solid. 
Rf  0.38 (SiO2, n-pentane:EtOAc  3:1, UV, KMnO4). 
1H NMR (300 MHz, CDCl3) δ  7.75 – 7.60 (m, 1H), 7.36 (ddq, J  8.2, 2.0, 0.8 Hz, 1H), 
4.69 (s, 1H), 2.18 (s, 1H). 
13C-NMR (75 MHz, CDCl3) δ  140.5, 135.1, 131.2, 130.3 (q, J  31.2 Hz), 126.2 (q, J  5.4 Hz), 
123.0 (q, J  273.4 Hz), 118.9 (q, J  1.6 Hz), 64.0. 
19F-NMR (282 MHz, CDCl3) δ  62.7. 
MS (EI) m/z (relative intensity): 254 (42) [M+], 237 (14), 225 (8), 207 (20), 175 (21), 155 (100), 
127 (72), 107 (6), 95 (7), 77 (26).  
HRMS (ESI-TOF, m/z): calculated for C8H6O1Br1F3 [M
+] 253.9549, found: 253.9547. 
IR (ATR, neat, cm-1): 3313 (m), 2927 (w), 1475 (m), 1314 (m), 1167 (m), 1097 (s), 1018 (m), 
813 (m), 654 (m). 




Compound 4.15 was prepared following a literature procedure.[152] The mixture of 
dithioethyleneglycol 4.14 (22.1 ml, 250 mmol, 5.0 equiv.) and powdered sodium hydroxide 
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(3.0 g, 75 mmol, 1.5 equiv.) was refluxed in THF (200 ml) under inert atmosphere for 30 min. 
A solution of ethyl iodide (4.1 ml, 50 mmol, 1.0 equiv.) in THF (50 ml) was added dropwise 
over the course of 1 h and the reaction mixture was refluxed for another 1 h. The residue 
obtained by solvent evaporation was poured into 50% aqueous solution of NH4Cl (40 ml) and 
the product was extracted with CH2Cl2 (3 x 30 ml). The combined organic phase was washed 
with brine (2 x 25 ml), dried over anhydrous sodium sulfate, filtered, and concentrated 
under reduced pressure. The concentrate was purified by vacuum distillation to give the title 
product 4.15 (3.8 g, 31 mmol, 62%) as a colorless liquid. 
1H NMR (300 MHz, CDCl3) δ  1.23 (t, J  7.4 Hz, 3H), 1.68 – 1.74 (m, 1H), 
2.53 (q, J  7.4 Hz, 2H), 2.65 – 2.77 (m, 4H). 
13C NMR (75 MHz, CDCl3) δ  35.6, 25.7, 24.6, 14.7. 
MS (EI) m/z (relative intensity): 122 (99) [M+], 89 (7), 75 (100), 61 (53), 47 (43), 35 (6), 
27 (17). 
HRMS (EI): calcd. for C4H10S2 [M]
+ 122.0218, found 122.0217. 
IR (ATR, neat, cm-1): 2965 (m), 2923 (m), 2546 (w), 1450 (m), 1426 (m), 1374 (w), 1260 (s), 
1208 (s), 1139 (w), 969 (m), 697 (s). 
Synthesis of bis(2-((2-(ethylthio)ethyl)thio)ethyl)amine (4.16): 
 
Compound 4.16 was prepared following a modified literature procedure.[140] Cs2CO3 
(150 mg, 455 µmol, 3.0 equiv.) was added to a solution of 3-thiapentan-1-thiol 4.15 (50 mg, 
409 µmol, 2.7 equiv.) in MeCN (1 ml). Next, a mixture of bis(2-chloroethyl)amine 
hydrochloride (27 mg, 152 µmol, 1.0 equiv.) in MeCN (1ml) was dissolved at 85 °C and added 
dropwise to the first solution of 4.15. The reaction mixture was allowed to stir overnight. 
Afterwards, the reaction mixture was filtered and dried under vacuum. the residue was then 
extracted with DCM (3x3ml) and water (5.0 ml), dried over sodium sulfate and dried under 
vacuum. Purification of the residue via column chromatography 
(dichloromethane:MeOH  50:1) generated desired product 4.16 (42 mg, 134 µmol, 88%). 
Rf  0.22 (dichlormethane:MeOH  40:1, KMnO4) 
Experimental section 
170 
1H NMR (300 MHz, CDCl3) δ  1.22 (t, J  7.4 Hz, 6H), 1.85 (bs, 1H), 2.53 (q, J  7.4 Hz, 4H), 
2.65 – 2.72 (m, 12H), 2.77 – 2.82 (m, 4H). 
13C NMR (75 MHz, CDCl3) δ  48.2, 32.4, 31.9, 31.6, 25.9, 14.7. 
MS (EI) m/z (relative intensity): 252 (24), 178 (19), 121 (11), 89 (100), 61 (14). 
HRMS (ESI-TOF, m/z): calcd. for C12H27NS4 [M+H]
+ 314.1104, found 314.1100. 
IR (ATR, neat, cm-1): 2959 (m), 2919 (s), 2821 (w), 1450 (s), 1423 (s), 1373 (w), 1259 (s), 




NaH (66 mg, 1.65 mmol, 2.1 equiv.) was added portionswise over 5 minutes to a solution of 
(4-bromo-3-(trifluoromethyl)phenyl)methanol (4.12) (201 mg, 788 µmol, 1.0 equiv.) in THF 
(4.5 ml) at 0 °C. The reaction mixture was allowed to stir for 15 minutes at 0 °C . Then, TsCl 
(157 mg, 824 µmol, 1.05 equiv.) was added and the reaction was stirred for 1.5 h at room 
temperature. bis(2-((2-(ethylthio)ethyl)thio)ethyl)amine (4.16) (545 mg, 1.74 mmol, 
2.2 equiv.) was dissolved in dry THF (3 ml) and added to the first solution of 4.12. The 
mixture was allowed to stir overnight at room temperature. Subsequently, the reaction 
mixture was extracted with EtOAc (3 x 20 ml), H2O and brine, dried over sodium sulfate and 
concentrated under vacuum. Purification of the residue via column chromatography 
(n-pentane:acetone:EtOAc  200:3:3) afforded desired product 4.18 (206 mg, 374 µmol, 
47%) as a colorless oil. 
Rf  0.42 (n-pentane:acetone:EtOAc  50:2:2, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  1.24 (t, 6H, J  7.4 Hz), 2.54 (q, 4H, J  7.4 Hz), 2.68 (s, 16H), 
3.63 (s, 2H), 7.41 (d, 1H, J  8.3 Hz), 7.64 (d, 1H, J  8.3 Hz), 7.70 (d, 1H, J  1.5 Hz). 
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13C NMR (75 MHz, CDCl3) δ  14.9, 26.2, 30.3, 31.9, 32.6, 53.9, 57.7, 118.4 (d, J  1.6 Hz), 
123.1 (d, J  274 Hz), 127.9 (q, J  6.2 Hz), 130.1 (d, J  31.3 Hz), 133.1, 135.0, 139.5. 
19F NMR (282 MHz, CDCl3) δ 62.5. 
MS (LCMS) m/z (relative intensity): 552 [M+H]+. 
HRMS (ESI-TOF, m/z): calcd. for C20H32BrF3NS4 [M+H]
+ 550.0553, found 550.0555. 
IR (ATR, neat, cm-1): 2962 (w), 2819 (w), 1451 (w), 1314 (m), 1259 (w), 1125 (s), 1022 (w), 
826 (w). 
Synthesis of N-(4-Bromo-3-(trifluormethyl)benzyl)-N-octyloctan-1-amin (4.19) 
 
NaH (67 mg, 1.68 mmol, 2.15 equiv.) was added portionswise over 5 minutes to a solution of 
(4-bromo-3-(trifluoromethyl)phenyl)methanol (4.12) (199 mg, 780 µmol, 1.0 equiv.) in THF 
(4.5 ml) at 0 °C. The reaction mixture was allowed to stir for 15 minutes at 0 °C . Then, TsCl 
(160 mg, 823 µmol) was added and the reaction was stirred for 1.5 h at room temperature. 
di-octylamine (4.17) (741 µl, 2.35 mmol, 3.0 equiv.) was dissolved in dry THF (3 ml) and 
added to the first solution of 4.12. The mixture was allowed to stir overnight at room 
temperature. Subsequently, the reaction mixture was extracted with EtOAc (3 x 20 ml), H2O 
and brine, dried over sodium sulfate and dried under vacuum. Purification of the residue via 
column chromatography (n-pentane:EtOAc 50:1) afforded desired product 4.19 (299 mg, 
624 µmol, 80%) as a colorless oil. 
Rf  0.81 (n-pentane:EtOAc  5:1, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  0.89 (dd, 6H, J  6.5, 6.0 Hz), 1.26 (s, 20H), 1.44 (m, 4H), 2.39 
(m, 4H), 3.56 (m, 2H), 7.32 – 7.44 (m, 1H), 7.45 – 7.72 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ = 14.2, 22.8, 27.2, 27.6, 29.5, 29.7, 32.0, 54.1, 58.0, 
117.7 (d, J  1.7 Hz), 123.6 (q, J  3.8 Hz), 125.5 (q, J  3.8 Hz), 128.0 (q, J  5.5 Hz), 128.6, 
133.1, 134.7, 141.0.  
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19F NMR (282 MHz, CDCl3) δ 62.5. 
MS (LCMS), m/z (relative intensity): 478 [M]+. 
HRMS (ESI-TOF, m/z): calcd. for C24H40F3NBr [M+H]
+ 478.2296, found 478.2289. 
Synthesis of 10-(4-((bis(2-((2-(ethylthio)ethyl)thio)ethyl)amino)methyl)-2-
(trifluoromethyl)phenyl)-7-morpholino-5-phenyl-3H-acridophosphin-3-one 5-oxide (4.20) 
 
Compound 4.20 was synthesized according to a modified literature procedure.[142] 
Polythioether 4.18 (106 mg, 192 µmol, 2.0 equiv.) was dissolved in 1.2 ml of dry THF and 
cooled to 78 °C. A 1.9 M solution of tert-butyl lithium (110 µl, 202 µmol, 2.1 equiv.) was 
added dropwise over 5 minutes. The resulting solution was stirred over 1 hour at 78 °C and 
10 minutes at room temperature. After cooling the reaction mixture back to 78 °C, a 
solution of phosphoacridone 4.10 (50 mg, 96 µmol, 1.0 equiv.) in 3 ml THF was added 
dropwise over 10 minutes and the solution was allowed to stirr for 15 minutes at 78 °C. The 
reaction mixture was allowed to warm to room temperature and was stirred for further 
1.5 hours. A solution of 6M HCl (5 ml) was added at 0 °C to the above solution and stirred at 
room temperature for 1 hour. Next, the dark solution was quenched with a solution of 15% 
w/w sodium hydroxide and extracted with dichloromethane (3x20 ml), dried over sodium 
sulfate and concentrated under reduced pressure. The residue was then purified by column 
chromatography (dichloromethane:MeOH  100:2) which afforded desired 4.20 (50 mg, 
58 µmol, 60%) as a blue solid.  
Rf  0.3 (dichloromethane:MeOH  9:1, UV, KMnO4). 
1H NMR (300 MHz, CD2Cl2) δ   1.23 (t, 6H, J  7.3 Hz), 2.55 (q, 4H, J  7.4 Hz), 2.72 (s, 10H), 
2.74 – 2.88 (m, 6H), 3.35 (br s, 4H), 3.75 (t, 4H, J  4.9 Hz), 3.83 (s, 2H), 6.20 
(d, 1H, J  9.9 Hz), 6.63 – 6.94 (m, 3H), 7.10 (dd, 1H, J  16.9, 1.1 Hz), 7.28 (d, 1H, J  7.7 Hz), 
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7.37 – 7.58 (m, 4H), 7.64 (dd, 1H, J  12.8, 1.5 Hz), 7.66 (d, 1H, J 12.6 Hz), 
7.77 (d, 1H, J  7.2 Hz), 7.94 (s, 1H). 
13C NMR (75 MHz, CD2Cl2) δ  15.1, 26.3, 30.5, 32.2, 32.9, 47.0, 54.4, 58.1, 66.6, 116.1 (m), 
117.2 (m), 125.2 (m), 126.9 (m), 128.0 (m), 129.2 (d, J  12.2 Hz), 130.5 (d, J  10.0 Hz), 
132.2 (m), 132.5, 132.7 (q, J  4.8 Hz), 134.0 (m), 134.4 (m), 135.4 (m), 135.7 (m), 139.7 (m), 
142.2 (m), 149.1 (m), 152.1 (m), 152.3 (m), 183.9 (m). 
31P NMR (122 MHz, CD2Cl2) δ  7.1. 
19F NMR (282 MHz, CD2Cl2) δ  59.3 
LCMS (ESI, m/z): 859 [M]+.  
HRMS (ESI-TOF, m/z): calculated for C43H50F3N2O3PS4 [M]
+ 859.2472, found 859.2492. 
IR (ATR, neat, cm-1): 3055 (w), 2919 (w), 1597 (w), 1378 (w), 1235 (w), 1200 (w), 1112 (w), 
857 (w), 692 (w). 
Synthesis of 10-(4-((dioctylamino)methyl)-2-(trifluoromethyl)phenyl)-7-morpholino-5-
phenyl-3H-acridophosphin-3-one 5-oxide (4.21) 
 
Compound 4.21 was synthesized according to a modified literature procedure.[142] 4.19 
(92 mg, 192 µmol, 2.0 equiv.) was dissolved in 1.2 ml of dry THF and cooled to 78 °C. A 
1.9 M solution of tert-butyl lithium (110 µl, 202 µmol, 2.1 equiv.) was added dropwise over 
5 minutes to the first solution of 4.19. The resulting solution was stirred for 1 hour at 78 °C 
and for further 10 minutes at room temperature. After cooling the reaction mixture back to 
78 °C, a solution of phosphoacridone 4.10 (50 mg, 96 µmol, 1.0 equiv.) in 3 ml THF was 
added dropwise over 10 minutes and stirred for 15 minutes at 78 °C. The reaction mixture 
was allowed to warm to room temperature and was stirred for further 1.5 hours. Next, a 
solution of 6M HCl (5 ml) was added at 0 °C to the reaction mixture and was allowed to stirr 
at room temperature for 1 hour. the dark solution was then quenched with a solution of 
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15% w/w sodium hydroxide and extracted with dichloromethane (3x20 ml), dried over 
sodium sulfate and dconcentrated under reduced pressure. The residue was then purified by 
column chromatography (dichloromethane:MeOH 100:3) which afforded desired 4.21 
(54 mg, 69 µmol, 71%) as a dark blue solid.  
Rf  0.25 (dichloromethane:MeOH  100:5, UV, KMnO4). 
1H NMR (300 MHz, CD2Cl2) δ   0.87 (t, 6H, J  7.1 Hz), 1.29 (s, 20H), 1.50 (q, 4H, J  7.1 Hz), 
2.49 (t, 4H, J  7.4 Hz), 3.35 (q, 4H, J  5.5 Hz), 3.71 (s, 2H), 3.76 (t, 4H, J  4.8 Hz), 6.18 
(dd, 1H, J  10.2, 1.8 Hz), 6.70 – 6.82 (m, 3H), 7.11 (dd, 1H, J  17.0, 1.8 Hz), 7.25 
(d, 1H, J  7.8 Hz), 7.39 – 7.56 (m, 4H), 7.61 – 7.74 (m, 3H), 7.90 (s, 1H) 
13C NMR (75 MHz, CD2Cl2) δ  14.3, 23.1, 27.6, 27.8, 29.9, 32.3, 47.1, 54.5, 58.5, 66.6, 116.0, 
117.2 (d, J  7.7 Hz), 123.1, 125.3 (d, J  5.8 Hz), 125.8, 126.9 (q, J  5.1 Hz), 
127.1 (d,  6.4 Hz), 128.0, 128.8 (d, J  30.8 Hz), 129.2 (d, J  12.8 Hz), 130.5 (d, J  10.3 Hz), 
132.2 (d, J  47.3 Hz), 132.5 (d, J  2.7 Hz), 132.9, 133.9, 143.7 (d, J  108.3 Hz), 135.3 
(d, J  9.9 Hz), 135.7 (d, J  2.7 Hz), 139.8 (d, J  8.9 Hz), 140.5 (d, J  90.5 Hz), 143.6, 149.3 
(d, J  7.2 Hz), 152.2 (d, J  12.3 Hz), 184.0 (d, J  13.0 Hz) 
31P NMR (122 MHz, CD2Cl2) δ  10.4. 
19F NMR (282 MHz, CD2Cl2) δ  60.1 
LCMS (ESI, m/z): 787 [M+H]+.  
HRMS (ESI-TOF, m/z): calculated for C47H58F3N2O3P [M+H]
+ 787.4215, found 787.4215. 
IR (ATR, neat, cm-1): 2923 (w), 2851 (w), 1600 (w), 1574 (w), 1307 (w), 1280 (m), 1123 (m), 




Compound 4.23 was prepared following a literature procedure.[198] Chloroacetyl chloride 
(513 mg, 4.5 mmol, 1.0 equiv.) was added dropwise into a stirred solution of 3-ethyl-2,4-
dimethylpyrrole 4.22 (1.15 g, 9.0 mmol, 2.0 equiv.) in argon-sparged dichloromethane 
(50 ml) under inert atmosphere, and the solution was stirred at 55 °C for 2 h. The mixture 
was dried under reduced pressure and the crude was dissolved in toluene (105 ml) and 
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dichloromethane (6 ml). Subsequently, triethylamine (2.96 ml, 21.0 mmol, 4.7 equiv.) was 
added under an inert atmosphere and the solution was stirred for 15 min. at room 
temperature. Next, boron trifluoride diethyl etherate (7.96 ml, 31 mmol, 6.8 equiv.) was 
added and the reaction mixture was stirred at 55 °C for 2 h. The solution was concentrated 
under reduced pressure, poured into saturated aqueous NaHCO3 (25 ml) and extracted with 
CH2Cl2 (3 x 25 ml). The combined organic phase was washed with brine (20 ml), dried over 
anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue 
was purified by column chromatography (n-pentane:acetone  150:1 → 10:1) to give the 
title product 4.23 (683 mg, 1.93 mmol, 43%) as a metallic green solid. 
m.p. = 185187 °C 
Rf  0.30 (n-pentane:acetone 20:1) 
1H NMR (300 MHz, CDCl3) δ  1.05 (t, J  7.6 Hz, 6H), 2.36–2.44 (m, 10H), 2.51 (s, 6H), 
4.80 (s, 2H). 
13C NMR (75 MHz, CDCl3) δ  154.9, 136.2, 134.2, 133.5, 130.9, 37.9, 17.1, 14.6, 12.6, 12.5. 
MS (EI) m/z (relative intensity): 352 (72) [M+], 337 (98), 318 (50), 303 (100), 298 (53), 
287 (32), 273 (9), 267 (14), 143 (12), 134 (12). 
HRMS (ESI-TOF, m/z): calcd. for C18H24BClF2N2 [M+H]
+ 353.1771, found 353.1777. 
IR (ATR, neat, cm-1): 2965 (w), 2927 (w), 2868 (w), 1549 (s), 1473 (m), 1405 (m), 1321 (m), 




Compound 4.24 was prepared following a literature procedure.[144] Aluminum chloride 
(468 mg, 3.5 mmol, 3.0 equiv.) was added to the solution of 4.23 (413 mg, 1.17 mmol. 
1.0 equiv.) in dichloromethane (11.7 ml) under inert atmosphere and sonicated for 5 min. at 
room temperature. Next, methanol (5.85 mL) was gently added to the suspension, and the 
reaction mixture was stirred for another 5 min. The mixture was then diluted with ethyl 
acetate (50 ml), washed with water (2×20 ml) and brine (20 ml). The combined organic 
phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced 
pressure. The residue was purified by column chromatography 
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(dichloromethane:EtOAc  2:1 → 1:1) to give the title product 4.24 (277 mg, 0.73 mmol, 
63%) as a golden-green solid. 
m.p.  133-135 °C (decomposition) 
Rf  0.30 (dichloromethane:EtOAc  1:2) 
1H NMR (300 MHz, CDCl3) δ  1.05 (t, J  7.5 Hz, 6H), 2.41 (q, J  7.5 Hz, 4H), 2.46 (s, 6H), 
2.49 (s, 6H), 2.80 (s, 6H), 4.86 (s, 2H). 
13C NMR (75 MHz, CDCl3) δ  155.2, 134.1, 134.0, 133.0, 132.3, 49.0, 38.4, 17.2, 14.8, 12.6, 
12.3. 
MS (EI) m/z (relative intensity): 376 (14) [M+], 344 (71), 309 (61), 295 (61), 279 (19), 267 (20), 
250 (18), 208 (20), 165 (15), 147 (17), 140 (19), 73 (16), 69 (18), 57 (24), 44 (38), 36 (81), 
32 (100). 
HRMS (ESI-TOF, m/z): calcd. for C20H30BClN2O2Na [M+Na]
+ 399.1992, found 399.1987. 
IR (ATR, neat, cm-1): 2958 (w), 2923 (w), 2867 (w), 2809 (w), 1548 (s), 1470 (m), 1383 (m), 





Compound 4.25 was prepared following a literature procedure.[144] The suspension of 4.24 
(75 mg, 0.2 mmol, 1.0 equiv.), polythioether amine 4.16 (82 mg, 0.26 mmol, 1.3 equiv.), KI 
(33 mg, 0.2 mmol, 1.0 equiv.) and K2CO3 (55 mg, 0.4 mmol, 2.0 equiv.) in CH3CN (2.0 ml) was 
stirred at 45 °C for 3 h under inert atmosphere. The mixture was concentrated under 
reduced pressure, the residue was dissolved in dichloromethane (50 ml) and washed with 
water (2×20 ml). The combined organic phase was dried over anhydrous sodium sulfate, 
filtered, and concentrated under reduced pressure. The residue was purified by column 
chromatography (dichloromethane:EtOAc  3:1 → 1:1) to give the title product 4.25 (57 mg, 
0.08 mmol, 43%) as a dark red oil. 
Rf  0.42 (dichloromethane:EtOAc  1:3) 
1H NMR (300 MHz, CDCl3) δ  1.04 (t, J  7.5 Hz, 6H), 1.24 (t, J  7.3 Hz, 6H), 2.36–2.44 
(m, 10H), 2.49 (s, 6H), 2.52–2.66 (m, 16H), 2.79 (s, 6H), 2.88–2.91 (m, 4H), 4.05 (s, 2H). 
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13C NMR (75 MHz, CDCl3) δ  153.8, 136.8, 135.0, 134.1, 132.8, 52.6, 49.7, 49.0, 32.3, 31.7, 
30.4, 26.0, 17.3, 14.9, 14.7, 14.1, 12.3. 
MS (EI) m/z (relative intensity): 653 (10) [M+], 621 (14), 340 (100), 325 (26), 309 (88), 
295 (30), 252 (14), 178 (17), 121 (16), 89 (97), 61 (18). 
HRMS (ESI-TOF, m/z): calcd. for C32H56BN3O2S4Na [M+Na
+] 676.3251, found 676.3253. 
IR (ATR, neat, cm-1): 2956 (w), 2922 (w), 2806 (w), 1542 (s), 1473 (m), 1358 (m), 1320 (m), 
1258 (m), 1173 (s), 1111 (s), 1064 (m), 1019 (m), 970 (s), 951 (s), 840 (w), 709 (m), 648 (w), 
527 (m). 
Synthesis of 2-(methyl(pyridin-2-yl)amino)ethan-1-ol (4.27): 
 
Compound 4.27 was prepared following a similar literature procedure.[155] 
2-(methylamino)ethanol (1.60 ml, 19.82 mmol, 3.0 equiv.) was added to a solution of 
2-chlorpyridine (638 µl, 6.61 mmol, 1.0 equiv.) at r.t. and the mixture was heated and stirred 
at 160 °C overnight. After the reaction was completed judging TLC, water (15 ml) was added 
to the solution. The aqueous solution was then extracted with DCM (3x20 ml). The combined 
organic phase was then washed with water (20 ml), brine (20 ml), and dried over Na2SO4. 
The solvent was removed afterwards under reduced pressure. The oily residue was purified 
by column chromatography (n-pentane:EtOAc 3:2) yielding the desired compound 4.27 
(935 mg, 6.13 mmol, 93%) as a light yellowish oil. 
Rf  0.14 (n-pentane:EtOAc  3:2, UV, KMnO4) 
1H NMR (300 MHz, CDCl3) δ  3.03 (s, 3H), 3.62 – 3.73 (m, 2H), 3.77 – 3.86 (m, 2H), 
5.36 (s, 1H), 6.44 – 6.64 (m, 2H), 7.44 (ddd, J  8.6, 7.1, 2.0 Hz, 1H), 8.03 (ddd, J  5.1, 2.0, 
0.9 Hz, 1H). 
13C NMR (75 MHz, CDCl3) δ  38.0, 54.4, 62.9, 106.4, 112.3, 137.9, 147.1, 159.3. 
MS (EI) m/z (relative intensity): 152 (15) [M+], 133 (11), 121 (100), 107 (12), 93 (10), 80 (17), 
78 (54), 67 (3), 51 (25), 42 (20), 31 (54). 
HRMS (ESI-TOF, m/z): calculated for C8H12N2O [M]
+ 152.09441, found: 152.09488. 
IR (ATR, neat, cm-1): 3289 (w), 2923 (w), 1594 (s), 1495 (s), 1421 (m), 1319 (m), 1160 (w), 
1044 (m), 984 (m), 766 (s).  




Compound 4.28 was prepared following a literature procedure.[156] To a stirred solution of 
2-(methyl-2-pyridinylamino)ethanol 4.27 (860 mg, 5.65 mmol, 1.0 equiv.) in dry DMF (10 ml) 
was added sodium hydride (60% dispersion)(249 mg, 6.22 mmol, 1.1 equiv.) portion-wise at 
r.t. under Argon. The mixture was the stirred at r.t. until the vigorous reaction ceased. Next, 
a solution of 4-Fluorobenzaldehyde (687 µl, 6.22 mmol, 1.1 equiv.) was added dropwise over 
15 minutes. The reaction mixture was stirred at r.t. for further 20 hours. Afterwards, the 
solution was carefully quenched with water and extracted with EtOAc (3x15 ml). The 
combined organic phase was then washed with water (2x10 ml), dried over Na2SO4, filtered, 
and evaporated under reduced pressure. The residual oil was purified by flash 
chromatography (dichloromethane:MeOH 200:1) yielding the desired compound 4.28 
(819 mg, 3.20 mmol, 57%) as a translucent oil. 
Rf  0.27 (dichloromethane:MeOH  50:1, UV) 
1H NMR (300 MHz, CDCl3) δ  3.14 (s, 3H), 4.02 (t, J  5.6 Hz, 2H), 4.28 (t, J  5.6 Hz, 2H), 6.52 
(dt, J  8.6, 0.9 Hz, 1H), 6.57 (ddd, J  7.1, 5.0, 0.9 Hz, 1H), 6.94 – 7.07 (m, 2H), 7.46 (ddd, J  
8.6, 7.1, 2.0 Hz, 1H), 7.74 – 7.87 (m, 2H), 8.15 (ddd, J  5.0, 2.0, 0.9 Hz, 1H), 9.86 (s, 1H). 
13C NMR (75 MHz, CDCl3) δ  38.1, 49.4, 66.8, 105.9, 112.1, 114.9, 130.1, 132.1, 137.6, 147.9, 
158.2, 164.0, 190.9. 
MS (EI) m/z (relative intensity): 256 (12) [M+], 151 (1), 147 (1), 135 (23), 133 (14), 121 (100), 
107 (12), 92 (13), 78 (49), 65 (20), 51 (18), 39 (12). 
HRMS (EI): calcd. for C15H16N2O2 [M]
+ 256.1206, found: 256.1201. 
IR (ATR, neat, cm-1): 2253 (w), 1692 (w), 1690 (m), 1599 (s), 1578 (w), 1562 (w), 1500 (m), 
1257 (w), 1160 (w), 902 (s), 722 (s), 649 (m). 





Compound 4.29 was prepared following a literature procedure.[156] 4-[2-(N-methyl-N-
(2-pyridyl)amino)ethoxy]benzaldehyde (4.28) (619  mg, 2.42 mmol, 1.0 equiv.) was dissolved 
in 10 ml of toluene before adding 2,4-thiazolidinedione (320 mg, 2.73 mmol, 1.13 equiv.) at 
25-30 °C. Piperidine (24 µl, 242 µmol, 0.10 equiv.) and acetic acid (14 µl, 242 µmol, 
0.10 equiv.) were added afterwards to the solution. Next, the reaction mixture was then 
heated to reflux over 3 hours. A yellow colored solid was formed. The reaction was then 
cooled to 25-30 °C. The precipitated solid was filtered off, washed with methanol, and dried 
afterwards at 70 °C under reduced pressure to obtain the title compound 4.29 (780 mg, 
2.19 mmol, 82%) as a pale yellow solid. 
m.p. = 192-194 °C 
Rf  0.42 (n-pentane:EtOAc  1:1, UV, KMnO4) 
1H NMR (300 MHz, DMSO-d6) δ  3.06 (s, 3H), 3.92 (t, J  5.8 Hz, 2H), 4.21 (t, J  5.9 Hz, 2H), 
6.56 (m, 1H), 6.64 (d, J  8.6, 0.9 Hz, 1H), 6.98 – 7.22 (m, 2H), 7.39 – 7.61 (m, 3H), 
7.72 (s, 1H), 8.08 (ddd, J  4.9, 2.0, 0.9 Hz, 1H), 12.50 (br. s, 1H). 
13C NMR (75 MHz, DMSO-d6) δ  37.1, 48.3, 65.8, 105.8, 111.6, 115.3, 120.4, 125.6, 131.7, 
132.1, 137.4, 147.5, 158.0, 160.2, 167.5, 168.0. 
MS (EI) m/z (relative intensity): 355 (5) [M+], 223 (1), 221 (19), 178 (1), 150 (47), 142 (2), 
136 (18), 135 (96), 121 (100), 108 (14), 94 (10), 78 (29), 51 (5). 
HRMS (ESI, m/z): calculated for C18H18N3O3S [M+H]
+ 356.1063, found: 356.1065. 
IR (ATR, neat, cm-1): 2935 (w), 2885 (w), 2620 (w), 2432 (w), 1689 (s), 1596 (s), 1503 (m), 
1427 (m), 1164 (m), 774 (m), 518 (s). 
Synthesis of 5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione 
(4.30): 
 
Compound 4.30 was prepared following a modified literature procedure.[157] A 2.0 M 
solution of lithium borohydride in THF (930 µl, 1.86 mmol, 2.2 equiv.) was added dropwise to 
a stirred solution of 5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzylidene)thiazolidine-2,4-
dione (4.29) (301 mg, 846 µmol, 1.0 equiv.) in pyridine (515 µl, 844 µmol, 1.0 equiv.) and dry 
THF (566 µl) over 10 min. under vigorous stirring. After approximately half of the LiBH4 had 
been added the effervescence ceased and a yellow solution was formed. The mixture was 
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heated afterwards to reflux for 2 h during which the color deepened to a wine-red solution. 
An orange solid precipitated after 1 h of refluxing. After cooling the mixture to r.t., it was 
added dropwise to a stirred solution of hydrochloric acid (406 µl) in water (2.65 ml) at 5 °C 
keeping the internal temperature of the solution below 20 °C. The resulting orange/white 
suspension was stirred below 15 °C for 15 minutes and was then heated to reflux while 
stirring for further 1 hour. The resulting reaction mixture was filtered hot through Celite to 
remove the formed brown residue and the brown mother liquor was allowed to cool to 
25 °C and left overnight in the fridge. An off-white solid precipitated which was filtered 
under vacuum, washed with cold water, and dried in an oven at 50 °C overnight to give 
crude product as an off-white solid. The isolated solid was then recrystallized out of ethanol 
yielding the desired compound 4.30 (184 mg, 515 µmol, 61%) as a white solid. 
m.p.  152155 °C 
Rf  0.48 (n-pentane:EtOAc 4:1, UV, KMnO4) 
1H NMR (300 MHz, DMSO-d6) δ  2.94 – 3.15 (m, 4H), 3.29 (dd, J  14.2, 4.3 Hz, 1H), 3.45 
(d, J  7.0 Hz, 0H), 3.89 (m, 2H), 4.10 (m, 2H), 4.85 (m, 1H), 6.56 (m, 1H), 6.63 
(dt, J  8.6, 0.9 Hz, 1H), 6.82 – 6.95 (m, 2H), 7.05 – 7.20 (m, 2H), 7.49 
(ddd, J  8.6, 7.1, 2.0 Hz, 1H), 8.08 (ddd, J 4.9, 2.0, 0.9 Hz, 1H), 11.98 (br. s, 1H). 
13C NMR (75 MHz, DMSO-d6) δ  36.3, 37.0, 48.5, 53.0, 65.3, 105.7, 111.5, 114.3, 128.6, 
130.4, 137.3, 147.5, 157.5, 158.0, 171.6, 175.7. 
MS (EI) m/z (relative intensity): 357 (35) [M+], 327 (1), 232 (1), 221 (1), 168 (1), 150 (2), 
136 (11), 135 (100), 133 (18), 94 (14), 78 (48), 51 (6). 
HRMS (EI): calcd. for C18H19N3O3S [M]
+ 357.1142, found: 357.1144. 
IR (ATR, neat, cm-1): 2933 (w), 2577 (w), 1737 (w), 1690 (s), 1608 (m), 1554 (w), 1506 (m), 
1473 (w), 1423 (m), 1244 (m), 1159 (m), 1036 (m), 993 (m). 
Synthesis of 4-chloro-6-(4-methoxyphenoxy)pyrimidine (4.32):  
 
Compound 4.32 was prepared following a modified literature procedure.[158] To a suspension 
of sodium hydride (60% dispersion in mineral oil) (128 mg, 3.20 mmol, 1.20 equiv.) in 
DMF (10 ml) under argon was added 4-Methoxyphenol (350 mg, 2.74 mmol, 1.02 equiv.) at 
0 °C (caution: gas evolution) and the mixture was allowed to stir for 5 minutes. 4,6-
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dichloropyrimidine (400 mg, 2.69 mmol, 1.0 equiv.) was then added to the mixture at once 
(the addition at once is important in order to avoid the formation of the 2,4-substituted 
side-product) at 0 °C and stirred at r.t. for further 2 hours. The reaction mixture was then 
quenched with cold water at 0 °C and extracted with EtOAc (3x15 ml). The combined organic 
layer was washed with water and brine, dried over Na2SO4, filtered, and concentrated under 
reduced pressure.  The colorless oily residue was then purified by column chromatography 
(n-pentane:EtOAc  10:1) yielding the title compound 4.32 (611 mg, 2.58 mmol, 96%) as a 
viscous oil which solidifies upon standing overnight into a white amorph solid. 
m.p.  70-72 °C  
Rf = 0.10 (n-pentane:EtOAc  10:1, UV, KMnO4) 
1H NMR (300 MHz, CD2Cl2) δ  3.82 (s, 3H), 6.90 (d, J  0.9 Hz, 1H), 6.92 – 6.99 (m, 2H), 
7.03  7.13 (m, 2H), 8.54 (d, J  0.9 Hz, 1H). 
13C NMR (101 MHz, CD2Cl2) δ = 56.1, 108.1, 115.4, 122.9, 146.0, 158.2, 159.0, 162.3, 171.3. 
MS (EI) m/z (relative intensity): 236 (34) [M+], 220 (1), 173 (1), 158 (1), 134 (100), 123 (5), 113 
(4), 107 (14), 86 (12), 77 (9), 63 (8), 51 (7).  
HRMS (EI): calcd. for C11H9O2N2Cl [M]
+ 236.0347, found: 236.0348. 
IR (ATR, neat, cm-1): 3085 (w), 3007 (w), 2836 (w), 1613 (m), 1561 (m), 1540 (s), 1502 (s), 
1317 (m), 1260 (w), 1237 (s), 1187 (s). 
Synthesis of 2-((6-(4-methoxyphenoxy)pyrimidin-4-yl)(methyl)amino)ethan-1-ol (4.33): 
 
Compound 4.33 was prepared following a literature procedure.[158] To a stirred solution of 
4-chloro-6-(4-methoxyphenoxy)pyrimidine (4.32)  (500 mg, 2.11 mmol, 1.0 equiv.) in 
anhydrous ethanol (12 ml) was added 2-methylaminoethanol (513 µl, 6.34 mmol, 3.0 equiv.) 
and the mixture was refluxed for 24 h under an argon atmosphere. The reaction mixture was 
then cooled to room temperature, quenched with aq. NH4Cl solution (5 ml), and extracted 
with EtOAc (3x15 ml). The extracted organic layers were combined and washed with water 
(15 ml) and brine (15 ml), respectively, dried over Na2SO4 and concentrated under reduced 
pressure. The residue was purified by column chromatography (n-pentane:EtOAc  2:3) 
yielding the title compound 4.33 as a colorless oil (580 mg, 2.11 mmol, quant.). 
Rf 0.12 (n-pentane: EtOAc  2:3, UV, KMnO4). 
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1H NMR (300 MHz, CD2Cl2) δ  3.02 (s, 3H), 3.49 (br. s, 1H), 3.69 – 3.78 (m, 4H), 3.81 (s, 3H), 
5.84 (s, 1H), 6.87 – 6.97 (m, 2H), 6.97 – 7.09 (m, 2H), 8.16 (s, 1H). 
13C NMR (75 MHz, CD2Cl2) δ  37.4, 53.4, 56.1, 61.9, 86.1, 115.1, 123.0, 147.0, 157.5, 157.9, 
165.1, 171.0. 
MS (EI) m/z (relative intensity): 275 (11) [M+], 244 (100), 231 (4), 216 (2), 201 (6), 134 (12), 121 
(4), 107 (4), 92 (5), 81 (8), 68 (4), 44 (7).  
HRMS (EI): calcd. for C14H17O3N3 [M]
+ 275.1264, found: 275.1266. 
IR (ATR, neat, cm-1): 3054 (w), 2987 (w), 2304 (w), 1596 (w), 1504 (w), 1264 (m), 896 (w), 




Compound 4.34 was prepared following a modified literature procedure.[158] To a suspension 
of sodium hydride (60% dispersion in mineral oil )(87 mg, 2.18 mmol, 1.9 equiv.) in 
anhydrous DMF (10 ml) at 0 °C was added 2-((6-(4-methoxyphenoxy)pyrimidin-4-
yl)(methyl)amino)ethan-1-ol (4.33) (316 mg, 1.15 mmol, 1.0 equiv.) in a slow manner and the 
mixture was stirred at r.t. for 30 minutes. Then, 4-fluorobenzaldehyde (270 mg, 2.18 mmol, 
1.9 equiv.) was added dropwise in the reaction mixture under argon atmosphere at room 
temperature. After stirring at the same temperature for 3 hours, the reaction mixture was 
quenched with aq. NH4Cl solution (2 ml) at 0 °C. Then, cold water was added (20 ml), and the 
solution was extracted with EtOAc (3x20 ml). The combined organic phase was washed with 
water (20 ml) and brine (20 ml), dried over Na2SO4, and concentrated under reduced 
pressure. The residue was purified by column chromatography using 
(n-pentane/EtOAc  2:1) as eluent to yield the title compound 4.34 (371 mg, 978 µmol, 85%) 
as pale-yellow viscous oil.  
Rf  0.32 (n-pentane:EtOAc  1:1, UV, KMnO4). 
1H NMR (300 MHz, CD2Cl2) δ  3.11 (s, 3H), 3.81 (s, 3H), 4.02 (t, J = 5.5 Hz, 2H), 4.27 
(t, J  5.5 Hz, 2H), 5.88 (s, 1H), 6.83 – 6.98 (d, 2H), 6.98 – 7.17 (m, 4H), 7.74 – 7.96 (m, 2H), 
8.22 (s, 1H), 9.87 (s, 1H). 
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13C NMR (75 MHz, CD2Cl2) δ  37.8, 49.5, 56.08, 67.1, 86.1, 115.0, 115.2, 123.1, 130.7, 132.3, 
147.1, 157.5, 158.0, 164.2, 164.5, 191.0. 
MS (ESI): 380.20 [M+H]+. 
HRMS (EI): calcd. for C21H21O4N3 [M]
+ 379.1527, found: 379.1522. 
IR (ATR, neat, cm-1): 3046 (w), 2930 (w), 2739 (w), 1741 (m), 1687 (m), 1584 (s), 1500 (s), 
1197 (s), 811 (m). 
Synthesis of (Z)-5-(4-(2-((6-(4-methoxyphenoxy)pyrimidin-4-yl)(methyl)amino)ethoxy) 
benzylidene)thiazolidine-2,4-dione (4.35): 
 
Compound 4.35 was prepared following a literature procedure.[158] A mixture of 4-(2-((6-(4-
methoxyphenoxy) pyrimidin-4-yl) (methyl)amino)ethoxy)benzaldehyde (4.34) (325 mg, 
857 µmol, 1 equiv.), 2,4-thiazolidinedione (130 mg, 1.11 mmol, 1.3 equiv.), and piperidine 
(111 µl, 1.11 mmol, 1.3 equiv.) in anhydrous ethanol (8 ml) was refluxed for 24 hours. The 
reaction mixture was then cooled to room temperature and diluted with EtOAc (20 ml). The 
diluted mixture was washed with water (3x20 m) and brine (20 ml), dried over Na2SO4, and 
concentrated under reduced pressure. The obtained residue was purified by column 
chromatography (dichloromethane:methanol  70:1) to give the title compound 
4.35 (320 mg, 668 µmol, 78%) as an off-white solid. 
Rf  0.27 (dichloromethane:methanol  30:1, UV, KMnO4) 
1H NMR (300 MHz, DMSO-d6) δ  3.07 (s, 3H), 3.75 (s, 3H), 3.94 (m, 2H), 
4.23 (t, J  5.6 Hz, 2H), 6.05 (s, 1H), 6.88 – 6.99 (m, 2H), 7.01 – 7.30 (m, 4H), 7.49 – 
7.58 (m, 2H), 7.73 (s, 1H), 8.17 (d, J  0.8 Hz, 1H), 12.50 (s, 1H). 
13C NMR  (75 MHz, DMSO-d6) δ  36.5, 48.1, 55.4, 65.7, 85.6, 114.5, 115.3, 120.6, 122.5, 
125.7, 131.6, 132.0, 146.1, 156.3, 157.2, 159.9, 163.6, 167.6, 168.0, 169.8. 
MS (EI)  m/z (relative intensity): 478 (3) [M+], 258 (100), 244 (35), 231 (6), 221 (21), 150 (55), 
135 (7), 124 (17), 109 (9), 81 (8), 77 (6), 44 (14).  
HRMS (EI): calcd. for C24H22O5N4S1 [M]
+ 478.13054, found: 478.12968. 
IR (ATR, neat, cm-1): 3132 (w), 3037 (w), 2935 (w), 1741 (m), 1679 (s), 1583 (s), 1226 (s), 
1008 (m), 807 (m). 
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7.2.4 Experimental section to Chapter 5 
Synthesis of tert-butyl ((benzyloxy)carbonyl)-L-valyl-L-prolinate (5.3): 
  
Compound 5.3 was prepared following a modified literature procedure.[199] To a cold 
solution of Z-Val-OH 5.2 (2.0 g, 7.94 mmol, 1.10 equiv.) in dichloromethane (15 ml) was 
added HOBt.H2O (1.11 g, 7.22 mmol, 1.0 equiv.) and the mixture was allowed to stir for 
15 minutes at 0 °C. Then, N,N′-Dicyclohexylcarbodiimid  (1.71 g, 8.31 mmol, 1.15 equiv.) was 
added at once at 0 °C and stirred for further 30 minutes. Pro.O-t-Bu.HCl 5.1 (1.5 g, 
7.22 mmol, 1.0 equiv.) was then added at 0 °C followed by triethylamine (1.56 ml, 
11.37 mmol, 1.57 equiv.) and the mixture was allowed to stir at r.t. overnight. The 
precipitated N,N´-dicyclohexylurea was filtered off and the filter cake was washed with 
dichloromethane (15 ml). Subsequently, the filtrate was washed with 10% citric acid, 4% 
NaHCO3, and brine, respectively. The organic phase was then dried over Na2SO4 and 
concentrated under reduced pressure. The crude was purified afterwards by flash 
chromatography (dichloromethane:methanol 300:1) yielding the title compound 
5.3 (2.78 g, 6.87 mmol, 95%) as a viscous colorless oil. 
Rf  0.82 (dichloromethane:methanol  30:2, UV, KMnO4).
1H NMR (300 MHz, CDCl3) δ  0.94 (d, J  6.7 Hz, 3H), 1.04 (d, J  6.7 Hz, 3H), 1.44 (s, 9H), 
1.80 – 2.27 (m, 5H), 3.52 – 3.69 (m, 1H), 3.75 (m, 1H), 4.27 – 4.45 (m, 2H), 
5.07 (d, J  2.1 Hz, 2H), 5.52 (d, J  9.2 Hz, 1H), 7.28 – 7.40 (m, 5H).
13C NMR (75 MHz, CDCl3) δ  17.4, 19.6, 25.0, 28.0, 29.2, 31.3, 47.3, 57.4, 59.8, 66.9, 81.4, 
128.0, 128.1, 128.6, 136.5, 156.6, 170.6, 171.3.
MS (EI) m/z (relative intensity): 404 (1) [M+], 348 (5), 331 (2), 303 (2), 261 (2), 234 (5), 206 
(5), 162 (14), 114 (15), 91 (100), 70 (42), 57 (39).
HRMS (EI): calcd. for C22H32N2O5 [M]
+ 404.2306, found: 404.2314.
IR (ATR, neat, cm-1): 2978 (w), 1719 (s), 1643 (s), 1508 (w), 1436 (w), 1369 (w), 1264 (m), 
1222 (w), 1152 (m), 1027 (w), 731 (s), 700 (m). 




Compound 5.4 was prepared following a literature procedure.[200] The Protected dipeptide 
5.3 (1.68 g, 4.15 mmol, 1.0 equiv.) was dissolved in methanol (10 ml). Next, 
10% Pd/C (177 mg, 166 µmol, 0.04 equiv.) was added and the mixture was allowed to stir 
under a H2 atm. for 6 hours. Afterwards, the mixture was filtered through a pad of celite and 
dried under reduced pressure. The crude was purified using flash chromatography 
(dichloromethane:methanol 30:2) yielding the title compound 5.4 (1.08 g, 4.0 mmol, 96%) 
as a colorless oil.
Rf  0.14 (dichloromethane:methanol 30:2, KMnO4).
1H NMR (300 MHz, CDCl3) δ  0.93 (d, J  6.8 Hz, 3H), 1.02 (d, J  6.8 Hz, 3H), 1.44 (s, 9H), 
1.75  2.32 (m, 7H), 3.33 (d, J  5.4 Hz, 1H), 3.55 – 3.62 (m, 2H), 4.35 – 4.44 (m, 1H).
13C NMR (75 MHz, CDCl3) δ  16.9, 20.1, 25.1, 28.1, 29.1, 32.0, 47.0, 58.3, 59.9, 81.3, 171.6, 
173.7.
MS (GCMS) m/z (relative intensity): 270 (1) [M+], 197 (2), 171 (6), 125 (4), 72 (100), 70 (41), 
57 (20), 55 (16), 41 (16), 29 (6).
HRMS (EI): calcd. for C14H26N2O3 [M]
+ 270.1938, found: 270.1935.
IR (ATR, neat, cm-1): 3309 (w), 2970 (w), 1736 (m), 1624 (m), 1501 (m), 1438 (m), 1250 (m), 
1148 (s), 1029 (m), 842 (m), 767 (m).
Synthesis of tert-butyl (4-methoxybenzoyl)-L-valyl-L-prolinate (5.5):  
 
Compound 5.5 was prepared following a literature procedure.[178] The t-Bu-dipeptide ester 
5.4 (839 mg, 3.30 mmol, 1.0 equiv.) was dissolved in THF (7 ml) and the solution was cooled 
to 0 °C. Then, 4-methoxy benzoyl chloride (474 µl, 3.47 mmol, 1.05 equiv.) was added 
dropwise to the mixture followed by triethylamine (1.30 ml, 9.25 mmol, 2.8 equiv.) at 0 °C. 
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The mixture was allowed to stir for further 2 hours. The solvent was then removed under 
reduced pressure and the crude was dissolved in EtOAc (20 ml) and washed with water, 
aq. sat. Na2CO3, aq. sat. NH4Cl, and brine, respectively. The organic phase was dried over 
Na2SO4 and the solvent was removed under reduced pressure. Subsequently, the crude 
material was purified by flash chromatography (dichloromethane:methanol 100:1yielding 
the title compound 5.5 (1.20 g, 2.98 mmol, 90%) as a white foam. 
m.p. = 4749 °C  
Rf  0.14 (dichloromethane:methanol  99:1, UV, KMnO4). 
1H NMR (300 MHz, CDCl3) δ  1.00 (d, J  6.8 Hz, 3H), 1.10 (d, J  6.8 Hz, 3H), 1.46 (s, 9H), 
1.85  2.28 (m, 6H), 3.63 – 3.75 (m, 1H), 3.83 (s, 3H), 3.84 – 3.91 (m, 1H), 4.32 – 4.42 (m, 1H), 
4.84 (dd, J  8.8, 6.2 Hz, 1H), 6.83 – 6.93 (m, 3H), 7.71 – 7.82 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ  17.9, 19.7, 25.1, 28.1, 29.3, 31.8, 47.5, 55.5, 55.7, 60.0, 81.5, 
113.8, 126.6, 129.0, 162.4, 166.9, 170.9, 171.3. 
MS (EI) m/z (relative intensity): 404 (1) [M+], 348 (2), 234 (3), 206 (7), 162 (15), 114 (6), 
91 (100), 70 (44), 65 (7), 57 (20), 41 (10). 
HRMS (EI): calcd. for C22H32N2O5 [M]
+ 404.2306, found: 404.2307. 
IR (ATR, neat, cm-1): 2972 (w), 1734 (m), 1640 (m), 1433 (m), 1365 (m), 1149 (s), 1093 (w), 
1046 (w), 850 (w), 472 (w). 
Synthesis of (4-methoxybenzoyl)-L-valyl-L-proline (5.6):  
 
Compound 5.6 was prepared following a literature procedure.[178] 
Tert-butyl (4-methoxybenzoyl)-L-valyl-L-prolinate 5.5 (901 mg, 2.47 mmol, 1.0 equiv.) was 
dissolved in trifluoroacetic acid (12 ml) at 0 °C and the solution was stirred at r.t. for further 
2 hours. After completion of the reaction, trifluoroacetic acid was removed under reduced 
pressure and the crude mixture was dissolved in ethylacetate (20 ml) and washed with water 
(2x15 ml). The organic fractions were dried over Na2SO4 and the solvent was removed under 
reduced pressure. The crude material was purified by flash chromatography 
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(dichloromethane:methanol:acetic acid 200:1:2)yielding the title compound 
5.6 (590 mg, 1.69 mmol, 76%) as a white foam. 
m.p.  6870 °C  
Rf 0.19 (dichloromethane:methanol:acetic acid = 97:3:1, UV, KMnO4). 
1H NMR (300 MHz, DMSO-d6) δ  0.95 (d, J  6.6 Hz, 3H), 1.00 (d, J  6.7 Hz, 3H), 1.77 – 2.02 
(m, 3H), 2.08 – 2.26 (m, 2H), 3.55 – 3.71 (m, 1H), 3.80 (s, 3H), 3.90 – 4.05 (m, 1H), 4.20 – 4.30 
(m, 1H), 4.45 (dd, J  9.4, 8.1 Hz, 1H), 6.93 – 7.02 (m, 2H), 7.86 – 7.97 (m, 2H), 
8.34 (d, J  8.1 Hz, 1H). 
13C NMR (75 MHz, DMSO-d6) δ  18.8, 19.2, 24.6, 28.8, 29.9, 46.9, 55.3, 56.7, 58.6, 113.4, 
126.1, 129.5, 161.7, 165.8, 170.4, 173.3. 
MS (EI) m/z (relative intensity): 348 (6) [M+], 234 (7), 207 (14), 206 (74), 191 (6), 153 (5), 
135 (100), 114 (3), 107 (9), 92 (15), 77 (19). 
HRMS (EI): calcd. for C18H24N2O5 [M]
+ 348.1680, found: 348.1684. 
IR (ATR, neat, cm-1): 3305 (w), 2964 (m), 1711 (m), 1601 (s), 1503 (m), 1453 (m), 1252 (s), 
1176 (s), 1027 (m), 843 (m), 767 (w), 598 (m). 
Synthesis of benzyl (S)-4-isopropyl-5-oxooxazolidine-3-carboxylate (5.10):  
 
Compound 5.10 was prepared following a similar literature procedure.[182] To a solution of 
N-benzyloxycarbonyl-L-valine 5.2 (3.0 g, 11.94 mmol, 1.0 equiv.) in toluene (20 ml) was 
added paraformaldehyde (477 mg, 15.88 mmol, 1.33 equiv.) and p-toluenesulfonic acid 
monohydrate (114 mg, 597 µmol, 0.05 equiv.) and the mixture was refluxed for 1 hour. Next, 
the reaction solution was washed successively with 5% aq. NaHCO3 solution (10 ml) and 
brine (10 ml). The organic phase was then dried over Na2SO4 and the solvent was evaporated 
under reduced pressure yielding compound 5.10 (2.93 g, 11.13 mmol, 93%) as a colorless oil 
which solidifies upon standing into a colorless amorph solid. 
m.p. = 5455 °C  
Rf  0.65 (dichloromethane:methanol = 99:1, UV, KMnO4). 
1H NMR (300 MHz, CDCl3) δ  1.04 (dd, J  18.6, 6.9 Hz, 6H), 2.36 (s, 1H), 4.23 (s, 1H), 
5.10  5.24 (m, 3H), 5.59 (s, 1H), 7.31 – 7.42 (m, 5H). 
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13C NMR (75 MHz, CDCl3) δ  17.9, 18.0, 31.3, 60.2, 68.1, 78.6, 128.4, 128.7, 128.8, 135.5, 
153.6, 171.6. 
MS (EI) m/z (relative intensity): 263 (3) [M+], 221 (1), 190 (1), 107 (1), 91 (100), 86 (5), 77 (4), 
65 (15), 43 (9), 39 (8). 
HRMS (EI): calcd. for C14H17N1O4 [M]
+ 263.1152, found: 263.1152. 
IR (ATR, neat, cm-1): 2965 (w), 2936 (w), 1784 (m), 1687 (s), 1446 (m), 1422 (m), 1235 (m), 
1125 (m), 1053 (s), 969 (m), 766 (m), 696 (s). 
Synthesis of benzyl ((3S)-1,1,1-trifluoro-2-hydroxy-4-methylpentan-3-yl)carbamate (5.11):  
 
Compound 5.11 was prepared following a literature procedure.[182] (4S)-4-isopropyl-5-oxo-
1,3-oxazolidine-3-carboxylic acid benzyl ester 5.10 (2.0 g, 7.6 mmol, 1.0 equiv.) was dissolved 
in THF (4 ml), and thereto was added cesium fluoride (231 mg, 1.52 mmol, 0.2 equiv.) at 0 °C 
all at once. Trimethyl(trifluoromethyl)silane (1.36 ml, 9.12 mmol, 1.2 equiv.) was added 
dropwise to the reaction mixture over a period of 30 minutes. Then, the mixture was stirred 
at 0 °C for 1 hour. Subsequently, to the above THF solution was added methanol (7.5 ml) at 
0 °C and the mixture was allowed to stir at r.t. for 30 minutes. Sodium borohydride (290 mg, 
7.67 mmol, 1.0 equiv.) was added slowly at 0 °C over 5 minutes and the mixture was stirred 
for further 1 hour. Then, water (7.5 ml) was added slowly to the reaction solution, and 
further thereto was added potassium carbonate (630 mg, 4.56 mmol, 0.6 equiv.) at 0 °C. The 
mixture was then stirred at r.t. for 15 hours. Afterwards, the mixture solution was extracted 
with EtOAc (3x20 ml) and the organic phase was washed with 5% aq. HCl solution (10 ml) 
and brine (20 ml) and dried over Na2SO4. The solvent was removed under reduced pressure 
and the crude was purified by flash chromatography (n-pentane:EtOAc 10:1 → 6:1) 
yielding the desired compound 5.11 (1.40 g, 4.58 mmol, 61%) as a waxy solid (mixture of 
diastereomers). 
Rf  0.33 (n-pentane:EtOAc  8:2, UV, KMnO4). 
1H NMR (400 MHz, CDCl3) δ  0.79 – 1.05 (m, 12H), 1.93 – 2.15 (m, 2H), 3.55 (t, 1H), 
3.76  3.97 (m, 1H), 4.02 – 4.25 (m, 3H), 4.87 (d, J  9.4 Hz, 1H), 5.05 – 5.20 (m, 4H), 
5.33 (d, J  9.2 Hz, 1H), 7.26 – 7.43 (m, 10H). 
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13C NMR (101 MHz, CDCl3) δ  18.0, 19.0, 19.5, 20.2, 28.7, 30.2, 55.6, 57.4, 65.4, 67.2, 67.5, 
69.2 (q, J  30.1 Hz), 70.8 (q, J  28.6 Hz), 124.9 (q, J 283.3Hz), 125.1 (q, J 283.63Hz), 
127.2, 127.8, 128.0, 128.1, 128.3, 128.4, 128.6, 128.7, 128.7, 136.1, 136.4, 157.1, 157.6. 
19F NMR (282 MHz, CDCl3) δ  77.45 (d, J  6.4 Hz), 74.41 (d, J  7.0 Hz). 
MS (EI) m/z (relative intensity): 305 (1) [M+], 218 (1), 206 (2), 162 (3), 115 (2), 108 (10), 
91 (100), 77 (8), 65 (16), 56 (3), 51 (7), 43 (12).  
HRMS (EI): calcd. for C14H18N1O3F3 [M]
+ 305.1233, found: 305.1235. 
IR (ATR, neat, cm-1): 3327 (m), 2971 (w), 1690 (s), 1540 (s), 1466 (w), 1295 (m), 1262 (s), 
1145 (s), 1099 (s), 1019 (m), 694 (s). 
Synthesis of (3S)-3-amino-1,1,1-trifluoro-4-methylpentan-2-ol hydrochloride (5.9):  
 
Compound 5.9 was prepared following a modified literature procedure.[182] benzyl ((3S)-
1,1,1-trifluoro-2-hydroxy-4-methylpentan-3-yl)carbamate (5.11) (3.86 g, 12.63 mmol, 
1.0 equiv.) was dissolved in EtOAc (9 ml), and thereto was added palladium hydroxide 
(20% on carbon) (160 mg, 228 µmol, 0.02 equiv.) all at once. The mixture was stirred under 
an H2 atmosphere for 24 hours. Thereafter, the catalyst was removed by filtration through a 
pad of Celite. The filtrate was concentrated under reduced pressure (max. of 100 mbar due 
to the sublimation of the free aminoalcohol). The oily residue was purified by column 
chromatography (n-pentane:EtOAc  5:3 and concentrated under reduced pressure 
(max. of 100 mbar vacuum).Thereto was added 1M HCl in diethyl ether (36 ml) and the 
mixture was immediately concentrated under reduced pressure and dried at 40 °C yielding 
the title compound 5.9 (2.085 g, 10.04 mmol, 80%) as a white solid. The analytical data is 
stated for the free amine base form of 5.9. 
m.p.  7879 °C 
1H NMR (300 MHz, CDCl3) δ  3.96 (qd, J  7.7, 5.6 Hz, 1H), 2.66 – 2.53 (m, 1H), 1.84 
(dt, J  13.5, 6.8 Hz, 1H), 1.06 – 0.92 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ  125.9 (q, J  284.8 Hz), 69.2 (q, J  28.2, 25.6 Hz), 59.4, 30.6, 
20.0. 
19F NMR (282 MHz, CDCl3) δ  73.25 (q, J  9.6, 8.9 Hz). 
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MS (EI) m/z (relative intensity): 171 (1) [M+], 128 (100), 108 (2), 80 (14), 73 (4), 72 (70), 
55 (24). 
IR (ATR, neat, cm-1): 3123 (br., w), 2962 (w), 2756 (w), 1576 (w), 1275 (m), 1153 (s), 1124 (s), 
1093 (s), 934 (s), 854 (s). 
Crystallographic Data of of (3S)-3-amino-1,1,1-trifluoro-4-methylpentan-2-ol (5.9) 
Data were collected on a Bruker Kappa APEX II Duo diffractometer using Mo-K radiation. 
The structures were solved by direct methods (SHELXS-97: Sheldrick, G. M. Acta Cryst. 2008, 
A64, 112.) and refined by full-matrix least-squares procedures on F2 (SHELXL-2014 and 










unit cell dimensions    
 a  6.3680(3) Å   90 ° 
 b  9.0144(5) Å   90 ° 
 c  14.1363(8) Å   90 ° 
V [Å3] 811.48(7)  
T [K] 150(2)  
space group P212121  
Z 4  
 [mm-1] 0.14  
density [g/cm3] 1.401  
no. of reflections measured 20076  
no. of independent reflections 1967 (Rint = 0.020)  
no. of observed reflections (I > 2σ(I)) 1920  
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no. of parameters 115  
R1 (I>2(I)) 0.025  
wR2 (all data) 0.068  
Goodness of fit on F2 1.05  
largest diff. peak and hole [e/Å3] 0.21 and -0.19  
 
Synthesis of (2S)-1-((4-methoxybenzoyl)-L-valyl)-N-((3S)-1,1,1-trifluoro-2-hydroxy-4-
methylpentan-3-yl)pyrrolidine-2-carboxamide (5.12):  
 
Compound 5.12 was prepared following a similar literature procedure.[178] 
(4-methoxybenzoyl)-L-valyl-L-proline (5.6) (81 mg, 232 µmol, 1.0 equiv.) was dissolved in 
DMF (4 ml), and thereto were added (3S)-3-amino-1,1,1-trifluoro-4-methylpentan-2-ol (5.9) 
(44 mg, 253 µmol, 1.1 equiv.) and N-hydroxybenzotriazole hydrate (72 mg, 471 µmol, 
2.05 equiv.) all at once and the mixture was allowed to stir for 10 minutes. Thereafter, 
triethylamine (82 µl, 586 µmol, 2.55 equiv.) was added followed by EDCI (69 mg, 366 µmol, 
1.55 equiv.) and the mixture was stirred at r.t. for 20 hours. The reaction mixture was then 
diluted with EtOAc (15 ml) and washed with 1N aq. HCl solution (10 ml), water (10 ml), 
1N aq. NaOH (10 ml) and brine, respectively. The organic phase was dried over Na2SO4 and 
concentrated under reduced pressure. The crude mixture was purified by flash 
chromatography (dichloromethane:methanol 99:  → 97: ) yiel ing the  esire  
compound 5.12 (84 mg, 167 µmol, 72%) as a white foam. 
Rf = 0.34 (dichloromethane:methanol  95:5, UV, KMnO4). 
1H NMR (300 MHz, DMSO-d6) δ  0.81 (d, J 6.9 Hz, 6H), 0.95 (dd, J  11.5, 6.7 Hz, 6H), 
1.62 – 2.21 (m, 6H), 3.54 – 3.67 (m, 1H), 3.80 (m, 4H), 3.86 – 4.14 (m, 2H), 
4.30 (dd, J  7.6, 5.0 Hz, 1H), 4.43 (t, J  8.7 Hz, 1H), 6.38 (d, J  7.5 Hz, 1H), 6.91 – 
7.05 (m, 2H), 7.69 (d, J  10.0 Hz, 1H), 7.85 – 7.95 (m, 2H), 8.30 (d, J  8.1 Hz, 1H). 
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13C NMR (75 MHz, DMSO-d6) δ  15.0, 18.8, 19.2, 19.4, 24.7, 27.5, 28.9, 30.1, 47.3, 50.9, 
55.3, 56.8, 59.5, 68.3 (q, J  27.4, 26.9 Hz), 113.3, 125.9 (q, J 284.9 Hz) 126.1, 129.4, 161.6, 
165.8, 170.1, 171.3. 
19F-NMR (282 MHz, DMSO-d6) δ  74.2. 
MS (EI) m/z (relative intensity): 501 (1) [M+], 295 (1), 269 (1), 234 (21), 206 (16), 191 (1), 
170 (1), 152 (1), 136 (9), 135 (100), 117 (1), 107 (4), 92 (6), 77 (9), 70 (44), 43 (5). 
HRMS (EI): calcd. for C24H32N3O5F3 [M-H] 499.2289, found: 499.2290. 
IR (ATR, neat, cm-1): 3300 (m), 2963 (m), 1622 (s), 1536 (m), 1500 (m), 1439 (m), 1307 (w), 
1253 (s), 1167 (m), 1139 (s), 1099 (m), 1028 (m). 
Synthesis of (S)-1-((4-methoxybenzoyl)-L-valyl)-N-((S)-1,1,1-trifluoro-4-methyl-2-
oxopentan-3-yl)pyrrolidine-2-carboxamide (5.13):  
 
Compound 5.13 was prepared following a similar literature procedure.[178] (2S)-1-((4-
methoxybenzoyl)-L-valyl)-N-((3S)-1,1,1-trifluoro-2-hydroxy-4-methylpentan-3-yl)pyrrolidine-
2-carboxamide (5.12)  (40 mg, 80 µmol, 1.0 equiv.) was dissolved in a mixture of t-BuOH 
(320 µl) and water (400 µl) and the solution was cooled to 0 °C. Then, 0.6 N aq. NaOH 
(400 µl) was added to the mixture followed by the dropwise addition of an aqueous solution 
of KMnO4 (39 mg, 240 µmol in 614 µl of water) over 1 h at 0 °C. The reaction was complete 
judging TLC after 1 hour. Methanol (155 µl) was then added to the reaction mixture to 
quench the remaining KMnO4 and the solution was stirred for further 1 hour at 0 °C. 
Thereafter, the solution mixture was filtered through Celite and extracted with 
EtOAc (3x10 ml). The organic fraction was washed with 1N aq. HCl (10 ml) and brine (10 ml) 
respectively and the solvent was removed under reduced pressure. The crude mixture was 
purified by flash column chromatography (dichloromethane:methanol = 99:1yielding the 
title compound 5.13 (40 mg, 80 µmol, quant.) as a white foam. 
Rf  0.26 (dichloromethane:methanol  97:3, UV (254 nm), KMnO4). 
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1H NMR (400 MHz, CDCl3) δ  0.94 – 1.02 (m, 3H), 1.06 – 1.21 (m, 9H), 1.90 – 2.05 (m, 1H), 
2.06 2.17 (m, 1H), 2.16 – 2.32 (m, 2H), 2.33 – 2.47 (m, 2H), 3.75 – 3.87 (m, 1H), 3.94 (s, 3H), 
4.03 (m, 1H), 4.75 (dd, J  8.1, 2.9 Hz, 1H), 4.86 – 5.00 (m, 2H), 6.85 – 7.10 (m, 3H), 
7.73 (d, J  7.4 Hz, 1H), 7.78 – 8.05 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ  16.8, 18.2, 19.6, 19.8, 25.2, 27.3, 29.2, 31.7, 48.1, 55.5, 56.1, 
59.2, 59.8, 113.8, 115.5 (q, j 292.91 Hz), 126.1, 129.1, 162.5, 166.9, 171.5, 172.8, 
190.56 (q, J  34.4 Hz). 
19F NMR (282 MHz, CDCl3) δ  76.41. 
MS (EI): m/z (relative intensity): 499 (1) [M+], 267 (1), 234 (12), 206 (14), 191 (1), 152 (1), 
135 (100), 125 (1), 107 (4), 92 (6), 77 (9), 70 (37), 43 (7). 
HRMS (EI): calcd. for C24H32F3N3O5 [M]
+ 499.2289, found: 499.2294. 
IR (ATR, neat, cm-1): 3257 (br., w), 2967 (w), 1767 (w), 1694 (w), 1622 (m), 1538 (w), 
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